1. A JR is an academic session in which we go through selected article summaries over 60-75 min.

2. It takes place every Monday and Thursday via our JR Discord channel โ€“ see calendar.
3. Its purpose is to:
     - Understand the main messages from the summarized articles.
     - Recall pivotal concepts pertinent to our clinical practice.
     - Train clinical reasoning by connecting key concepts to real-life scenarios.

4. The articles are chosen during the session from a curated, labeled, and codified list of remarkable summarized articles.

5. We take interactive and pedagogic notes in a shared document, using visual aids, highlighting, underlining, arrows, and conceptual links to connect ideas and facilitate understanding.
6. For each session, we create RECAP key points and publish them on our website.

7. In the following session, we briefly recall the previous JRโ€™s RECAP to reinforce learning through retrieval practice.

Glossary (most used)

๐Ÿซƒ๐Ÿฝ = abdomen = abdominal, ๐Ÿค“ = analysis, ๐Ÿ“ˆ = arrhythmia, ๐Ÿฉธ = blood = hematology, ๐Ÿง  = brain, โšก๏ธ = cardiac arrest, โญ•๏ธ = circulation, โ†“ = decrease, ๐—˜๐—ซ = exclusion, ๐Ÿ’จ = flow, ๐Ÿซ€ = heart, โ†—๏ธ = improve, ๐—œ๐—ก = inclusion, โ†‘ = increase, ๐ŸฅŠ = inflammation, ๐Ÿชฒ = infections, โ™พ๏ธ = kidneys = renal, โ—ธ = liver = hepatic, ๐Ÿซ = lungs, ๐Ÿ’ช๐Ÿฝ = muscle, โžฐ = pressure, ๐Ÿณ๏ธ = prevention, โ˜… = recommendation(s), โœ‹๐Ÿฝ = stop, ๐Ÿ—ฃ = suggestion(s), โ†˜๏ธ = worsen, CIpxs = critically ill patients, DX = diagnosis, h_LOS = Hospital length of stay, icu_LOS = ICU length of stay, inc_ = incident, MA = metaanalysis, mc = multicentric, MM = mortality, MM90 = mortality at 90 days, pOC = primary outcome(s), pxs = patients, RCT = randomized controlled trial, sOC = secondary outcome(s), sr = systematic review, SS = survival, w_ = with, wo_ = without, yo = years old.

๐™„๐™Œ๐˜พ ๐™จ๐™˜๐™ค๐™ฅ๐™š โ†’ Y, J, C โž– T โž• N โž• t โž– P I C O: 

  • year (Y), journal (J), country (C)
  • type of study (T) โž• number of patients/sample (N) โž• time (t)
  • population (P), intervention (I), comparison (C), outcome (O, OC).
๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พแดฎแดผ scope (glossary)
Glossary (complete)
March, 2026

2025 NEJMc - Watchful Waiting or Oral Antihypertensives f_, Asymptomatic Hypertension (NEJM).pdf

2025 NEJMcd - To Treat or Not to Treat Watchful Waiting or Oral antiHTA (Gorey) [case].pdf

Codified by YAPG + ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ (MASP)


Glossary: AdvEve = adverse events, ATC = awareness, TTO and control, MI = myocardial infarction, OSA = obstructive sleep apnea, PCP = primary care physician, Sโ€  = stroke, โšก๏ธ = cardiac arrest, ๐Ÿค“ = analysis, ๐Ÿง  = brain, ๐Ÿซ€ = heart, ๐Ÿซ€ injury = myocardial injury, ๐Ÿซ = lungs

1. 63yo โ™‚๏ธŽ โžฉ uncomplicated diverticulitis + ATB + conservative TTO

2. Vitals โžฉ 185/115, the rest โœ”๏ธŽ , no symptoms (headache, dyspnea, chest or ab pain)

3. Slightly stressed at being admitted

4. Physical exam โžฉ 166/97, 4h earlier.

5. LAB โžฉ โ†‘LEU + inflammatory markers โž– renal and liver profiles โœ”๏ธŽ 

6. Monitors have been calibrated recently. 

7. 10min rest โžฉ 182/103

8. NOT TO TREAT 

      a. Michael Rothberg

      b. No immediate danger.

      c. Not treated HTA โžฉ โ†‘r ๐Ÿซ€DIS + โ™พ๏ธ DIS + ๐Ÿง  Stroke โ–ถ๏ธŽ over years, NOT DAYS

      d. SEVERAL REASONS:

         i. Acute illness

             1. TRANSIENT โ†‘ABP

             2. Incorrect to treat 

             3. Inaccurate measurements

               a. Mispositioning

               b. Cuff size

               c. Situational factors (anxiety + pain + wakened from sleep)

         ii. Side effects

            1. AntiHTA ๐Ÿ’‰ โžฉ โ†“ABP โ–ถ๏ธŽ โ†‘ โ†‘ โ†‘ dangerous than โ†‘HTA โžฉ hypoperfusion

            2. โ†“K or โ†‘K

            3. For inpatient settings โ–ถ๏ธŽ No RCTs โž• Yes OBS (need for caution)

            4. Propensity-matched ๐Ÿค“ โ–ถ๏ธŽ โ†‘ ๐Ÿซ€ injury โž• AKI

            5. Target trial emulation โ–ถ๏ธŽ if TTO 48h ๐ŸŸฐ โ†‘ incidence of AdvEve 

         iii. Time and resources

            1. GL โ–ถ๏ธŽ if immediate TTO = f-up 4w

            2. Monitoring at least every shift 

            3. Pressure to โ†‘ therapy โžฉ overTTO

            4. Might seem likely to f-up + better BP control โžฉ BUT OBS studies do not support this assertion but DO suggest potential harm. 

            5. Readmitted within 30d (filling and refilling of the medication)

            6. PCP is needed. 

       e. MOST IMP โžฉ education โž• f-up

             i. Shortage of PCP in the US

             ii. f-up is challenging. 

             iii. It should be done. 
9. TO TREAT

      a. GL outpatient setting โ–ถ๏ธŽ STRONG EVIDENCE (epidemiologic โž• RCTs)

      b. Inpatient setting โ–ถ๏ธŽ ๐Ÿคท๐Ÿฝโ€โ™‚๏ธ when + how to treat ASYMPTOMATIC HTA

      c. RCTs lacking

      d. OBSs โžฉ โ†‘r of adverse clinical OCs: death + AKI + Sโ€ 

      e. Modest reductions ๐ŸŸฐ โ†“r MI โž• Sโ€  โž• HF โž• MM

      f. ATC โ–ถ๏ธŽ Awareness โž• TTO โž• control โžฉ Low prevalence: 60, 51, 21%, respectively. 

      g. Demographics โ–ถ๏ธŽ โ™‚๏ธŽ โž• >60yo โ–ถ๏ธŽ 70% are โ™‚๏ธŽ โž• 63yo โ†ช๏ธŽ HTA most likely

      h. Multiple checks + calibrated device + after 10min rest + no pain + no meds ๐ŸŸฐ chronic HTA (vignette case)

      i.  UNIQUE OPPORTUNITY to ATC

          i. Better chance to receive help

          ii. Discharge management to refills and control 

          iii. outpatient f-up โžฉ weight โž• OSA

          iv. PCP + pharmacists + technology โžฉ TRANSITION โ€œinpatient โ†’ outpatientโ€

          v. "we should seize each chance we have to make a positive change."

2026 NEJMc - Updated Guidelines for Advanced, ACLS (Circulation).pdf

Codified by YAPG


Glossary: โ˜… = recommendation(s), AED = automated external defibrillator, AF = atrial fibrillation, Afib = atrial fibrilation, ARDS = acute respiratory distress syndrome, CA = cancer, FA = flutter, GE = gastroenterology, IO = intraosseus, OHCA = out of hospital cardiac arrest, PEA = pulseless electrical activity, ๐Ÿ’‰ = intravenous, ๐Ÿ—ฃ = suggestion(s), ๐Ÿง  = brain, ๐Ÿซ€ = heart, ๐Ÿซ = lungs, ๐Ÿซƒ๐Ÿฝ = abdomen = abdominal

1. ๐™„๐™Œ๐˜พ BS โžฉ Y, J, C โž– T โž• N โž• t โž– P I C O:

2. ๐™„๐™Œ๐˜พ BS ๐ŸŸฐ 2025, CIRCULATION, USA โž– GL โž• NA โž• UPDATE from 2020 โž– P I C O:

      - P: adults
      - ๐Ÿ…ธ: ACLS
      - ๐Ÿ…ฒ: NA
      - O: NA

3. No substantive additions, few relevant changes

4. OPIODS

      a. Do not DELAY CPR, EVEN when naloxone is being considered

5. CPR, mechanical devices

      a. Only in special circumstances โžฉ d_transport

      b. OHCA not recommended

6. ACCESS

      a. ๐Ÿ’‰ before IO

      b. IO only if ๐Ÿ’‰ fails OR is inaccesible 

7. DEFIBRILLATION

      a. 1st synchronized cardioversion at 200J (biphasic) โžฉ Afib โž• AF
      b. For refractory ventricular fibrillation โžฉ DO NOT USE vector change โž• double sequential defibrillation
      c. In polymorphic ventricular tachycardia โžฉ immediate defibrillation

8. ULTRASOUND
      a. Use by an experienced clinician
      b. Purpose โžฉ to DX reversible causes (pneumothorax โž• ๐Ÿซ€ tamponade)
      c. Do not STOP CPR

9. POST ROSC

      a. 36ยบC for at least 36h

10. EDUCATION

      a. 12yo โžฉ can learn CPR โž• AED use

      b. Cognitive aids: 

         i. NOT for lay rescuers
         ii. YES for health care professionals

11. RATIONALE

      a. POCUS valuable in PEA and asystole

      b. Education + training โ˜… โžฉ encourage the team to use smart devices + teens to get training.

โณ TIME MANAGEMENT
02:18:20

Round: 16 02:42:36  Comments
Round: 15 26:43:61  Wrap-up
Round: 14 13:37:28  Interpretation
Round: 13 04:26:72  Reading + notes
Round: 12 17:42:78  Interpretation
Round: 11 04:14:13  Reading + notes
Round: 10 07:02:71  Reading + notes (+4 min)
Round: 9   05:05:57  Comments
Round: 8   12:01:55  Wrap-up
Round: 7   15:07:75  Interpretation

Round: 6   04:02:34  Reading + notes

Round: 5   06:57:57  Reading + notes

Round: 4   01:26:84  Discussion

Round: 3   03:52:58  ART Selection

Round: 2   00:59:82  Comments

Round: 1   12:17:29  Past JR

Thursday, March 26, 2026 at 17:15:45 in BE

MG, LH, EQO, YZE, ASCA, MASP, AAQC

2026 CC - Citrate accumulation during CRRT, the impact of DX criteria (Perschinka) [ma].pdf

Codified by ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ (ABFL)


Glossary:
๐Ÿง  = brain
๐Ÿซ = lungs
๐Ÿซ€ = heart
๐Ÿซƒ๐Ÿฝ = abdomen = abdominal

โ—ธ = liver = hepatic
โ™พ๏ธ = kidneys = renal
๐Ÿฉธ= blood = hematology
๐Ÿชฒ = infections
๐Ÿ’จ = flow
โžฐ = pressure
๐Ÿค“ = analysis;
โšก๏ธ = cardiac arrest;
๐Ÿ“ˆ = arrhythmia;
๐Ÿ—ฃ = suggestion(s)
โ˜… = recommendation(s)


AF = atrial fibrillation;
CVVHDF = continuous veno-venous hemodiafiltration
MM = mortality;
GE = gastroenterology;
ALB = albumin



1. ๐™„๐™Œ๐˜พ BS โžฉ Y, J, C โž– T โž• N โž• t โž– P I C O:

2. ๐™„๐™Œ๐˜พ BS ๐ŸŸฐ 2026, CC, AT โž– ma โž• Muller et al. Citrate accumulation โž• 2025 โž– P I C O:

      - P: CI pxs
      - ๐Ÿ…ธ: CVVHD
      - ๐Ÿ…ฒ: CVVHD**F**
      - O: **pOC** = MM | **sOC** = incidence, accumulation

3. EVIDENCE.

      a. Definition โ–ถ๏ธŽ โ†‘ tCa/iCa > 2,5

      b. tCa was corrected to ALB

      c. 17% โžฉ citrate accumulation affectation: 

         i. 64% CVVHD

         ii. 36% CVVHDF

4. Ca correction.

      a. Uncorrected tCa/iCa is the standard practice

      b. Bohr et al. โ–ถ๏ธŽ ALB โ†” tCa/iCa ratio

      c. โ†‘ALB โžฉ โ†‘tCa/iCa ratio

      d. CIRCULATION Ca is protein-bound OR ionized. 

5. DX criteria.

      1. The ratio solely was used.
      2. Usually CITRATE ACCUMULATION ๐ŸŸฐ metabolic acidosis โž• systemic โ†“Ca (requires Ca substitution).
      3. In Muller study โ–ถ๏ธŽ did not have Ca requirement OR metabolic acidosis.
      4. So MM was underestimated.
      5. Other studies โžฉ โ†‘MM w_comprehensive DX criteria
      6. Kjadzhynov et al โ–ถ๏ธŽ

         i. โ†“iCa despite Ca supplementation
         ii. At least 2 criteria were used:

             1. โ†‘ tCa
             2. โ†‘ tCa/iCa
             3. Relevant metabolic acidosis (pH < 7,2 ยฑ BE < -5)
             4. โ†‘anion gap (>11)

         iii. No multivariate ๐Ÿค“ 

         iv. MM โ†‘ โ†‘ โ†‘
         v. All died, at 22h or 48h due to citrate accumulation.
         vi. SEVERITY **was comparable** to Muller et al.

6. Third point INCIDENCE to continue. 

โณ TIME MANAGEMENT
01:18:17

Round: 11 00:47:41 Comments
Round: 10 15:51:98 Wrap-up
Round: 9 16:01:46 Interpretation
Round: 8 08:42:97 Reading + notes
Round: 7 01:14:96 Comment
Round: 6 13:35:28 Wrap-up
Round: 5 11:55:52 Interpretation
Round: 4 03:13:34 Reading + notes
Round: 3 06:03:45 ART selection
Round: 2 00:42:78 Comments

Round: 1 00:08:02 +15min Past JR

Thursday, March 12, 2026 at 17:08:55 in BE

MG, KH, JM, EM, EQO, ASCA,HIBN, MASP, AAQC

2026 PsyAdv - Psychotherapy Can Improve Grief Disorder f_Bereaved Pxs (AIM).pdf

Codified by YAPG


Glossary:
๐Ÿง  = brain
๐Ÿซ = lungs
๐Ÿซ€ = heart
๐Ÿซƒ๐Ÿฝ = abdomen = abdominal

โ—ธ = liver = hepatic
โ™พ๏ธ = kidneys = renal
๐Ÿฉธ= blood = hematology
๐Ÿชฒ = infections
๐Ÿ’จ = flow
โžฐ = pressure
๐Ÿค“ = analysis;
โšก๏ธ = cardiac arrest;
๐Ÿ“ˆ = arrhythmia;
๐Ÿ—ฃ = suggestion(s)
โ˜… = recommendation(s)

AF = atrial fibrillation;
ARDS = acute respiratory distress syndrome;
CA = cancer;
RCT = randomized controlled trial
ROB = risk of bias


1. ๐™„๐™Œ๐˜พ BS โžฉ Y, J, C โž– T โž• N โž• t โž– P I C O:

2. ๐™„๐™Œ๐˜พ BS ๐ŸŸฐ 2026, AIM, USA, California โž– r โž• 169 RCT, 303 publications โž• -Feb 3 โž– P I C O:

      - P: Adults + children: bereaved persons
      - ๐Ÿ…ธ: Pshychotherapy โž– expert-facilitated support groups โž– ๐Ÿ’Š โž– ๐Ÿ‘จ๐Ÿฝโ€๐Ÿคโ€๐Ÿ‘จ๐Ÿป โž– self-help ๐Ÿ…ธ โž– โœ๏ธ โž– ๐ŸŽถ โž–             ๐ŸŽจ โž– โž– enhanced provider contact โž– integrative medicine
      - ๐Ÿ…ฒ: NA
      - O: **pOC** = โ†—๏ธ grief disorder, grief, depression symptoms

3. EVIDENCE.

      a. Also for soon-to-be bereaved persons

4. RESULTS.

      a. ROB = substantial

      b. Children only in 15 RCT

      c. Strenght of evidence:

         i. MODERATE โžฉ individual psychoterapy

         ii. LOW โžฉ expert-facilitated support groups

         iii. CONFLICTING โžฉ other ๐Ÿ…ธ 

         iv. INSUFFICIENT โž• NO EVIDENCE โžฉ others
5. RATIONALE.

     a. Growth in research โžฉ past 3 decades.

      b. More info is needed to TARGET these ๐Ÿ…ธ โžฉ specific circumstances

2026 ICM - Ups and downs of CAR in the ICU, why should we care (Robba) [r].pdf

Codified by YAPG


Glossary: โ˜… = recommendation(s), ABP = arterial blood pressure, af_ = after, CA = cerebral autoregulation, CBF = cerebral blood flow, CPP = cerebral perfusion pressure, HTA = arterial hypertension, IC = intracerebral, ICP = intracranial pressure, iStroke = ischemic stroke, NIRS = near-infrared spectroscopy, SAH = subarachnoid hemorrhage, TBI = traumatic brain injury, TCD = transcranial doppler, ๐Ÿง  = brain


1. CAR impairment โžฉ dependent:

      a. severity

      b. Time af_injury โžฉ 2-3d โ–ถ๏ธŽ deeper disturbances โžฉ then, gradual โ†—๏ธ

      c. 3d is significative to define survival and death. 

      d. Factors influencing CAR:

         i. CO2. 

            1. Complex relationship.
            2. Part of CBF regulation, BUT โ‰ mech.
            3. Conceptually + functionally โ‰ 
            4. โ†‘PaCO2 โžฉ CAR impairs โ–ถ๏ธŽ lower limit โ†‘ โž• upper limit โ†“
            5. โ†“ PaCO2 โžฉ CAR improves โ–ถ๏ธŽ lower limit โ†“ โž• upper limit โ†‘
            6. Hypocapnia โžฉ โ›”๏ธ โ€œโ†“๐Ÿ’จ  โž• โ†“O2โ€œ (secondary ๐Ÿง  damage)

         ii. Vasogenic waves (ICP)

            1. Require INTACT CAR at baseline โžฉ to develop the CASCADE (vasodilatotary)
            2. Top of the wave โ–ถ๏ธŽ โ†“ CPP ๐ŸŸฐ loss of CAR
            3. Plateu ๐ŸŸฐ 5-15min (vasodilatation TO vasoconstriction)
            4. IF โ€œplateau โ†‘ ICPโ€ last longer โžฉ HYPERVENTILATION should be applied (as a vasocontrictory stimulus)

         iii. โ†‘ ICP

         iv. โ†‘ flow + โ†“ CPP ischemia

         v. โ†‘ Tยบ

         vi. Anesthetics

         vii. post-traumatic SAH

         viii. Ht changes

โณ TIME MANAGEMENT
43:51:52

Round: 4 01:02:45 Comments
Round: 3 31:39:78 Wrap-up (past JR)
Round: 2 02:16:58 ART selection

Round: 1 08:52:69 Past JR

Thursday, March 5, 2026 at 17:45:08 in BE

KH, EQO, HIBN, AAQC

2026 NEJMc - Where to Place a Central Line, Revisiting Site Choice in the Age of US (CC).pdf

Codified by YAPG


Glossary: AF = atrial fibrillation, ARDS = acute respiratory distress syndrome, BSI = bloodstream infections, CIpxs = critically ill patients, DVT = deep venous thrombosis


1. ๐™„๐™Œ๐˜พ BS โžฉ Y, J, C โž– T โž• N โž• t โž– P I C O:

2. ๐™„๐™Œ๐˜พ BS ๐ŸŸฐ 2025, CC, ? โž– obs โž• 3SITES - 3400 โž• one decado ago โž– P I C O:

      - P: CIpxs
      - ๐Ÿ…ธ: CVCs placement
      - ๐Ÿ…ฒ: NA
      - O: **pOC** = safety

3. EVIDENCE.

      a. Nowadays, we use US โ†‘ frequently.

      b. Time to revisit 3SITES to test the safety of its results.

      c. Perhaps even more few complications w_US

      d. 3SITES:

         i. Subclavian CVCs โžฉ โ†“ BSI โž• โ†“ DVT 

         ii. โ†‘ mechanical complications (PNEUMOTHORAX) w_subclavian CVCs, compared to:

            1. internal juguylar vein

            2. femoral vein

         iii. US was used < 1/3 of cases

         iv. US was used in 5% of subclavian lines. 

4. METHODS.

      - INTERV โž  TARGET-TRIAL EMULATION

      - As if US guidance had been performed

      - Adjusting for potential COUNFOUNDERS
5. RESULTS.
      a. Subclavian CVCs ๐ŸŸฐ NO DVT โž• NO BSI ๐Ÿ†š 3% in internal yugular & femoral veins.

      b. Mechanical complications ๐ŸŸฐ RARE (~1%) โžฉ similar FOR ALL CVCs sites.


6. RATIONALE..

      a. Zero INF โŒ„ Zero thrombosis:

         i. LIMITATION of target-trial emulation trials.

         ii. but ALSO reflect safety. 

         iii. Michael suggests: 1st. Subclavian, 2nd. Internal yugular, 3rd. Femoral. 

         iv. Hard to justify otherwise. 

2026 ICM - Ups and downs of CAR in the ICU, why should we care (Robba) [r].pdf

Codified by YAPG


Glossary: โ˜… = recommendation(s), ABP = arterial blood pressure, af_ = after, CA = cerebral autoregulation, CBF = cerebral blood flow, CPP = cerebral perfusion pressure, HTA = arterial hypertension, IC = intracerebral, ICP = intracranial pressure, iStroke = ischemic stroke, NIRS = near-infrared spectroscopy, SAH = subarachnoid hemorrhage, TBI = traumatic brain injury, TCD = transcranial doppler, ๐Ÿง  = brain


1. ๐™„๐™Œ๐˜พ BS โžฉ Y, J, C โž– T โž• N โž• t โž– P I C O:

2. ๐™„๐™Œ๐˜พ BS ๐ŸŸฐ 2026, ICM, IT+UK โž– r โž• NA โž• NA 

3. CA โžฉ protective mechanism + maintains stable CBF โžฉ despite CHANGES in ABP & CPP. .

      a. โ†‘ ABP โŒ„ CPP โ–ถ๏ธŽ VASOCONSTRICTION โžฉ to prevent โ†‘ CBF

      b. โ†“ ABP โŒ„ CPP โ–ถ๏ธŽ VASODILATION โžฉ to maintain CBF

      c. Healthy limits of CAR ๐ŸŸฐ 50-150mmHg

      d. Limits VARY in DIFFERENT CONDITIONS:

         i. age

         ii. history or HTA

         iii. dysautonomy
         iv. endothelial function
         v. acute brain lesion, etc.

4. In ABI โžฉ CA is disturbed, especially af_:.

      a. TBI

      b. SAH

      c. IC bleeding

      d. iStroke 

5. The ABILITY to maintain CA FLUCTUATES OVER TIME, responding to intra- + extracranial factos: CO2 โŒ„ ICP.

6. GL โžฉ CPP = 60-70mmHg. โ–ถ๏ธŽ the target may depend on the specific patient. 

7. Neuromonitoring:

      a. Invasive: ICP, PbtO2, thermodilution CBF, etc.

      b. Non-invasive: TCD, NIRS.

8. Static CAR: 

      a. MAP challenge  

      b. Observing changes in ICP

      c. โ˜… SIBICC GL โžฉ tier 2 therapy. 

9. Dynamic CAR

      a. PRx โžฉ to detect changes of CA status. 

         i. 5-min windowed coefficient

         ii. 10s average MAP + ICP

         iii. >0.25 = impaired โ–ถ๏ธŽ MM 20-60%

10. Dynamic is MORE APPROPRIATE for continuous monitoring. 

โณ TIME MANAGEMENT
01:13:32

Round: 12 01:34:40 Comments
Round: 11 15:39:39 Wrap-up
Round: 10 09:46:42 Interpretation
Round: 9 08:50:08 Reading + notes
Round: 8 01:14:86 Intro
Round: 7 01:40:64 Comments
Round: 6 12:26:67 Wrap-up
Round: 5 07:55:92 Interpretation
Round: 4 04:38:52 Reading + notes
Round: 3 04:25:97 ART selection
Round: 2 00:34:19 Comments

Round: 1 04:45:58 Past JR

Monday, March 2, 2026 at 17:13:47 in BE

YAPG, AS, RCH,HIBN, MASP, AAQC

February, 2026

Monday, February 23, 2026 at 17:00:35 in BE

BAR, HIBN, MASP, AAQC

2026 HEALIO - Harms of tramadol โ€˜likely outweigh its limited benefitsโ€™ for chronic pain (BMJ).pdf

Codified by JQB


Glossary:
๐Ÿง  = brain
๐Ÿซ = lungs
๐Ÿซ€ = heart
๐Ÿซƒ๐Ÿฝ = abdomen = abdominal

โ—ธ = liver = hepatic
โ™พ๏ธ = kidneys = renal
๐Ÿฉธ= blood = hematology
๐Ÿชฒ = infections
๐Ÿ’จ = flow
โžฐ = pressure
๐Ÿค“ = analysis;
โšก๏ธ = cardiac arrest;
๐Ÿ“ˆ = arrhythmia;
๐Ÿ—ฃ = suggestion(s)
โ˜… = recommendation(s)

AF = atrial fibrillation;
ARDS = acute respiratory distress syndrome;
CA = cancer;
GE = gastroenterology;
MV = mechanical ventilation


1. ๐™„๐™Œ๐˜พ BS โžฉ Y, J, C โž– T โž• N โž• t โž– P I C O:


2. ๐™„๐™Œ๐˜พ BS ๐ŸŸฐ 2026, BMJ, UK โž– srMA โž• 19 RCTs โž• -Nov 11, 2020 โž– P I C O:

      - P: hALT pregnant
      - ๐Ÿ…ธ: preg hALT
      - ๐Ÿ…ฒ: preg non-hALT
      - O: **pOC** = hALT impact on LBW, SGA, SPTB | **sOC** = magnitude LBW

3. EVIDENCE.

4. METHODS.

      - ๐—œ๐—ก โž 
      - ๐—˜๐—ซ โž 
      - RANDOM โž 
      - INTERV โž 

5. RESULTS

6. RATIONALE

7. LIMITATIONS.

2021 Intl J Gynecology Obste - Fetal growth and spontaneous preterm birth in highโ€altitude pregnancy (grant) [srMA].pdf

Codified by ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ (ABFL)


Glossary
๐Ÿง  = brain
๐Ÿซ = lungs
๐Ÿซ€ = heart
๐Ÿซƒ๐Ÿฝ = abdomen = abdominal

โ—ธ = liver = hepatic
โ™พ๏ธ = kidneys = renal
๐Ÿฉธ= blood = hematology
๐Ÿชฒ = infections
๐Ÿ’จ = flow
โžฐ = pressure
๐Ÿค“ = analysis;
โšก๏ธ = cardiac arrest;
๐Ÿ“ˆ = arrhythmia;
๐Ÿ—ฃ = suggestion(s)
โ˜… = recommendation(s)

AF = atrial fibrillation;
ARDS = acute respiratory distress syndrome;
CA = cancer;
GE = gastroenterology;
MV = mechanical ventilation



1. ๐™„๐™Œ๐˜พ BS โžฉ Y, J, C โž– T โž• N โž• t โž– P I C O:

2. ๐™„๐™Œ๐˜พ BS ๐ŸŸฐ 2021, IJGO, UK โž– srMA โž• 2524, 59 IN โž• -Nov 11, 2020 โž– P I C O:

      - P: hALT pregnant
      - ๐Ÿ…ธ: preg hALT
      - ๐Ÿ…ฒ: preg non-hALT
      - O: **pOC** = hALT impact on LBW, SGA, SPTB | **sOC** = magnitude LBW

3. EVIDENCE.

4. METHODS.

      - ๐—œ๐—ก โž 
      - ๐—˜๐—ซ โž 
      - RANDOM โž 
      - INTERV โž 

5. RESULTS

6. RATIONALE

7. LIMITATIONS.

โณ TIME MANAGEMENT
01:06:16

Round: 4 02:14:97 Comments
Round: 3 47:33:86 Wrap-up
Round: 2 05:52:83 CONTINUE previous JR
Round: 1 10:35:10 Past JR

[2025 ICM - Serum sickness, a mimic of SSโ€ข (Todaka) [img].pdf]

Codified by YAPG


Glossary: HD = hemodynamic, INF = infection, mm = management, PO = per os, SeSi = serum sickness, ๐Ÿ’‰ = intravenous.


1. โ™€ 84yo โžฉ 13d af_equine-derived habu antivenom

      a. Rash: lower legs

      b. Vasoplegic shock
2. Labs: โ†“ complement โž• โ†‘ lactate โž• AKI


3. SERUM SICKNESS (SeSi).

      a. Manifests 7-14d af_ exposure

      b. Heterologous proteins: antivenoms โž• vax โž• immune-modulating agents (RITUXIMAB + INFLIXIMAB)

      c. Resolve w_withdrawal the offending agent

      d. If severe systemic involvement โžฉ CORTICOSTEROIDS

      e. Immune complex-mediated type III reaction 

4. INVASIVE PNEUMOCOCCAL or MENINGOCOCCAL INF:

      a. โ†“ AP

      b. โ†‘ HR

      c. โ†‘ lactate
5. SeSi Clinical characteristics:.
      a. pruritic rash: heterogenous, urticarial, morbiliform, maculopapular, palpable purpura. Mucous spared.

      b. fever

      c. malaise

      d. polyarthralgia

      e. Severe cases โžฉ โ†“ C3, C4, CH50.
6. SeSi differentials:.

      a. Invasive meningococcal INF โžฉ rash โž• shock

         i. Resuscitation concurrently 

      b. Local INF โžฉ control precautions

7. SeSi mm.

      a. Prognosis โ–ถ๏ธŽ excellent โžฉ recovery in days or weeks wo_scarring or sequelae

      b. In ICU โ–ถ๏ธŽ prioritize: resuscitation โž• HD support

      c. If systemic involvement โ–ถ๏ธŽ hydrocortisone ๐Ÿ’‰ 200mg/day โž• taper 5-7 w_prednisone/prednisolone PO

      d. Stop the exposure โž• document the product โž• counsel against re-exposure (anaphylaxis). 

โณ TIME MANAGEMENT
49:24:59

Round: 7 00:48:48 Comments
Round: 6 13:53:30 Wrap-up
Round: 5 10:59:23 Interpretation
Round: 4 06:14:45 Reading + notes
Round: 3 02:23:81 ART selection
Round: 2 00:42:47 Comments

Round: 1 14:22:83 Past JR

Thursday, February 19, 2026 at 17:42:35 in BE

YZE, RCH, BAR,HIBN, MASP, AAQC

2021 Intl J Gynecology Obste - Fetal growth and spontaneous preterm birth in highโ€altitude pregnancy (grant) [srMA].pdf 

Codified by ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ (ABFL)


Glossary::

      ๐Ÿง  = brain
      ๐Ÿซ = lungs
      ๐Ÿซ€ = heart
      ๐Ÿซƒ๐Ÿฝ = abdomen = abdominal

      โ—ธ = liver = hepatic
      โ™พ๏ธ = kidneys = renal
      ๐Ÿฉธ= blood = hematology
      ๐Ÿชฒ = infections
      ๐Ÿ’จ = flow
      โžฐ = pressure
      ๐Ÿค“ = analysis;
      โšก๏ธ = cardiac arrest;
      ๐Ÿ“ˆ = arrhythmia;
      ๐Ÿ—ฃ = suggestion(s)
      โ˜… = recommendation(s)

      VOL = volume

      โ†˜๏ธ = worse

      โ†—๏ธ = better

      ๐Ÿท = obesity

      AFib = atrial fibrilation

      mcREG = multicenter registry
      SSC = surviving sepsis campaign
      VP = vasopressor;
      NE = norepinephrine;

      ยฎ = result(s)
      AVP = vasopressin

      mm = management

      PDMS = patient data management systems

1. AVP is better started early:

      a. Before, it โ†“ NE doses

      b. Earlier โžฉ โ†“: Sร˜ duration โž• hMM
2. AVP ok as a second VP

3. SSC 2025 โ–ถ๏ธŽ start AVP at NE of 0.25-0.5 โˆ‚

4. Dutch mcREG (Melchers et al, 2025):

      a. NE: โ†‘ doses โž• โ†‘ durations = โ†‘ Sร˜ durations (from onset of AVP). 

      b. Although: NEโ‰ฅ0.3 = โ†—๏ธ HD response to AVP โžฉ UNKOWN relation to โ†“ Sร˜ duration OR โ†—๏ธSS. 

      c. Pxs had โ†“ AFib โž• โ†“ VOL load โ–ถ๏ธŽ due to NE sparing effect 

      d. Benefits โœ”๏ธŽ (short-term) ๐Ÿค” (long-term)

5. Dose or time โ“ 

      a. OVISS โ–ถ๏ธŽ optimal AVP administration: NE dose = 0.2โˆ‚ โž• Sร˜ duration = 4h af_ (Kalimouttou et al, 2025)

      b. Retrospective (White et al, 2024) โ–ถ๏ธŽ 6h โžฉ โ†“ hMM

      c. Multiple ๐Ÿค“ โ–ถ๏ธŽ pH โž• lactate:

         i. โ†‘lactate + โ†“pH ๐ŸŸฐ โ†˜๏ธ HD response

         ii. Acidosis โžฉ โ†“ V1 receptor sensitivity (smooth muscle) โ–ถ๏ธŽ NOT A REASON TO DELAY AVP.  

      d. Sร˜ + ๐Ÿท (Melchers et al, 2025) โ–ถ๏ธŽ โ†“ response โž• โ†‘ Sร˜ duration

      e. Current practice โ–ถ๏ธŽ protolized NE โ†” NE infusion rate = +0.16

         i. โŠ• โ†‘ response rate 

         ii. โŠ– other OC โžฉ โ†‘duration โž• โ†“ SS

6. PROPOSAL.

      a. START AVP โ–ถ๏ธŽ โ‰ฅ0.2โˆ‚ โž• 6h 

      b. PREPARE AVP โ–ถ๏ธŽ if rapid NE escalation = >0.05โˆ‚ per 30min

      c. AVP BEFORE โ–ถ๏ธŽ NE โ‰ฅ0.3โˆ‚
7. How to implement โžฉ adjust PDMS triggers โž• team training โž• inventory mm

8. Clinical context is ALSO A FUNDAMENTAL FACTOR. 

โณ TIME MANAGEMENT
01:27:15

Round: 6 01:17:43 Comment
Round: 5 34:55:67 Wrap-up
Round: 4 25:56:35 Interpretation
Round: 3 05:18:93 Reading + notes
Round: 2 05:29:39 ART selection
Round: 1 14:17:69 Past JR

Thursday, February 5, 2026 at 17:03:56 in BE

YAPG, RMF, PFLC, MNVC, LH, HIBN, EM, APES, MASP, AAQC

2025 NEJMjw - Statin Use Might Affect Breast Cancer SS (JAMA).pdf

Codified by JJTM


Glossary: CA = cancer

1. ๐™„๐™Œ๐˜พ BS โžฉ Y, J, C โž– T โž• N โž• t โž– P I C O:
2. ๐™„๐™Œ๐˜พ BS ๐ŸŸฐ 2025, JAMA, DK โž– OBS (registry) โž• 67k โž• 21y (2000-2021), f-up 10y OR death โž– P I C O:

      - P: โ™€ breast cancer stage I-III

      - ๐Ÿ…ธ: statin initiation = INITIATORS

      - ๐Ÿ…ฒ: no statin = NONINTIATORS

      - O: pOC = breast cancer-related MM
3. EVIDENCE.

      a. โŠ– mevalonate pathway

      b. โ†“ cholesterol production

      c. CA cell proliferation, SS, metastases

4. METHODS

      - ๐—œ๐—ก โž  wo_prior stating exposure
5. RESULTS.
      a. 3y af_CA โ–ถ๏ธŽ โ†“ MM (10y breast CA-related) โžฉ 12% ๐Ÿ…ธ ๐Ÿ†š ๐Ÿ…ฒ 14%

      b. MM (all-cause) โ–ถ๏ธŽ numeric but not statistical โ†“ MM โžฉ ๐Ÿ…ธ ๐Ÿ†š ๐Ÿ…ฒ

      c. CLOSER TO THE DX โ–ถ๏ธŽ more-favorable EFFECTS โžฉ MM (all cause โž• breat CA-related)

      d. 5y SS (overall) โ–ถ๏ธŽ significantly BETTER โžฉ 90% ๐Ÿ…ธ ๐Ÿ†š ๐Ÿ…ฒ 88%

 6. RATIONALE.

      a. Emulation of MASTER

      b. MASTER = Mammary Cancer Statin ER Positive study

      c. Atorvastatin is being studied.

      d. This OBS not enough due to:

         i. residual counfounding

         ii. causality not defined

2025 NEJMc - Does Coffee Really Worsen Afib (JAMA).pdf

Codified by JJTM


Glossary: advE = adverse events, AFib = atrial fibrilation, AFL = atril flutter, F-up = follow-up, w = week


1. ๐™„๐™Œ๐˜พ BS โžฉ Y, J, C โž– T โž• N โž• t โž– P I C O:
2. ๐™„๐™Œ๐˜พ BS ๐ŸŸฐ 2025, JAMA, ? โž– mc_RCT โž• 200 โž• f-up 6m โž– P I C O:

      - P: persistent AFib or AFL

      - ๐Ÿ…ธ: 1 cup of caffeinated coffee / day

      - ๐Ÿ…ฒ: no caffeine at all (even decaffeinated)

      - O: pOC = Afib + AFL recurrence | sOC = Afib, advE. 
3. EVIDENCE.

      a. Believed coffee was PROARRHYTHMIC

4. METHODS

      - ๐—œ๐—ก โž  underwent CARDIOVERSION + history of coffee consumption
5. RESULTS.
      a. Baseline coffee โ–ถ๏ธŽ 7cups/w โžฉ BOTH groups

      b. F-up (6m) โ–ถ๏ธŽ 7/w (๐Ÿ…ธ) ๐Ÿ†š 0/w (๐Ÿ…ฒ)

      c. pOC (lasting โ‰ฅ30s) โ†“ in ๐Ÿ…ธ 47% ๐Ÿ†š 64% ๐Ÿ…ฒ

      d. AE โ–ถ๏ธŽ no difference

      e. Same benefit โ–ถ๏ธŽ AFib recurrence only
6. RATIONALE.

      a. It definitely contradicts the conventional thinking (proarrhythmic)

      b. Mechanisms still unknown. 

      c. The benefit with MORE THAN 1 cup/d is still in question. 

      d. We can let these type of patients take their morning coffee (Paul Mueller)

โณ TIME MANAGEMENT
01:09:47

Round: 10 01:59:19 Comments
Round: 9 11:47:81 Wrap-up
Round: 8 12:03:26 Interpretation
Round: 7 03:32:76 Reading + notes
Round: 6 01:17:72 Comments
Round: 5 15:02:89 Wrap-up
Round: 4 07:09:52 Interpretation
Round: 3 05:49:09 Reading + notes
Round: 2 03:07:86 ART selection
Round: 1 07:57:68 Past JR + 10min

Monday, February 2, 2026 at 17:05:43 in BE

YAPG, RMF, PFLC, MNVC, LH, HIBN, EM, APES, MASP, AAQC

January, 2026

[2025 HEALIO - Addiction, depression, cognition, How GLP-1s may benefit the brain (JAMA).pdf]

Codified by JJTM


Glossary: ๐Ÿง  = brain, AUD = alcohol use disorder, CVr = cardiovascular risk, GLP-1 RA = Glucagon-Like Peptide-1 Receptor Agonist(s), HPA = hypothalamicโ€“pituitaryโ€“adrenal axis, MACE = major adverse cardiovascular event, MECHS = mechanisms of action, OSA = obstructive sleep apnea, RCT = randomized clinical trial, SUDs = substance use disorders, Sx = surgery


1. GLP-1s in the ๐Ÿง   โžฉ SYMPTOMS โžฉ psychiatric (addiction)โž• neurologic (dementia)
2. Understanding MECHS is important
3. GLP-1 was approved for DM2 โžฉ โ†“ weight โžฉ APPETITE regulation.

4. 2024 โžฉ 12% use in US had ever used โžฉ 6% currently.
5. FDA-approved indications:.
      a. โ†“ MACE

      b. address OSA

      c. โ†“ โ™พ๏ธ  disease โž• โ™พ๏ธ failure โž• CVr
6. Research in EARLY stages.

7. Preliminary finding s in OFF LABEL

8. Repurposing drugs has ADVANTAGES of data โž• experience. (Rebecca Edelmayer)

9. ADDICTION: GLP-1 โžฉ in the response-reward PATHWAYS โ–ถ๏ธŽ addictive behaviors. Proposed MECHANISMS:

      a. Modulation of dopamine release (reward centers)

      b. Impact on the HPA axis

      c. Regulation of stress-related pathways

10. GLP-1 โžฉโ†“ nicotine โž• opioid use โžฉ evidence less conclusive than for โ†“ alcohol craving

11. Real-world data: โžฉโ†“ 40% opioid overdose/โ†“ 50% alcohol intoxication in AUD

12. RCT: Semaglutide (low dose) โžฉโ†“ weekly alcohol craving โžฉโ†“ consumption โžฉ 9 weeks โžฉ 48 patients with AUD

13. Population-based study (Sweden): GLP-1 use in T2DM/obesity โžฉ โ†“ alcohol-related hospitalization

14. Anti-obesity pharmacotherapy โžฉ โ†“ problematic alcohol use

15. Bariatric surgery โ–ถ๏ธŽ โ‰  effect โžฉ up to 33% pxs developed AUD postSx

16. Treating obesity with pharmacotherapy โžฉ โ†“ problematic eating โž•โ†“ alcohol consumption

17. LIMITATIONS: Evidence insufficient for widespread use in SUDs

      a. SUD neurobiology = heterogeneous โžฉ single target โ‰  universal solution

      b. GLP-1 safety profile in SUDs โžฉ not well defined

โณ TIME MANAGEMENT
01:00:45

Round: 5 11:56:02 Wrap-up + comments
Round: 4 18:41:90 Interpretation
Round: 3 08:29:06 Reading + notes
Round: 2 05:50:12 ART selection
Round: 1 09:28:04 Past JR

Thursday, January 29, 2026 at 17:20:15 in BE

CDRA, MNVC, EM, PFLC, AJRM, MASP, AAQC

[2025 NEJMc - Frailty Predicts Outcomes in Resistant Klebsiella pneumoniae Bacteremia (JAC).pdf]

Codified by (AHRM)


Glossary: CR-Kp BSIs = carbapenemase-resistant Klebsiella pneumoniae bloodstream infections, FI-Lab = frailty index laboratory, H+ = hospitalization, HR = hazard ratio, INF = infection(s), OD = organ dysfunction, S+E = sensitivity and specificity.


1. ๐™„๐™Œ๐˜พ BS โžฉ Y, J, C โž– T โž• N โž• t โž– P I C O:
2. ๐™„๐™Œ๐˜พ BS ๐ŸŸฐ 2025, JAC, โ“ โž– retro_cohort โž• 182 โž• โ“ โž– P I C O:
      - P: older pxs
      - ๐Ÿ…ธ: hospitalized for bacteriemia multidrug-resistant K. pneumoniae (CR-Kp BSIs)
      - ๐Ÿ…ฒ: NA
      - O: pOC = MM | sOC = MM28, relapse
3. EVIDENCE.

      - Invasive INF from drug-resistan bacteria โ‰ˆ โ†‘ MM โ–ถ๏ธŽ particularly in OLDER PXS
      - Specially w_frailty โž• comorbidities
4. METHODS.
      - ๐—œ๐—ก โž  1st 4 days of H+

      - INTERV โž  FI-Lab score (35 tests) was used: higher score = greater frailty
5. RESULTS.
      a. Hight frailty score at hospitalization for CR-Kp BSIs โžฉ strong predictor: RELAPSE โž• MM

      b. 26% died

      c. Older = NON-survivors (age: 70 ๐Ÿ†š 60):
          i. โ†‘ SEVERE OD (at onset of INF)
          ii. โ†‘ frailty scores (0.66 ๐Ÿ†š 0.33)        
      d. Frailty index โžฉ EXCELLENT PREDICTIVE POWER โ–ถ๏ธŽ MM โž• MM28 โž• relapse

      e. S+E = ihMM โ–ถ๏ธŽ 100% + 76%

      f. Multivariate analysis โ–ถ๏ธŽ โ†‘ 0,10 frailty score ๐ŸŸฐ โ†‘ 2.07 HR
6. RATIONALE.
      a. Px FRAILTY โžฉ โ†‘ antimicrobial RESISTANCE (gram -)
      b. REASONS to wider range of INF by less-virulent BUT more-resistant organisms:
         i. repetitive cycles of INF
         ii. relapse of INF af_TTO

         iii. opportunistic conditions 

      c. Leading to โžฉ โ†‘ ATB exposure

      d. INCORPORATE โ€˜px frailtyโ€™ into medical decision making to:

         i. โ†—๏ธ selection of ATBs (px-specific)

         ii. set appropriate GOALS OF CARE. 

โณ TIME MANAGEMENT
58:42:66

Round: 6 02:16:60 Comments
Round: 5 24:08:93 Wrap-up
Round: 4 15:01:75 Interpretation
Round: 3 04:24:33 Reading + notes
Round: 2 03:31:42 ART select
Round: 1 09:19:59 Past JR

Monday, January 26, 2026 at 17:08:59 in BE

MNVC, PFLC, AHO, AJRM, HIBN, MASP, AAQC

2000 NEJM - ARDS network (wiedemann) [RCT].pdf

Codified by ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ


Glossary:

๐Ÿซ = lungs, ALI = acute lung injury, ARDS = acute respiratory distress syndrome, fdMV = free day of mechanical ventilation, hMM = hospital mortality, PBW = predicted body weight, Vt = tidal volume.


1. ๐™„๐™Œ๐˜พ BS ๐ŸŸฐ 2000, NEJM, USA โž– mc_RCT โž• >800 โž• Mar 1996-1999 โž– P I C O
      - P: ALI + ARDS
      - ๐Ÿ…ธ: Vt 6 โž• Pplat 30
      - ๐Ÿ…ฒ: Vt 12 โž• Pplat 50
      - O: 1st. pOC = hMM | 2nd. pOC = fdMV
2. EVIDENCE.

      a. Traditional Vt = 10 to 15 mL/Kg PBW
      b. May cause stretch-induced ๐Ÿซ injury. 
3. RESULTS..
      a. Trial stopped at 861 pxs

      b. MM โ†“ in ๐Ÿ…ธ โžฉ 31 ๐Ÿ†š 40% (p=0.007)

      c. fdMV โ†‘ in ๐Ÿ…ธ โžฉ 12 ๐Ÿ†š 10 (p=0.007)4. . RATIONALE.  

โณ TIME MANAGEMENT
01:12:27

Round: 4 01:21:73 Wrap-up
Round: 3 33:04:13 โˆ† pressure
Round: 2 00:09:39 Comments + ARDS network
Round: 1 37:52:37 Past JR

Thursday, January 22, 2026 at 17:05:10 in BE

EMQC, AJRM, MASP, AAQC

2025 ICUmmp - Ventilatory Management of the Qx Clpx (ICM).pdf

Codified by ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ (RICH)


Glossary: af_ = after, d_ = during, EIT = electrical impedance tomography, MV = mechanical ventitation, PO = postoperative, Pp = plateau pressure, Vt = tidal volume, _r = risk, โˆ†P = driving pressure


1. MV in PO ICU pxs โžฉ NEEDS a TAILORED APPROACH but after the core principles
2. IMPROVE trial โžฉ ๐Ÿซ protective ventilation + โ†“ Vt + โ†“ PEEP + recruitment โžฉ โˆ‘ โ†“ COMPLICATIONS (intra      & extra ๐Ÿซ) intermediate-high_r pxs (๐Ÿซƒ๐Ÿฝ Qx)

3. Trials โžฉ PEEP or Vt ALONE โ–ถ๏ธŽ do not reduceK ๐Ÿซ complications

      a. PROVILHO & PROBESE โžฉ no benefit in โ†‘ ๐Ÿ†š โ†“ PEEP
      b. Australian trial โžฉ no difference: โ†“ ๐Ÿ†š โ†‘ Vt

      c. Evidence โ–ถ๏ธŽ EFFECTIVENESS d_Qx โžฉ โ†“โˆ†P โž• โ†“Vt ๐ŸŸฐ MOST BENEFICIAL (in low ๐Ÿซ compliance)

      d. โˆ†P = Pplat - PEEP
4. MV in OR-to-ICU transfer

      a. Qx pxs have healthier ๐Ÿซ (than other ICU pxs)

      b. Practices differ (OR ๐Ÿ†š ICU)

      c. Registry data โ–ถ๏ธŽ โ†“Vt in the ICU af_OR โžฉ worse OC (โ†‘RR + โ†‘MV intensity + โ†‘MM28)

5. Weaning

     a. Inhomogeneous ventilation patterns โžฉ measured by EIT โ–ถ๏ธŽ worse OC (DELAYED weaning + โ†‘         

         ๐Ÿซ complications + โ†‘ icuLOS)

[2025 JAMAno - Calorie Restriction, Obesity, and the Aging Process (lorenzini) [comm].pdf]

Codified by ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ (RICH)


Glossary: โ“ = not mentioned, AAs = amino acids, CalRe = caloric restriction, FM = fasting-mimicking, GF = growth factor, IF = intermittent fasting, par = participants, Q = quality, yo = years old.


1. ๐™„๐™Œ๐˜พ BS ๐ŸŸฐ 2025, JAMAno, โ€ฆ โž– commโž• โ€ฆ โž• โ€ฆ โž– P I C O โ€ฆ
2. In humans
      a. Controlled studies are hard, due to human lifespan. 

      b. Correa-Burrows:

         i. DNA methylation โ†’ most accurate to estimate biological age. 

            1. Conflicting interpretations โžฉ โˆ‘ no solidity to recommend them, yet. 

            2. Anyhow, they are the most reliable.

         ii. Key findings: by the 2 epigenetic clocks โ†’ Horvath & GrimAge โ†’ show the EXTENT of effect     

             (when superimposed in the graph)

         iii. Multiple factos โžฉ influence BIOLOGICAL AGE

            1. Obesity (most important)

            2. Genetic variants

            3. Q of diet

            4. Tobacco

            5. Environmental pollutants

         iv. Epigenetic pattern โžฉ has โ†‘ technical variability โ–ถ๏ธŽ makes the graph have ups and downs. 

            1. Despite it, OBESITY is present in both groups (multiple factors โž• epigenetic pattern)

            2. The elevation suggests โžฉ TIME TO CHANGE from โ€œcalRe to obesityโ€

3. We can hypothesize that either ๐Ÿ‘‡๐Ÿฝ MAY ACCELERATE the aging process.

      a. excess calories โžฉ precede + accompany obesity 
      b. obesity itself (modified hormonal balance)

      c. combination of both
4. Gerontologist found the same in bibliographic research โžฉ aging โ†” obesity โ†’ CLEAR OVERLAP.     
5. We should make EDUCATIONAL CAMPAIGNS to address the globesity epidemic. .
      a. Not only hunger
      b. avoid mental + physical STRESS
      c. โ†‘ physical activity 

      d. Modifiy the diet โžฉ โ†‘ prevent obesity โž• โ†“ promote obesity. 
6. ๐™„๐™Œ๐˜พ BS ๐ŸŸฐ 2021, IJGO, UK โž– srMA โž• 2524, 59 IN โž• -Nov 11, 2020 โž– P I C O:.
      - P: hALT pregnant
      - ๐Ÿ…ธ: preg hALT

      - ๐Ÿ…ฒ: preg non-hALT

      - O: pOC = hALT impact on LBW, SGA, SPTB | sOC = magnitude LBW

โณ TIME MANAGEMENT
01:21:28

Round: 8 04:23:30 Comments
Round: 7 34:56:73 Interpretation
Round: 6 04:27:37 Reading + notes
Round: 5 02:30:52 Comments
Round: 4 15:38:87 Wrap-up
Round: 3 09:00:47 Interpretation
Round: 2 04:41:40 Select ART
Round: 1 05:50:19 Past JR

Monday, January 19, 2026 at 17:05:02 in BE

RMF, EMQC, PFLC, AHO, MASP, AAQC

[2025 HEALIO - Lifestyle intervention may lower CKD r for pxs w_type 2 DM.pdf]

Codified by ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ (RICH)


Glossary: โ“ = not mentioned, AAs = amino acids, CalRe = caloric restriction, FM = fasting-mimicking, GF = growth factor, IF = intermittent fasting, par = participants, yo = years old. 


1. ๐™„๐™Œ๐˜พ BS โžฉ Y, J, C โž– T โž• N โž• t โž– P I C O:
2. QUESTION โ–ถ๏ธŽ if aging process is SLOWED by CalRe? โ€œhas been hoveringโ€
3. Correa-Burrows study:.

      a. 2025, JAMAno, CL โž– obs_coh_Santiago Long. Study โž• 205 par โž• โ“ โž– PICO:

         i. P. Healthy volunteeers.

         ii. I: caloric restriction โžฉ from birth to 28-31yo. 

         iii. C: NA

         iv. O: pOC = aging

         v. METHOD: 

            1. Biological age: several methods. 

               a. 2 estimations: DNA methylation โž• methylation-based leukocyte telomere length. 

               b. Cytokines, adipokines, myokines,

               c. GF levels

            2. Assessments are RECOGNIZED as valid. (gerontological community). 

         vi. RESULTS: โ†‘ BMI since (childhood/adolescence) โ†” โ†‘ epigenetic age (compared to chronological                  age) โžฉ 2 - 5 years (depending on OBESITY + EPIGENETIC CLOCK).  

4. 90y โžฉ prolongevity effect of CalRe BEFORE โ€œbiology of agingโ€
5. Over the years โžฉ EXPERIMENTAL TOOL to modulate the models: yeast and Caenorhabditis elegans to ๐ŸŸ, ๐Ÿฆ, ๐Ÿ•, ๐Ÿ„.
6. To date โžฉ many experimental approaches: 
      a. simple CalRe, ketogenic diets, IF, FM diets, time-restricted feeding, protein restriction, and AAs         

          restricted.
      b. All w_CalRe as the common component โ–ถ๏ธŽ โ†‘โ†‘โ†‘ lifespan
      c. IF CalRe is absent, โ†‘LONGEVITY is SMALLER.

7. RATS + MICE:

      a. Brevity of lifespans (1-2y) โžฉ choice in gerontology. 

      b. โ†‘ longevity โ‰ˆ โ†“ weight โžฉ when fed AD LIBITUM (conventional housing approach)

8. PRIMATES: Rhesus monkeys โžฉ the benefit might be on PREVENTION of EXCESS WEIGHT. 

9. In humansโ€ฆ.

โณ TIME MANAGEMENT
01:28:23

Round: 7 08:36:23 Comments
Round: 6 03:08:85 Summary
Round: 5 52:43:43 Interpretation + wrap-up
Round: 4 08:21:51 Reading + notes
Round: 3 06:59:29 ART selection
Round: 2 00:46:85 Comments
Round: 1 07:47:40 Past JR

Thursday, January 15, 2026 at 17:23:13 in BE

JJTM, MJVA, PFLC, MASP, AAQC

Monday, January 12, 2026 at 17:05:39 in BE

EMQC, PFLC, EM, MASP, AAQC

[2025 HEALIO - Lifestyle intervention may lower CKD r for pxs w_type 2 DM.pdf]

Codified by: JQB


Glossary: ACEI = angiotensin-converting enzyme inhibitors, CKD = chronic kidney disease, life_iNT = lifestyle interventions, r = risk, rt = real-time, SGLT2i = Sodium-Glucose Cotransporter-2 Inhibitors, T2DM = type 2 diabetes.


1. ๐™„๐™Œ๐˜พ BS โžฉ Y, J, C โž– T โž• N โž• t โž– P I C O:
2. ๐™„๐™Œ๐˜พ BS ๐ŸŸฐ 2025, ?, IN โž– observational โž• >1k โž• 2020-2024 (1y ๐Ÿ…ธ ) โž– P I C O:
      - P: T2DM + CKD drug-naive
      - ๐Ÿ…ธ: life_INT (diet + exercise + psycho + consultations)
      - โ€œ๐Ÿ…ฒโ€: renoprotective therapy โžฉ hypoglycemiants (95%) + ACEI or SGLT2i or statins
      - O: pOC = r_CKD progression | sOC = BMI + HbA1c + UACR + eGFR
3. EVIDENCE.

      a. Pramod Tripathy โžฉ Freedom from Diabetes, India
      b. Study presented in Dallas โžฉ American College of Lifestyle Medicine annual conference 2025
4. METHODS.
      - ๐—œ๐—ก โž  UACR >73,1 mg/g

      - ๐—˜๐—ซ โž 

      - INTERV โž  4 components of life_INT:

         - DIet โ–ถ๏ธŽ plant-based renal diet (smoothies, juice, water fasting + int. fasting)
         - Exercice โ–ถ๏ธŽ lymphatic circulation + muscle activation + yoga + strength + stamina + flexibility
         - Psychological โ–ถ๏ธŽ group goal + journal writing + meditation
         - Medical consultation โ–ถ๏ธŽ lat tests

      - All 4 in the pocket โžฉ electronic support (mobile app)

      - Initially every week or 2, then every month. 

      - Daily blood sugar โž• rt feedback









5. RESULTS.
      a. Drug-naive pxs โžฉ more benefi
      b. โ†—๏ธ BMI (โ†“:27 to 25), HbA1c (โ†“:8 to 7), UACR (โ†“:73 to 34), eGFR (โ†“:97 to 96).
      c. โ†—๏ธ moderate/high_r to low_r โžฉ CKD (79%/21% ๐Ÿ†š 53%/10%)

      d. pOC โ–ถ๏ธŽ low_r for CKD โžฉ drug naive ๐Ÿ†š renoprotective group (68% ๐Ÿ†š 41%)
6. RATIONALE.
      a. โ€œlegitimate, powerful therapeutic toolโ€ Tripathi
      b. โ€œifestyle intervention as a serious first-line treatment optionโ€ Tripathi
      c. Not as definitive proof.
      d. eGFR finding โžฉ UNIQUE (compared to others) โ–ถ๏ธŽ further research needed.

      e. Drug-naive classified as low_r

      f. โ€œDelaying progression of the diseaseโ€โ€ฆ extract. 

7. LIMITATIONS.

      a. It was not randomized. 

โณ TIME MANAGEMENT
01:22:08

Round: 5 02:26:95 Comments
Round: 4 01:00:06 Interpretation + wrap-up
Round: 3 08:25:93 Reading + notes
Round: 2 05:24:25 ART selection
Round: 1 05:45:12 Past JR

Monday, January 5, 2026 at 17:15:21 in BE

MT, MJVA, JJTM, HIBN, AHRM, MASP, AAQC

[2002 NEJM - Hypocapnia (laffey) [r].pdf]

Codified by ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ (RICH)


Glossary:
CI = critically ill, CPR = cardiopulmonary resuscitation, ICH = intracranial hypertension, PAH = pulmonary-artery hypertension, ๐Ÿ’จ = flow, ๐Ÿซ = lungs


1. PaCO2 = production ๐Ÿ†š elimination




2. Healthy โžฉ narrow physiologic limits
3. Well tolerated โžฉ few effects. .

4. Transient INDUCTION:.
      a. Lifesaving: ICH + neonatal PAH
      b. Damage: longer duration in CI pxs
5. CAUSES
















.
6. Appear in many diseases, usually UNDERESTIMATED. .

7. BELIEF hypocapia is SAFE or PREFERABLE โžฉ โ†‘ hypocapnia (โ†“CO2). .

8. CO2 โ†“ more DUE TO โ†‘ elimination (unusual the โ†“ production) โ–ถ๏ธŽ rate of elimination. So:

      a. MAIIN CAUSE โžฉ hyperventilation that comes from:

         i. MV

         ii. ECMO

      b. Hypocapnic alkalosis 

         i. โ†“ ๐Ÿซ ๐Ÿ’จ 

         ii. E.g. CPR

         iii. Dissociation: VENOUS ๐Ÿ†š ARTERIAL blood (โ†“ ๐Ÿ’จ โž• N ventilation):

             1. V: โ†‘CO2 + โ†“pH

             2. A: โ†“CO2 + โ†‘pH

             3. This is PSEUDORESPIRATORY ALKALOSIS.

โณ TIME MANAGEMENT
01:12:51

Round: 5 01:23:70 Comments
Round: 4 16:17:05 Wrap-up
Round: 3 31:43:30 Reading + notes
Round: 2 04:46:28 Selection
Round: 1 18:40:70 +30 min Past JR

Monday, March 30, 2026 at 18:34:27 in BE

EQO, MASP, AAQC

2026 NEJMc - Reassessing the Role of Fever in the Duke Endocarditis Criteria (Clin Infect Dis).pdf

Codified by YAPG


Glossary: DX = diagnosis, E = specificity, IE = infective endocarditis, ISCVID = International Society for Cardiovascular Infectious Diseases, S = sensitivity

1. ๐™„๐™Œ๐˜พ - S โžฉ Y, J, C โž– T โž• N โž• t โž– P I C O:


2. ๐™„๐™Œ๐˜พ - S ๐ŸŸฐ 2025, CID, CH โž– retro โž• 3700 โž• 2014-2024 โž– P I C O:

       - ๐Ÿ…ฟ: pxs w_suspected IE

       - ๐Ÿ…ธ: modified criteria (wo_fever)

       - ๐Ÿ…ฒ: 2023 Duke-ISCVID criteria 

       - ๐Ÿ…พ: pOC = S + E | sOC = possible IE cases โž• erroneus non-IE


3. EVIDENCE.

       a. Duke criteria = > and < criteria

       b. Revised multiple times to โ†—๏ธ accuracy. 

       c. Last revision 2023 (ISCVID)

       d. Fever has remained โ–ถ๏ธŽ would criteria โ†—๏ธ wo_FEVER โ“


4. METHODS.

   - INTERV โž 

      > Classified as: DEFINITE | POSSIBLE | NO IE

      > 1st โ–ถ๏ธŽ 2023 Duke-ISCVID criteria

      > 2nd โ–ถ๏ธŽ modified criteria


5. RESULTS.

      a. 35% confirmed IE DX

      b. Fever: = prevalent

          i. with confirmed IE

          ii. without confirmed IE

      c. Modified criteria performed BETTER:

          i.  โ†—๏ธ S โžฉ 77% ๐Ÿ†š 74%

          ii. โ†—๏ธ E โžฉ 80% ๐Ÿ†š 49%

          iii. โ†“ possible IE โžฉ 17% ๐Ÿ†š 39%

          iv. โ†“ โ†“ non-IE cases  โžฉ 0.4%


6. RATIONALE.

      a. Modified criteria halved the โ€œpossible IEโ€ category. 

      b. โ†“ extensive WORKUP 

      c.  If confirmed (additional studies), โ†—๏ธ ability to DISCRMINATE:

           i.  true IE

           ii. Alternative DXs

โณ TIME MANAGEMENT
40:26:43

Round: 5   00:53:29  Comments

Round: 4   21:06:71  Wrap-up

Round: 3   11:39:59  Interpretation

Round: 2   03:03:12  Reading + notes

Round: 1   03:43:71  ART selection

April, 2026

2025 NEJMc - Real-World Data on Helicobacter pylori TTO Success (Clin Gastroenterol Hepatol).pdf

Codified by YAPG


Glossary: ATB = antibiotic, HP = Helicobacter pylori, INF = infection, OCAM = PPI (omeprazol, etc.) โž• clarithro โž• amoxi โž• metro, PBMT-14 = PPI, bismuth, metronidazole, and tetracycline, PPI = proton-pump inhibitor

1. ๐™„๐™Œ๐˜พ BS โžฉ Y, J, C โž– T โž• N โž• t โž– P I C O:


2. ๐™„๐™Œ๐˜พ BS ๐ŸŸฐ 2025, CG&H, USA โž– OBS_cohort_real-world โž• 25k โž• 2y (2000-2022) โž– P I C O:

       - ๐Ÿ…ฟ: pxs w_HP

       - ๐Ÿ…ธ: comparison of regimens

       - ๐Ÿ…ฒ: NA

       - ๐Ÿ…พ: pOC = efficacy | sOC = frequency of use


3. EVIDENCE.

       a. TTO is complicated by 2 problems:

            i. โ†‘ rates of community ATB resistance

            ii. No data on resistance patterns for HP

       b. GL โžฉ 2017, reviewed 2024 โžฉ PBMT-14

       c. Other regimens are still used


4. METHODS.

      -  Completed DIETARY INTAKE ASSESSMENTS โžฉ SELF-REPORTED (2-4y)

      -  Levels of intake โžฉ subgroups

      - 11k w_dementia


5. RESULTS.

      a. 17 โ‰  regimens for INITIAL INF, the 3 most EFFECTIVE:

           i.   OCAM โ–ถ๏ธŽ 90%

           ii.  PBMT-14 โ–ถ๏ธŽ 88%

           iii.  OCA โ–ถ๏ธŽ 87%

      b. Stable EFFICACY of the 3 regimens, through 20y of study.

      c. Salvage regimens โžฉ LESS EFFECTIVE

          i.   Particularly, IF duplicated previous regimens.

          ii.  PBMT-14 = best โ–ถ๏ธŽ 69%

      d. Prior use of MACROLIDES โŒ„ METRONIDAZOL โžฉ >3y โ–ถ๏ธŽ โ†“ SUCESS RATES using clarithromycin โŒ„ metronidazole

     

6. RATIONALE.

      a. Amoxi regimens still work well, despite not 1st line TTO option.

      b. Caution โžฉ study done in Nothern California โž• applies to other communities ๐Ÿค” โ“ 

      c. MAIN LESSION โžฉ carefully query pxs (PREVIOUS ATB use) before constructing a regimen.

      d. Multiple drug exposure โžฉ perform HP susceptibility testing.

        

โณ TIME MANAGEMENT
01:03:09

Round: 7   01:45:77   Comments

Round: 6   27:52:42   Wrap-up

Round: 5   17:56:59   Interpretation

Round: 4   04:09:25   Reading + notes

Round: 3   04:28:50   ART selection

Round: 2   01:07:46   Comments

Round: 1   05:49:28   Past JR

Thursday, April 9, 2026 at 18:15:02 in BE

AS, MASP, HIBN, AAQC

2026 NEJMc - Can Coffee and Tea Prevent Dementia (JAMA).pdf

Codified by YAPG


Glossary: HCP = healthcare providers, Q = quartiles

1. ๐™„๐™Œ๐˜พ BS โžฉ Y, J, C โž– T โž• N โž• t โž– P I C O:


2. ๐™„๐™Œ๐˜พ BS ๐ŸŸฐ 2026, JAMA, USA โž– obs, long, 2 cohorts โž• 130k HCP โž• 40y โž– P I C O:

       - ๐Ÿ…ฟ: HCP

       - ๐Ÿ…ธ: caffeinated coffee, decaffeinated coffee, tea

       - ๐Ÿ…ฒ: NA

       - ๐Ÿ…พ: pOC = dementia prevention


3. EVIDENCE.

       a. Short-term cognitive effect โžฉ โ†—๏ธ focus + โ†—๏ธ alertness

       b. OBS โžฉ possible long-term benefit โ–ถ๏ธŽ โ†“r DEMENTIA


4. METHODS.

      -  Completed DIETARY INTAKE ASSESSMENTS โžฉ SELF-REPORTED (2-4y)

      -  Levels of intake โžฉ subgroups

      - 11k w_dementia


5. RESULTS.

      a. โ†“ 2 Q โžฉ median caffeinated โ˜•๏ธ = <1/2 cup daily

      b. โ†‘ 2 Q โžฉ median caffeinated โ˜•๏ธ:

          i. 2,5-4,5 cups daily โ™€

          ii. 1 - 2,5 cups daily โ™‚๏ธŽ

      c. Social โž• clinical variables ADJUSTED:

          i.  Caffeinated โ˜•๏ธ โ–ถ๏ธŽ โ€œโ†‘2Qโ€ (โ†“r dementia) ๐Ÿ†š โ€œโ†“2Qโ€

      d. Tea โ–ถ๏ธŽ โ†“r dementia EVEN w_only 0.07 โ˜•๏ธ daily. 

      e.  Decaffeinated NOT ASSOCIATED w_โ†“r dementia. 


6. RATIONALE.

      a. caution

      b. Self-reported intake + residual confounding

      c.  Caffeine might be NEUROPROTECTIVE.

        

Monday, April 6, 2026 at 18:10:24 in BE

MG, EQO, AHO, MASP, HIBN, AAQC

โณ TIME MANAGEMENT
42:16:57

Round: 6   02:09:52  Comments

Round: 5   15:54:71  Wrap-up

Round: 4   09:28:65  Interpretation

Round: 3   03:33:02  Reading + notes

Round: 2   04:28:54  ART selection

Round: 1   06:42:11  Past JR

โณ TIME MANAGEMENT
28:12:44

Round: 7   00:52:82  Comments

Round: 6   10:34:69  Wrap-up

Round: 5   06:22:19  Interpretation

Round: 4   00:05:81  Interpretation

Round: 3   03:10:71  Reading + notes

Round: 2   02:48:35  ART selection

Round: 1   04:17:84  Past JR 

Thursday, April 16, 2026 at 18:10:02 in BE

LH, MASP, AAQC

2026 NEJMc - A New Noninvasive Testing Strategy P. jirovecii pneumonia. (Open Forum Infect Dis)

Codified by ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ (YAPG)


Glossary: BAL-PCR = bronchoalveolar lavage PCR testing, DX = diagnosis, JPJ = Pneumocystis jirovecii, โ†“ supression = immunosupression


1. ๐™„๐™Œ๐˜พ BS โžฉ Y, J, C โž– T โž• N โž• t โž– P I C O:


2. ๐™„๐™Œ๐˜พ BS ๐ŸŸฐ 2026, OFID, ? โž– retro, single center โž• 114 โž• ? โž– P I C O:

       - ๐Ÿ…ฟ: pxs w_suspected JPJ + non-HIV โ†“ supression

       - ๐Ÿ…ธ: รŸ-D-glucan, oral wash PCR or both

       - ๐Ÿ…ฒ: bronchoalveolar lavage PCR testing

       - ๐Ÿ…พ: pOC = DX


3. EVIDENCE.

       a. PJP DX wo_BAL is challenging due to the limitations of tests of:

                i.  sputum

                ii. serum

       b. Combining both NON-INVASIVE to โ†—๏ธ DX accuracy โžฉ MAKES SENSE


4. METHODS.

      a.  Oral wash PCR โžฉ vigorous gargling of saline for 30s


5. RESULTS.

      a. PJP โžฉ 15/114 pxs โ–ถ๏ธŽ symptoms + imaging + BAL

      b. รŸ-D-glucan:

          i.  โŠ• 14/15 PJP cases (S 93%)

          ii. false โŠ• 13/99 cases wo_PJP.

      c. Oral wash PCR:

          i. 47 pxs
          ii. 11 DX w_PJP
          iii. โŠ• 11 PJP cases
          iv. false โŠ• 4/36 nonPJP

      d. Both:

          i. 1. โŠ• 10pxs, all w_PJP
          ii. both โŠ– โžฉ PJP ruled out

  

6. RATIONALE.

      a. This combination appears DECISIVE

      b. Px selection would be an issue โžฉ only a subset had โ€œoral wash PCRโ€

      c.  Check w_your local laboratory for the tests available.


7. SOURCE: Falcรณ-Roget A, et al. Combined serum (1,3)-ฮฒ-D-glucan and oral wash PCR as a noninvasive diagnostic strategy for early detection of Pneumocystis jirovecii pneumonia: An observational retrospective study. Open Forum Infect Dis 2026 Feb; 13:ofag033.

DOI: 10.1093/ofid/ofag033.     

โณ TIME MANAGEMENT
46:34:63

Round: 7   02:03:28  Comments

Round: 6   23:07:23  Wrap-up

Round: 5   08:38:45  Interpretation

Round: 4   02:57:45  REading + notes

Round: 3   07:39:86  ART selection

Round: 2   00:42:01  Comments

Round: 1   01:26:32  Past JR (+5min)

2025 NEJMc - Phosphatidylethanol Can Inform the DX SLD. (J Hepatol + Lancet GH).pdf

Codified by YAPG


Glossary: -ol = alcohol, AF = atrial fibrillation, ALD = alcohol-associated liver disease, ARDS = acute respiratory distress syndrome, CA = cancer, GE = gastroenterology, JH = Journal of Hepatology, MASLD = metabolic-associated steatotic liver disease, MetALD = metabolic and alcohol-associated liver disease, SLD = steatotic liver disease

1. ๐™„๐™Œ๐˜พ BS โžฉ Y, J, C โž– T โž• N โž• t โž– P I C O:


2. ๐™„๐™Œ๐˜พ BS ๐ŸŸฐ 2025, JH, USA โž– obs, cross-sec โž• ~400 โž• ? โž– P I C O:

       - ๐Ÿ…ฟ: overweight/obesity + SLD

       - ๐Ÿ…ธ: phosphatidylethanol

       - ๐Ÿ…ฒ: NA

       - ๐Ÿ…พ: pOC = DX reclassification


3. ๐™„๐™Œ๐˜พ BS ๐ŸŸฐ 2025, LANCET GH, DK โž– ฮฉ pros, cohort โž• ~2000 โž• ? โž– P I C O:

        - ๐Ÿ…ฟ: -ol consumption โŒ„ metabolic DYSF wo_โ†‘โ†‘โ†‘ -ol use

        - ๐Ÿ…ธ: phosphatidylethanol

        - ๐Ÿ…ฒ: NA

        - ๐Ÿ…พ: pOC = DX reclassification


4. EVIDENCE.

       a. MASLD ๐Ÿ†š ALD depends โžฉ ACCURACY โ–ถ๏ธŽ self-reported alcohol use

       b. Phosphatidylethanol โžฉ biomarker of recent -ol use (1-4 weeks)


5. METHODS.

      -  Correspondence: ๐Ÿ…ธ ๐Ÿ†š self-reported -ol intake

      -  Then assessed to reclassify the DX.

      - Steatotic liver disease was categorized (in both studies) on either:

           >  MASLD

           >  ALD

           >  MetALD

      - Cutoffs:

           >  light ๐ŸŸฐ ๐Ÿ…ธ <25 ng/mL

           >  moderate ๐ŸŸฐ ๐Ÿ…ธ 25-200 ng/mL

           >  heavy ๐ŸŸฐ ๐Ÿ…ธ >200 ng/mL


6. RESULTS.

      a. US study โ–ถ๏ธŽ MASLD โžฉ 95% โ†’ 16%:

           i.  13% MetALD

           ii.  3% ALD

      b. DK study โ–ถ๏ธŽ MASLD โžฉ 70% โ†’ 39%:

          i.  31% MetALD

          ii. 8% ALD

          iii. Reclassification w_ALD โŒ„ MetALD โžฉ rare (<1%)

    

7. RATIONALE.

      a. ๐Ÿ…ธ helps:

          i.  DX + TTO

          ii.  classifying SLD

      b. There is room for error โžฉ due to 1-4-week window

      c.  Never use ๐Ÿ…ธ IN ISOLATION โ–ถ๏ธŽ ALWAYS w_other factors (careful history)


8. SOURCES.

       a.  Tavaglione F, et al. Clinical utility of phosphatidylethanol to detect underreported alcohol use and enhance steatotic liver disease subclassification. J Hepatol 2025 Jun
13; [e-pub]. DOI: 10.1016/j.jhep.2025.05.030.

       b.  Torp N, et al. Phosphatidylethanol and self-reported alcohol intake to subclassify in individuals at risk of steatotic liver disease: An analysis of data from a prospective
cohort study. Lancet Gastroenterol Hepatol 2025 Sep 10; [e-pub]. DOI: 10.1016/S2468-1253(25)00187-6.

        

Monday, April 13, 2026 at 18:10:09 in BE

MG, AS, AHO, MASP, HIBN, AAQC

Thursday, April 30, 2026 at 18:00:36 in BE

TGA, HIBN, MASP, AAQC

2025 NEJMc - Ceftriaxone for Patients Hospitalized w_Pneumonia, One Gram or Two (J Antimicrob Chemother).pdf

Codified by ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ (TGA)


Glossary: CAP = community acquired pneumonia



1. ๐™„๐™Œ๐˜พ BS โžฉ Y, J, C โž– T โž• N โž• t โž– P I C O:


2. ๐™„๐™Œ๐˜พ BS ๐ŸŸฐ 2025, JAC, JP โž– retro_cohor โž• 470k โž• 7d โž– P I C O:

- ๐Ÿ…ฟ: CAP
- ๐Ÿ…ธ: 2g ceftriaxone
- ๐Ÿ…ฒ: 1g ceftriaxone
- ๐Ÿ…พ: pOC = MM30


3. EVIDENCE

a. 2019 GL โžฉ ATS + IDSA: 1-2g ceftriaxone for H+ pxs w_CAP, wo_precise advice about DOSING


4. METHODS.

- 55% โ™‚๏ธŽ
- weight ~50Kg
- 63% 2g = ๐Ÿ…ธ
- 37% 1g = ๐Ÿ…ฒ


5. RESULTS

a. MM30 = NO DIFFERENCES = 4,5% overall
b. s_CAP 2g โžฉ โ†“MM30 (17% ๐Ÿ†š 20%)


6. RATIONALE.

a. Cannot be GENERALIZABLE to Western natios (e.g. US)

i. 40% are obese
ii. Few <50Kg

b. Georgeโ€™s hospital โžฉ 2g q12h for nonmeningeal INF (โ‰ฅ120Kg)
c. Georgeโ€™s practice โžฉ 2g daily in non-obese w_CAP. (regardless of severity)
d. Rather than BASAL GANGLIA, PD is likely a whole-brain action network.


7. SOURCE: Taniguchi J, Aso S, Matsui H, Fushimi K, Yasunaga H. Outcomes of ceftriaxone 2โ€…g versus 1โ€…g daily in hospitalized patients with pneumonia: a nationwide retrospective cohort study. J Antimicrob Chemother. 2025;80(8):2194-2202. doi:10.1093/jac/dkaf189

โณ TIME MANAGEMENT
33:37:12

Round: 6 00:36:43 Comments
Round: 5 14:34:96 Wrap-up
Round: 4 05:23:99 Interpretation
Round: 3 03:29:88 Reading + notes
Round: 2 05:03:64 ART selectionRound: 1 04:28:20 Past JR

Thursday, April 27, 2026 at 18:00:36 in BE

LH, TGA, MASP, AAQC

2025 CC - Reconsidering the urea-to-creatinine ratio as a signal of muscle catabolism in patients with cirrhosis (Oussalah) (ma).pdf

Codified by ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ (TGA)


Glossary: AA = aminoacid, ACLD = acute on CLD, AUR = ammonia to urea ratio, CI = critically ill, CLD = chronic liver disease, CREA = creatinine, giBLEED = gastrointestinal bleeding, HRS = hepatorenal syndrome, imp = impaired, ma = matters arising, MECHS = mechanisms, N = nitrogen, R = research = original, sr = systematic review, UCR = urea-to-creatinine ratio, โˆ‘ = so = therefore



1. UREA issues

a. Portal hypertension โž• hepatocelualr DYS โ–ถ๏ธŽ alter N METABOLISM (โ†“UREAGENESIS efficiency)
b. Ammonia (intestines) โ†’ urea (water-soluble, excreted in the urine) โ–ถ๏ธŽ โ—ธ

i. Both are indicators of the same pathway
ii. They reflect urea-cycle efficiency

c. Cirrhosis perturbs this pathway:

i. โ†‘ vascular R โž• portosystemic shunts ๐ŸŸฐ imp โ—ธ clearance โžฉ โ†‘ ammonia (systemically)
ii. imp hepatocellular function ๐ŸŸฐ โ†“ urea-cycle โžฉ โ†“ urea (for a given N load)

d. Combined effect โ–ถ๏ธŽ โ†‘ ammonia โž• โ†“ urea
e. CLINICALLY โ–ถ๏ธŽ pxs have โ†“ โŒ„ โ€œnormalโ€ UCR โžฉ limited โ—ธ capacity to convert ammonia to urea.
f. AUR > 1,53 mg/g โ†” portal hypertension

i. Complications can modify it.
ii. giBLEED (e.g. variceal) โžฉ ยซโ†‘N load โ†’ portal โญ•๏ธยป due to ๐Ÿซƒ๐ŸฝHb โ€œdigestion + reabsorptionโ€
iii. N input โ–ถ๏ธŽ โ†‘ ureagenesis + โ†‘ urea (not โ†” to ๐Ÿ’ช๐Ÿฝ catabolism)
iv. โ†‘UCR ๐ŸŸฐ exogenous N influx + prerenal dynamics (not AA use โŒ„ protein breakdown)


2. INCLUSION of these pxs in pooled ๐Ÿค“ wo_ stratification = conflating distinct MECHS + limits generalizability.


3. SOLUTIONS

a. Studies should:

i. PROSPECTIVELY stratify

1. cirrhosis
2. portal hypertension

ii. UCR reported

b. โ™พ๏ธ assessment in cirrhosis โžฉ internationally validated approaches OVER CREA-only:

i. cystating C-based equations
ii. measured CREA clearance

c. In NUTRITIONAL ๐Ÿ…ธ

i. plasma ammonia
ii. plama N balance
iii. Both **distinguish** imp ureageneis **from** protein intake.
iv. In cirrhosis โžฉ โ†‘ UCR + โ†‘ ammonia = urea-cycle oveload (not excessive catabolism) โ–ถ๏ธŽ โˆ‘: ยซammonia โ†“ strategiesยป ARE THE PRIORITY (OVER reflective protein restriction)
v. Avoid protein RESTRICTION in โ—ธ encephalopathy (GL) โžฉ 1,2 - 1,5 g/Kg/day to **preserve** N balance + **prevent** sarcopenia

d. giBLEED โŒ„ preโ™พ๏ธ states

i. UCR should prompt TARGETED DX evaluation.
ii. Do not interpret as a STAND-ALONE SIGNAL of ๐Ÿ’ช๐Ÿฝ proteolysis


4. SOURCE: Oussalah A, Haghnejad V, Audouy A, et al. Reconsidering the urea-to-creatinine ratio as a signal of muscle catabolism in patients with cirrhosis. Crit Care. 2025;29(1):428. Published 2025 Oct 8. doi:10.1186/s13054-025-05703-1.

โณ TIME MANAGEMENT
01:20:58

Round: 3 00:36:85 Comments.
Round: 2 49:20:47 Abbreviations update
Round: 1 31:01:59 Past JR recap 

2025 CC - Reconsidering the urea-to-creatinine ratio as a signal of muscle catabolism in patients with cirrhosis (Oussalah) (ma).pdf

Codified by ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ (TGA)

 

Glossary: AA = aminoacid, ACLD = acute on CLD, AUR = ammonia to urea ratio, CI = critically ill, CLD = chronic liver disease, CREA = creatinine, giBLEED = gastrointestinal bleeding, HRS = hepatorenal syndrome, imp = impaired, ma = matters arising, MECHS = mechanisms, N = nitrogen, R = research = original, sr = systematic review, UCR = urea-to-creatinine ratio, โˆ‘ = so = therefore



1. ๐™„๐™Œ๐˜พ BS โžฉ Y, J, C โž– T โž• N โž• t โž– P I C O:


2. ma โ–ถ๏ธŽ 2025, CC, FR โž– ma โž• Paulus et al. (MA, UTC CC 2025) โž• โ“


3. R โ–ถ๏ธŽ 2025, CC, NL โž– srMA โž• 47/1450 โž• Sep 3, 2024 โž– P I C O:

- ๐Ÿ…ฟ: CI pxs
- ๐Ÿ…ธ: UCR value (at least 1)
- ๐Ÿ…ฒ: NA
- ๐Ÿ…พ: pOC = protein catabolism


4. CAUTION. Cirrhosis โž• portal hypertension:

a. This type of admissions are frequent โžฉ 2-4,5% (national cohorts + sr)
b. In ICU ():

i. 20% = cirrhosis โžฉ decompensation + ACLD + variceal hemorrhages + HRS
ii. 1/3 = CLD (high-dependency)

c. Both components of UCR are influenced by OTHER processes:

i. ureagenesis
ii. sarcopenia

d. IF this subgroup is taken in the pooled ๐Ÿค“ โ†’ BIAS (inflatingโŒ„attenuating: โ†” ).


5. CREA issues

a. Cirrhosis โžฉ ๐Ÿ’ช๐Ÿฝ homeostasis
b. Sarcopenia:

i. 14-55% in cirrhosis
ii. โ†”: โ†“ skeletal ๐Ÿ’ช๐Ÿฝ

c. CLD MECHS โžฉ โ†“ CREA (not โ†‘GFR)

i. imp โ—ธ creatine synthesis
ii. โ†‘ fractional tubular secretion
iii. underestimation in โ†‘bilirrubinemia
iv. Combined effect โžฉ โ†“shift in CREA for any GFR
v. โˆ‘: โ†‘UCR in cirrhosis REFLECTS โ†“CREA production (not โ†‘ protein catabolism)


6. UREA issues.

a. Portal hypertension โž• hepatocelualr DYS โ–ถ๏ธŽ alter N METABOLISM (โ†“UREAGENESIS efficiency)
b. Ammonia (intestines) โ†’ urea (water-soluble, excreted in the urine) โ–ถ๏ธŽ โ—ธbrain action network.

i. Both are indicators of the same pathway
ii. They reflect urea-cycle efficiency

c. Cirrhosis perturbs this pathway:

i. โ†‘ vascular R โž• portosystemic shunts ๐ŸŸฐ imp โ—ธ clearance โžฉ โ†‘ ammonia (systemically)
ii. imp hepatocellular function ๐ŸŸฐ โ†“ urea-cycle โžฉ โ†“ urea (for a given N load)

d. Combined effect โ–ถ๏ธŽ โ†‘ ammonia โž• โ†“ urea
e. CLINICALLY โ–ถ๏ธŽ pxs have โ†“ โŒ„ โ€œnormalโ€ UCR โžฉ limited โ—ธ capacity to convert ammonia to urea.
f. AUR > 1,53 mg/g โ†” portal hypertension

i. Complications can modify it.
ii. giBLEED (e.g. variceal) โžฉ ยซโ†‘N load โ†’ portal โญ•๏ธยป due to ๐Ÿซƒ๐ŸฝHb โ€œdigestion + reabsorptionโ€
iii. N input โ–ถ๏ธŽ โ†‘ ureagenesis + โ†‘ urea (not โ†” to ๐Ÿ’ช๐Ÿฝ catabolism)
iv. โ†‘UCR ๐ŸŸฐ exogenous N influx + prerenal dynamics (not AA use โŒ„ protein breakdown)


7. INCLUSION of these pxs in pooled ๐Ÿค“ wo_ stratification = conflating distinct MECHS + limits generalizability.


8. SOLUTIONS 

a. Studies should:

i. PROSPECTIVELY stratify

1. cirrhosis
2. portal hypertension

ii. UCR reported

b. โ™พ๏ธ assessment in cirrhosis โžฉ internationally validated approaches OVER CREA-only:

i. cystating C-based equations
ii. measured CREA clearance

c. In NUTRITIONAL ๐Ÿ…ธ

i. plasma ammonia
ii. plama N balance
iii. Both **distinguish** imp ureageneis **from** protein intake.
iv. In cirrhosis โžฉ โ†‘ UCR + โ†‘ ammonia = urea-cycle oveload (not excessive catabolism) โ–ถ๏ธŽ โˆ‘: ยซammonia โ†“ strategiesยป ARE THE PRIORITY (OVER reflective protein restriction)
v. Avoid protein RESTRICTION in โ—ธ encephalopathy (GL) โžฉ 1,2 - 1,5 g/Kg/day to preserve N balance + prevent sarcopenia

d. giBLEED โŒ„ preโ™พ๏ธ states

i. UCR should prompt TARGETED DX evaluation.
ii. Do not interpret as a STAND-ALONE SIGNAL of ๐Ÿ’ช๐Ÿฝ proteolysis


9. SOURCE: Oussalah A, Haghnejad V, Audouy A, et al. Reconsidering the urea-to-creatinine ratio as a signal of muscle catabolism in patients with cirrhosis. Crit Care. 2025;29(1):428. Published 2025 Oct 8. doi:10.1186/s13054-025-05703-1.

Thursday, April 23, 2026 at 18:10:36 in BE

LH, TGA, MASP, YAPG,HIBN,  AAQC

โณ TIME MANAGEMENT
01:20:58

Round: 3 00:36:85 Comments.
Round: 2 49:20:47 Abbreviations updateRound: 1 31:01:59 Past JR recap 

2025 NEJMc - Is Exercise a Brain-Changer Parkinson Dis (Neurology)

Codified by YAPG


Glossary:  l-t = longer-term, PA = physical activity, PD = Parkinsonโ€™s disease, TTO = treatment(s)

1.  ๐™„๐™Œ๐˜พ BS โžฉ Y, J, C โž– T โž• N โž• t โž– P I C O:


2.  ๐™„๐™Œ๐˜พ BS ๐ŸŸฐ 2025, NEUROLOGY, USA โž– long, obs โž• 120 โž• 4y โž– P I C O:

       - ๐Ÿ…ฟ: very early PD, older adults

       - ๐Ÿ…ธ:exercise โž• MRI

       - ๐Ÿ…ฒ: NA

       - ๐Ÿ…พ:  pOC = correlation w_๐Ÿง  changes


3. EVIDENCE.

       a. Exercise is GOOD for:

            i. general health

            ii. symptomatic effect.

       b. Changes in STRUCTURE โŒ„ COGNITIVE health โ“


4. METHODS.

        - regular PAโ€ โ†” โ€œneurodegeneration + cognitive โ†“โ€
        - Databse: Parkinsonโ€™s Progression Markers Initiative.
        - PA โžฉ Physical Activity Scale for the Elderly
        - MRI โžฉ at 2 points

          

5. RESULTS.

      a. โ€œโ†‘ average regular PAโ€ โ‰ˆ SLOWER cortical thinning (in multiple ๐Ÿง  regions)

      b. โ€œโ†‘ regular PAโ€ โ‰ˆ SLOWER volume loss:

          i.  Hippocampus

          ii.  Amygdala

      c. โ†‘ memory + attention by slower โ†“ in: 

           i. TEMPOROPARIETAL CORTICAL thickness

           ii. Hippocampal volume

    

6. RATIONALE.

      a. Exercise โ‰ˆ < ๐Ÿง  thinning.

      b. CAUTIOUS โžฉ overinterpreting this study:

           i.  too selective + small

           ii.  very early PD

       c.  CAUTIOUS to infer โžฉ EXERCISE โ‰ˆ w_:

            i.  slower rate of neurodegeneration

            ii.  โ†—๏ธ l-t cognitive functions

       d.  Current TTO might MODULATE this network.

       e.  Rather than BASAL GANGLIA, PD is likely a whole-brain action network.

       f.  SCAN dysfunction ๐ŸŸฐ core circuit abnormality.

       g.  If validated, it will influence:

           i. the neuromodulation

           ii. how we think about IMAGING BIOMARKERS โžฉ personalizad therapy.

       h.  Primary care doctors + neurologist SHOULD precribe exercise for PD pxs.


7. SOURCE: Diaz-Galvan P, et al. Association of physical exercise with structural brain changesand cognitive decline in patients with early Parkinson disease. Neurology 2025 Sep9; 105:e21393210.1212/WNL.0000000000213932.40768688

Monday, April 20, 2026 at 18:05:06 in BE

AHO, TGA, MASP, YAPG, AAQC

2026 NEJMc - Reconceiving Parkinsonโ€™s Disease as Whole-Brain Action Netw. Disord. (Nature).pdf

Codified by YAPG


Glossary: somato-cognitive action network, PD = Parkinsonโ€™s disease, TTO = treatment(s), US = ultrasound, ๐Ÿง  = brain

1. ๐™„๐™Œ๐˜พ BS โžฉ Y, J, C โž– T โž• N โž• t โž– P I C O:


2. ๐™„๐™Œ๐˜พ BS ๐ŸŸฐ 2026, NATURE, โ“ โž– obs โž• 863 โž• โ“ โž– P I C O:

       - ๐Ÿ…ฟ: PD pxs

       - ๐Ÿ…ธ: imaging: SCAN

       - ๐Ÿ…ฒ: NA

       - ๐Ÿ…พ: pOC = impairment


3. EVIDENCE.

       a. Dopaminergic degeneration: basal ganglia โžฉ motor โ†” nonmotor PATHWAYS

       b. Explains TREMOR โž• RIGIDITY

       c. Cognitive โž• motivational โž• autonomic FEATURES โžฉ NOT EXPLAINED

       d. Is a broader, integrated ๐Ÿง  network the problem?


4. METHODS.

      -  SCAN ๐ŸŸฐ recently described. Network linking the control of:

           >  movement
           >  cognition
           >  motivation
           >  autonomic

    

5. RESULTS.

      a. PD โ–ถ๏ธŽ โ†‘ connectivity:

           i.  SCAN โ†” subcortical structures

           ii.  โ†‘ โ†‘ โ†‘ hyperconnectivity โ‰ˆ WORSE motor โž• cognitive impairment.

      b. Effective TTOs, ALL โ†“ SCAN:

          i.  levodopa

          ii. Deep brain stimulation

          iii. transcranial magnetic stimulation

          iv. focused US

      c. โ†‘ normalization of CONNECTIVITY โ‰ˆ โ†‘ clinical โ†—๏ธ 

      d. Targeting SCAN โ–ถ๏ธŽ โ†—๏ธ TTO EFFECTIVENESS for:

           i. transcranial magnetic stimulation

           ii. focused US

    

6. RATIONALE.

      a. SCAN might underlie PD

      b. Current TTO might MODULATE this network.

      c.  Rather than BASAL GANGLIA, PD is likely a whole-brain action network.

      d.  SCAN dysfunction ๐ŸŸฐ core circuit abnormality. 

      e.  If validated, it will influence:

           i. the neuromodulation

           ii. how we think about IMAGING BIOMARKERS โžฉ personalized therapy.


7. SOURCE: Ren J, et al. Parkinsonโ€™s disease as a somato-cognitive action network disorder.Nature 2026 Feb 4; [e-pub]. DOI: 10.1038/s41586-025-10059-1. 

โณ TIME MANAGEMENT
01:40:51

Round: 13   27:59:21   Comments

Round: 12  16:49:89    Wrap-up 2

Round: 11   00:42:85   Wrap-up 1

Round: 10   06:03:38   Interpretation

Round: 9     02:26:33   Reading + notes

Round: 8     02:16:18   Comments

Round: 7    18:14:10    Wrap-up

Round: 6     09:51:46   Interpretation
Round: 5     02:28:02   Reading + notes

Round: 4     04:17:67   ART Selection

Round: 3     00:32:04   Comments

Round: 2     08:37:45    Last JR

Round: 1     00:33:00    Opening

2026 CC - Phenotype, subphenotype, and endotype in Sโ€ข and ARDS, a new layer of heterogeneity (Zhao) (corr).pdf

Codified by ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ (TGA)


Glossary: I2 = heterogeneity, PD = Parkinsonโ€™s disease, POV = point of view, PSE = phenotype, subphenotype, endotype, Sโ€ข = sepsis, SCAN = somato-cognitive action network, SOC = standard of care, TTO = treatment(s), US = ultrasound



1. ๐™„๐™Œ๐˜พ BS โžฉ Y, J, C โž– T โž• N โž• t โž– P I C O:


2. ๐™„๐™Œ๐˜พ BS ๐ŸŸฐ 2026, CC, CH โž– corr โž• NA โž• NA โž– P I C O:

- ๐Ÿ…ฟ: CIpxs
- ๐Ÿ…ธ: USG โ†’ lower limb muscle
- ๐Ÿ…ฒ: NA
- ๐Ÿ…พ: pOC = utility


3. ARDS = syndrome โžฉ masks BIOLOGICAL I2 ๐ŸŸฐ primary obstacle to TTO


4. Studies identify PSE โžฉ but THE EFFORTS create new layer of I2

a. IMPEDE rather than enable discarding the โ€œsyndromeโ€ label.
b. despite inventive cogitation + methodological sophistication


5. PURPOSE

a. Deconstruct heterogeneous clinical syndromes โžฉ biological homogeneous + clinical TTO subgroups
b. Facilitate PRECISION medicalโž• optimize INDIVDUAL TTO


6. CLASSIFICATIONS

a. Derive from multiple analytical approaches:

i. high-dimensional clinical variables
ii. multi-omics data โžฉ integrated analysis of multiple molecular layers (e.g., genomics, transcriptomics, proteomics, metabolomics) to obtain a holistic view of biological systems.
iii. AI-driven deep learning

b. Evidence shows INCOMPLETE CONCORDANCE โ†’ loosely correlate biological phenomena.
c. Question: which type or subtype, if any, represents โ€œtrueโ€ disease biology?
d. The risk of multiplicity classification โžฉ fragmented atlas INSTEAD OF unified map of Sโ€ข + ARDS pathobiology.


7. ACHIEVEMENT

a. RCT โžฉ hidden TTO effect obscured in unselected populations.
b. They are retrospective + hypothesis-generating โžฉ โˆ‘ yet to be incorporated in SOC. (intellectually fascinating + mechanistically informative)
c. Solution โžฉ to validate prospectively
d. Assumption โžฉ the subgroups reflect DISTINCT EXPRESSIONS of a single underlying disease.
e. Sth more unsettling โžฉ Sโ€ข โž• ARDS ๐ŸŸฐ represents a multitude of distinct diseases โ“ โ–ถ๏ธŽ โ€œENDEAVOR built on shifting sandsโ€.

i. Unique utility โ†’ ID subgroups that responds to a given therapy.
ii. DOES NOT RESOLVE:

1. definition problem

2. question if Sโ€ข is a coherent disease


8. POV

a. PSE โžฉ implies complexity of โ–ถ๏ธŽ pxs โž• methodology & taxonomy
b. Instead of DESCRIPTIVE, go for CAUSAL investigation
c. Statistical artifacts ๐Ÿ†š biological realities.


9. SOURCE: Z[hao, L., Zhao, C., Wang, M. *et al.* Phenotype, subphenotype, and endotype in sepsis and ARDS: a new layer of heterogeneity?. Crit Care 30, 173 (2026). https://doi.org/10.1186/s13054-026-06022-9 

Thursday, May 14, 2026 at 18:21:36 in BE

TGA, RCH, SLDC, HIBN, AAQC

โณ TIME MANAGEMENT
01:17:25

Round: 7 02:51:40 Comments
Round: 6 27:58:20 Recap
Round: 5 30:54:32 Interpretation
Round: 4 03:56:45 Reading + notes
Round: 3 06:15:83 ART selection
Round: 2 00:34:26 Comments
Round: 1 04:55:17 Past JR

โณ TIME MANAGEMENT
58:48:87

Round: 6 00:43:28 Comments
Round: 5 25:52:54 Wrap-up
Round: 4 15:16:22 Interpretation
Round: 3 04:16:43 Reading + notes
Round: 2 07:13:41 ART selection
Round: 1 05:26:98 Past JR

2026 CC - Ultrasound assessment of muscle atrophy and its association with functional OC in CIpxs (Lin) (srMA).pdf

Codified by ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ (TGA)


Glossary: AF = atrial fibrillation, CI pxs = critically ill patients, CT = computed tomography, DEXA = dual-energy X-ray absorptiometry, ICU-AW = ICU-acquired weakness, MRI = magnetic resonance imaging, USG = ultrasound, โ‰  = differences



1. ๐™„๐™Œ๐˜พ BS โžฉ Y, J, C โž– T โž• N โž• t โž– P I C O:


2. ๐™„๐™Œ๐˜พ BS ๐ŸŸฐ 2026, CC, TW โž– srMA โž• 69 โž• -Oct 11, 2025 โž– P I C O:

- ๐Ÿ…ฟ: CIpxs
- ๐Ÿ…ธ: USG โ†’ lower limb muscle
- ๐Ÿ…ฒ: NA
- ๐Ÿ…พ: pOC = muscle atrophy monitoring


3. EVIDENCE

a. CIpxs โ†’ skeletal muscle wasting:

i. immobility
ii. systemic inflammation

b. Accuracy ๐Ÿ†š impracticality โžฉ cost + radiation + logistics

i. CT
ii. MRI
iii. DEXA

c. USG โžฉ bedside + radiation-free + repeatable โž• assess:

i. quantitative โ†’ cross-sectional area + muscle tickness
ii. qualitative โ†’ echointensity + pennation angle


4. RESULTS.

a. D7 of ICU admission

i. CROSS-SECTIONAL AREA:

1. Rectus femoris ๐ŸŸฐ โ†“16%
2. Quadriceps ๐ŸŸฐ โ†“ 11%

ii.. ECHOINTENSITY โ†‘
iii. PENNATION ANGLE โ†“
iv. โˆ‘ โ–ถ๏ธŽ compositional + architectural **deterioration.**
v. Heterogeneity is โ†‘ โ†‘ โžฉ reflects โ‰  in px characteristics

1. pxs characteristics
2. anatomical landmarks
3. USG technical factors

vi. Limited data โ–ถ๏ธŽ USG changes โ†” ICU-AW

b. D1-3 of ICU admission (excluding an outlier)

i. CROSS-SECTIONAL AREA:

1. Rectus femoris ๐ŸŸฐ GREATER โ†“ โ†“ โ†“ in ICU-AW
2. Compared to non ICU-AW


5. CONCLUSIONS.

a. USG detects: early, rapid muscle wasting โ†’ concurrent QUALITY degradation.
b. Very low CERTAINTY OF EVIDENCE:

i. Heterogeneity
ii. Methodological limitations
iii. BOTH โžฉ hinder clinical translation.

c. Needs clarification of the USG potential clinical utility.

.
6. SOURCE: Lin CC, Lin YJ, Chen CT, Chou HM, Hsu WC. Ultrasound assessment of muscle atrophy and its association with functional outcomes in critically ill patients: a systematic review and meta-analysis. Crit Care. Published online March 31, 2026. doi:10.1186/s13054-025-05825-6

Monday, May 11, 2026 at 18:28:41 in BE

TGA, BAR, RCH, SLDC, ASCA, AAQC

May, 2026

2026 ICM - Temperature control in ABI (Lavinio) [r].pdf

Codified by ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ 


Glossary: โ˜… = recommendation(s), GL = guidelines, icHTA = intracranial hypertension, ICP = intracranial pressure, AvBI = acute vascular brain injury, ABI = acute brain injury, CA = cardiac arrest, โ†“T = hypothermia, fOC = functional outcome , SOC = standard of care



1. ๐™„๐™Œ๐˜พ BS โžฉ Y, J, C โž– T โž• N โž• t โž– P I C O:


2.๐™„๐™Œ๐˜พ BS ๐ŸŸฐ 2026, ICM, UK โž– r โž• NA โž• NA โž– P I C O:

๐Ÿ…ฟ: Tยบ control in ABI


3. EVIDENCE:

a. Temperature:

i. Key determinant of ๐Ÿง  VULNERABILITY
ii. Physiological variable

b. Continous monitoring + active control โžฉ ICU
c. Role evolution โžฉ hypothermia โ†’ early recognition โ†’ normothermia.
d. Review โžฉ physiological rationale โž• clinical evidence โž• contemporary practice


4. METHODS.

a. Synthesised evidence:

- RCTs
- OBS
- Consensus
- Monitoring + implementation approaches


5. RESULTS.

a. General.

i. Fever โ†” WORSE ๐Ÿง  OC

b. TBI. โ†“T:

i. โ†“ICP but **does not** โ†—๏ธ fOC (when used prophylactically)
ii. Reserved for refractory icHTA
iii. NEJM 1997 โž• NABIS:H I (NEJM 2001) โž• NABIS:H II (LANCETn 2011) โž• EUROTHERM3235 (NEJM 2015) โž• POLAR-RCT (JAMA 2018)
iv. Fixed 33ยบC (1997-2011) โ†’ interval 32/33ยบC - 35ยบC (2015-2018)
v. EUROTHERM3235 โ†’ comparator SOC
vi. All RCTs
vii. POLAR โ†’ โ‰ฅ72h โ†’ 7d (if ICP โ†‘)

c. AvBI (neutral trial + feasibility constraints)

i. Early detection
ii. Treat fever rather than โ†“T
iii. 3 RCTs โ†’ ILUSTRATES: feasibility + safety challenges โž– barriers in awake pxs
iv. 1 OBS โ†’ โ†‘severity + โ†‘infarct size + โ†‘ MM + โ†˜๏ธ OC
v. LANCET 1996 โž• ICTuS 2 (STROKE 2016) โž• EuroHYP-1 (EUR STROKE 2019) โž• INTREPID (JAMA 2024)'

d. Post CA. Contemporary GL โ˜… protocolised T control w_target:

i. 32ยบC - 37,5ยบC (โ‰ฅ36h)
ii. active prevention of fever (not mandatory โ†“T)


6. EVIDENCE

a. Use core T probes.


7. SOURCE: Lavinio, A., Busl, K.M., Coles, J.P. et al. Temperature control in acute brain injury. *Intensive Care Med* (2026). https://doi.org/10.1007/s00134-026-08367-9

โณ TIME MANAGEMENT
01:17:55

Round: 9 02:44:16 Comments
Round: 8 16:39:23 Table + RECAP
Round: 7 05:44:46 RECAP
Round: 6 15:57:97 Images
Round: 5 15:47:41 Key-points
Round: 4 06:20:65 Interpretation (abstract)
Round: 3 04:12:62 Reading + notes
Round: 2 06:16:95 ART selection
Round: 1 04:11:81 Past JR

Thursday, May 21, 2026 at 18:33:07 in BE

RCH, AHO,TGA, DEPZ, ASCA, SLDC, HIBN, AAQC

2026 NEJM - Side effects of Radiotherapy (NEJM)

Codified by ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ 


Glossary: antiDiarr = antidiarrheals, CAD = coronary artery disease, H2B = H2 blockers, PPI = protom pump inhibitors, SE = side effects, โ†“ Hb = anemia, โ†“ N = neutropenia, โ†“ PLT = thrombocytopenia



1. ๐™„๐™Œ๐˜พ BS โžฉ Y, J, C โž– T โž• N โž• t โž– P I C O:


2. ๐™„๐™Œ๐˜พ BS ๐ŸŸฐ 2026, NEJM, USA โž– r โž• NA โž• NA โž– P I C O:

๐Ÿ…ฟ: onco pxs w_radiotherapy


3. EVIDENCE.

a. Radiotherapy is a KEY TTO โžฉ cancers
b. INNOVATIONS โžฉ imaging + radiation delivery โžฉ โ†—๏ธ :


4. REVIEW. Side effect from radiation TTOs:

a. Acute SE

i. ๐Ÿ‘… Mucosal. 

1. MUCOSITIS โŒ„ ESOPHAGITIS โ–ถ๏ธŽ top_Anest โž• nystatin โž• analgesics โž• sucralfate โž• H2B โž• PPI โž• nutriSupport

iii.๐Ÿซƒ Gastric

1. GASTRITIS โ–ถ๏ธŽ H2B โž• PPI โž• sucralfate โž• antiemetics

iv. ๐Ÿฆ  Intestinal

1. ENTERITIS โ–ถ๏ธŽ antiDiarr โž• low-residue diet โž• somatostatin
2. Acute PROCTITIS โ–ถ๏ธŽ symp_mm โž• antiDiarr

iv. ๐Ÿฉธ Hematologic

1. โ†“N โ–ถ๏ธŽ G-CSF
2. โ†“Hb โ–ถ๏ธŽ erythropoietin โž• transfusion
3. โ†“PLT โ–ถ๏ธŽ transfusion

v. ๐Ÿšฝ Urinary

1. OBSTRUCTIVE โ–ถ๏ธŽ โ™พ๏ธ blocker โž• NSAIDs
2. IRRITATITVE โ–ถ๏ธŽ antiMusc โž• NSAID โž• phenazopyridine

vi. ๐Ÿฉน Cutaneous

1. DERMATITIS โ–ถ๏ธŽ โ†“friction โž• โ†‘ barriers (hydrogel, silicone) โž• topSteroids โž• topMoisturizers โž• silver dressing โž• silver sulfadiazine

b. Subacute โŒ„ late SE

i. ๐Ÿง  Central nervous system

1. NEUROCOGNITIVE defects โ–ถ๏ธŽ neurostimulants โž• memantine โž• donepezil
2. NECROSIS โ–ถ๏ธŽ steroids โž• bevacizumab โž• resection
3. CATARACTS โ–ถ๏ธŽ surgical removal
4. OPTICAL neuropathy โ–ถ๏ธŽ bevacizumab

ii. ๐Ÿ’ง Salivary

1. XEROSTOMIA โ–ถ๏ธŽ saliva substitutes โž• parasympathomimetic drugs โž• hyperbaric O2 therapy

iii. ๐Ÿ”ฝ Esophageal

1. STRICTURE โ–ถ๏ธŽ dilation โž• H2B โž• PPI

iv. ๐Ÿซ Pulmonary

1. PNEUMONITIS โ–ถ๏ธŽ steroids โž• O2
2. FIBROSIS โ–ถ๏ธŽ O2

v. โค๏ธ Cardiac

1. PERICARDITIS โ–ถ๏ธŽ NSAIDs
2. VALVULAR disease โž• CAD โ–ถ๏ธŽ med_mm โž• surgery
3. ARRHYTHMIAS โ–ถ๏ธŽ HR control โž• pacemaker

vi. ๐Ÿฆ  Intestinal

1. CHRONIC enteritis โ–ถ๏ธŽ antiDiarr โž• bile-acid sequestrants
2. CHRONIC proctitis โ–ถ๏ธŽ sucralfate โŒ„ formalin enemas โž• argon plasma coagulation โž• hyperbaric oxygen therapy
3. FISTULA โ–ถ๏ธŽ surgical repair

vii. ๐Ÿšฝ Urinary

1. IRRITATIVE โ–ถ๏ธŽ antiMusc โž• NSAIDs โž• phenazopyridine
2. HEMORRHAGIC cystitis โ–ถ๏ธŽ irrigation โž• laser treatment โž• alum โž• hyperbaric O2 therapy โž• formalin โž• diversion
3. STRICTURE โ–ถ๏ธŽ dilation โž• surgical repair

viii. โšฅ Sexual

1. ERECTILE dysfunction โ–ถ๏ธŽ PDE5 โŠ– โž• mechanical aids โž• other pharmacologic aids
2. VAGINAL stenosis โ–ถ๏ธŽ dilators โž• lubricants โž• topEstrogens

ix. ๐Ÿ’ช Muscular or cutaneous ๐Ÿฉน

1. ATROPHY โŒ„ FIBROSIS โ–ถ๏ธŽ physical therapy โž• botulinum toxin โž• pentoxifylline โž• tocopherol
2. LYMPHEDEMA โ–ถ๏ธŽ compression
3. NECROSIS โ–ถ๏ธŽ antibiotics โž• dรฉbridement โž• hyperbaric O2 therapy


5. RATIONALE.

a. Despite all TTOs, radiation carries its own risks.


6. SOURCE: [New England Journal of Medicine, Volume 394 โ€ข Number 10 โ€ข March 5, 2026](https://www.nejm.org/doi/full/10.1056/NEJMra2506017) 

Monday, May 18, 2026 at 18:30:33 in BE

LH, TGA, RCH, BAR, DEPZ, ASCA, HIBN, AAQC

โณ TIME MANAGEMENT
01:01:41

Round: 7 01:07:26 Comments
Round: 6 23:43:83 Recap
Round: 5 14:46:79 Interpretation
Round: 4 02:44:07 REad + notes
Round: 3 10:14:52 ART methodology
Round: 2 03:37:07 ART selection
Round: 1 05:27:60 Past JR

2026 NEJMc - Reconceiving Parkinsonโ€™s Disease as Whole-Brain Action Netw. Disord. (Nature).pdf

Codified by YAPG 


Glossary: โ†“๐Ÿ’จ = hypoperfusion, ยตCIR = microcirculation, ompSOFA = obstetrically modified quick SOFA, RRT = rapid response teams, SSร˜ = septic shock, Sx = surgery, UVA = universal vital assessment, ๐Ÿฉธ hh = hemorrhage
โ†“๐Ÿ’จ = hypoperfusion



1.๐™„๐™Œ๐˜พ BS โžฉ Y, J, C โž– T โž• N โž• t โž– P I C O:


2. ๐™„๐™Œ๐˜พ BS ๐ŸŸฐ 2025, CC, MX โž– obs, pros โž• 1448 (110 admitted ICU) โž• Nov 2021 - Mar 2024 โž– P I C O:

- ๐Ÿ…ฟ: obstetric pxs (3rd trimester + early postpartum = w_RRT activated)
- ๐Ÿ…ธ: CRT evaluation as ICU admission criterion
- ๐Ÿ…ฒ: NA
- ๐Ÿ…พ: pOC = ICU admission


3. EVIDENCE:

a. Maternal MM โžฉ global public health priority (developing world)
b. Detection + treatment (physiological derangements) โžฉ PROMPT
c. Maternal & neonatal OC = ๐Ÿฉธhh โž• HTA โž• Sโ€ข
d. RRT โžฉ rapid response teams โ†’ OC
e. Monitoring tools โ†’ for early ID + supportive TTO + optimization resources.
f. Shock + other conditions โžฉ CRT is used (marker of tissue โ†“๐Ÿ’จ )
g. CRT โžฉ cost-free โž• universally available โž• bedside

4. METHODS.

  • Ex
    • Admitted directly from ED
    • Deteriorated in wards by non-obstetric Sx.
  • Recorded severe scores:
    • MEOWS
    • UVA
    • omqSOFA
  • Cutoff = 3,5s
    ICU admission decision case-by-case by RRT leader considering:
    • clinical context
    • Bed availability
    • Clinical Gestalt

5. RESULTS

a. Pregnant = 62% โž• postpartum = 39%

b. 7,6% admitted to the ICU.
c. Causes

i. HTA

ii. ๐Ÿฉธ hh

iii. SSร˜

d. UNIVARIATE

i. diastolic HTA (RR 2,7. p=0.0001) AUROC 0,58. p=0.003
ii. severe bleeding > 1000mL (RR 11. p=0.0001) AUROC 0,56. p=0.03
iii. CRT > 3,5s (RR 14,2. p=0.0001) AUROC 0,72. p=0.001

e. MULTIVARIATE

i. severe bleeding > 1000mL
ii. CRT > 3,5s

f. Better RR with CRT.

6. RATIONALE

a. Pregnancy is related to microcirculation derangements. 
b. Sublingual alterations shown.
c. Strong prolonged CRT โ†” sublingual ยตCIR โžฉ SSร˜
d. Current TTO might MODULATE this network.
e. Rather than BASAL GANGLIA, PD is likely a whole-brain action network.
f. SCAN dysfunction ๐ŸŸฐ core circuit abnormality.
g. If validated, it will influence:

i. the neuromodulation
ii. how we think about IMAGING BIOMARKERS โžฉ personalizad therapy.

h. Future studies are warranted (utility + applications)


7. SOURCE: Monares Zepeda et al. Critical Care https://doi.org/10.1186/s13054-025-05404-9 (2025) 29:231

Thursday, May 28, 2026 at 18:20:27 in BE

RCH, TGA, BAR, SLDC, MASP, HIBN, AAQC

โณ TIME MANAGEMENT
01:25:51

Round: 6 02:13:52 Comments
Round: 5 25:07:88 RECAP
Round: 4 36:11:17 Interpretation
Round: 3 09:30:58 Reading + notes
Round: 2 05:32:34 JR selection
Round: 1 07:16:23 Past JR

2025 NEJMc - Updates in Hypertension Management (H).pdf

Codified by YAPG 


Glossary: LT = levothyroxine, SH = subclinical hypothyroidism, โ†‘T = hyperthyroidism



1. ๐™„๐™Œ๐˜พ BS โžฉ Y, J, C โž– T โž• N โž• t โž– P I C O:


2  ๐™„๐™Œ๐˜พ BS ๐ŸŸฐ 2025, HYPERTENSION, USA โž– GL โž• NA โž• NA โž– P I C O:

  • ๐Ÿ…ฟ: adults w_HTA
  • ๐Ÿ…ธ: NA
  • ๐Ÿ…ฒ: NA
  • ๐Ÿ…พ: pOC = function + symptoms

3. EVIDENCE:

a. New evidence published by AHA, ACC/ AANP/AAPA/ABC/ACCP /ACPM/AGS /AMA/ASPC/NMA/PCNA/SGIM
b. 2017 GL โ†’ โ†‘HTA = >130 / >80
c. Past GL โ†’ โ†‘HTA = >140 / >90 โž• target 130/80 only in hrPxs
d. Evidence supports the case of lower BP targets.
e. Previously โ†’ BP CONTROL only if CVr>10%.
f. 15 million adults = โ†‘r for HF
g. Risk categories (10y ๐Ÿซ€r โž– PREVENT calculator):

i. low (<10%),
ii. intermediate (10โ€“19.9%),
iii. high (โ‰ฅ20%)4. METHODS.


4. METHODS

  • SCAN ๐ŸŸฐ recently described. Network linking the control of:
  • movement
  • cognition
  • motivation
  • autonomic


5. RESULTS.

a. Early + aggresive TTO is promoted. 

i. nearly all pxs w_HTA
ii. target BP <130/<80
iii. encouragement โ†’ achieve SBP <120

b. Risk estimation:

i. new PREVENT risk calculator
ii. Low BP TARGETS, โ˜…:

1. strong = 10y ๐Ÿซ€r โ‰ฅ7,5%
2. weak = 10y ๐Ÿซ€r <7,5%

c. Measures

i. Home โœ”๏ธŽ ๐Ÿ†š office โœ–๏ธŽ
ii. Clinicians should give > โ“˜ of HOW TO...
iii. โ–ถ๏ธŽ Survey in HTA pxs (self-monitoring):

1. Less than 1/2 โžฉ receive โ“˜ from their clinicians
2. Most โžฉ did NOT follow BEST PRACTICES

d. Aldosterone + renin levels

i. Used for primary aldosteronism

1. resistant HTA
2. โ†“K
3. sleep apnea
4. early Sโ€  (<40yo)

i. โ–ถ๏ธŽ Endocrine Society GL 2025 โ†’ screening in all pxs w_HTA
ii. โ–ถ๏ธŽ Both GL โ†’ test (can and should) both biomarkers

1. d_HTA TTO
2. except w_mineralocorticoid-receptor antagonists.
3. nuanced guidance (Endocrine Society GL) on MEDS

a. to hold
b. how long

6. RATIONALE.

1. Target BP <130/<80 โžฉ norm rather than exception.
2. BEtter home than office.
3. Benefits vary w_risk (PREVENT calculator)


7. SOURCE: Jones DW, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Hypertension 2025 Oct; 82:e212 10.1161/HYP.0000000000000249. PubMed

Thursday, June 4, 2026 at 18:05:17 in BE

TGA, KEPA, KYEC, JCAS, SLDC, AAQC

2026 NEJMc - Deprescribing Levothyroxine in Older Adults (JAMA).pdf

Codified by YAPG 


Glossary: LT = levothyroxine, SH = subclinical hypothyroidism, โ†‘T = hyperthyroidism



1. ๐™„๐™Œ๐˜พ BS โžฉ Y, J, C โž– T โž• N โž• t โž– P I C O:


2 .๐™„๐™Œ๐˜พ BS ๐ŸŸฐ 2026, JAMA, NL โž– ol โž• 370 โž• 1y โž– P I C O:

  • ๐Ÿ…ฟ: older adults (mean 70yo) โ†’ โ‰ฅ60yo
  • ๐Ÿ…ธ: stepwise dose (levothyroxine) reduction
  • ๐Ÿ…ฒ: NA
  • ๐Ÿ…พ: pOC = function + symptoms

3. EVIDENCE:

a. Older adults take LT โ†’ prescribed inappropriately for SH.
b. LT โ†’ polypharmacy + iatrogenic โ†‘T
c. Evidence to discontinue is LIMITED


4. METHODS.

  • Stable dose of LT โ†’ โ‰ค150 ug/day, at least 1y.
  • Stepwise dose reduction:
    • 12,5-50 ug/day โžฉ baseline visit
    • 25-38 ug/day โžฉ 6-12w = 1,5-3 months
    • 25 ug/day โžฉ af_18, 24, 30w = 4,5 - 7,5 months

5. RESULTS.

a. 80% women
b. TSH = 2,2 mIU/L โž– LT dose = 84ug/d
c. FUNCTION โ–ถ๏ธŽ 1y โžฉ 26% suspended LT (TSH <10, T4l โœ”๏ธŽ )
d. DISCONTINUATION โ–ถ๏ธŽ 64% when LT โ‰ค50ug/d.
e. SYMPTOMS โ–ถ๏ธŽ similar: continue ๐Ÿ†š discontinue


6. EVIDENCE

a. Not surprising. (TSH normalize spontaneously in half pxs with mild TSHโ†‘)
b. Her practice โžฉ trial of discontinuing SUPPLEMENTATION:

i. low dose: no known history of overt โ†“T
ii. high dose: given due to SH (documented)

c. Good idea to keep monitoring SYMPTOMS + FUNCTION for longer.


7. SOURCE: Ravensberg J, et al. Discontinuation of levothyroxine in adults aged 60 years or older. JAMA 2026 Apr 6; [e-pub]. DOI: 10.1001/jama.2026.2864. 

โณ TIME MANAGEMENT
01:00:10

Round: 7 02:58:81 Comments
Round: 6 18:02:88 RECAP
Round: 5 22:21:08 Interpretation
Round: 4 02:54:24 Reading + notes
Round: 3 05:28:01 ART selection
Round: 2 00:29:63 Comments
Round: 1 07:55:67 Past JR

Monday, June 1, 2026 at 18:02:15 in BE

EMS, TGA, SLDC, HIBN, AAQC

Monday, June 15, 2026 at 18:20:30 in BE

TGA, KSQV, KYEC, DEPZ, SLDC, HIBN, AAQC

4. RATIONALE.

a. We can tell survivors they can return to play.
b. Keep prevention + preparation
c. Have an emergency plan.


5. SOURCE: Lampert R, Harmon KG. Sudden Cardiac Arrest in Athletes. N Engl J Med. 2026;394(3):268-280. DOI doi:10.1056/NEJMra2312555

2026 NEJMc - Sudden Cardiac Arrest in Athletes (NEJM).pdf

Codified by YAPG


Glossary: DX = diagnostic, ฦ’-up = follow-up, SCA = sudden cardiac arrest, TTO = treatment, ๐Ÿซ€ = heart



1. ๐™„๐™Œ๐˜พ BS โžฉ Y, J, C โž– T โž• N โž• t โž– P I C O:


2  ๐™„๐™Œ๐˜พ BS ๐ŸŸฐ 2026, NEJM, โ“ โž– r โž• NA โž• NA โž– P I C O:

  • ๐Ÿ…ฟ: Athletes
  • ๐Ÿ…ธ: SCA
  • ๐Ÿ…ฒ: NA
  • ๐Ÿ…พ: NA

3. EVIDENCE

a. Incidence varies by:

- Age

- Race

- Ethnic Group

- Sex

- Social Determinants

- Sport

b. Casus include:

- ๐Ÿซ€ cardiomyopathies 

-  Coronary artery anomalies

- ๐Ÿ“ˆ Electrical disorders

- Structural abnormalities

c. Prevention โžฉ SCREENING โž• EMERGENCY ACTION (recognition + TTO)

d. Athletic adaptation professionals โ†’ DX EVALUATION for SCA survivors

- mirrors that of any in the same age group

- Attention to SPORT-SPECIFIC causes

e. Return to sport:

i.  Af_disease-specific TTO
ii.  Shared decision making
iii.  Emergency plan โž• ฦ’-up plan
iv. Tailor mm of ๐Ÿซ€ conditions (athlete + sport)

โณ TIME MANAGEMENT
42:15:54

Round: 7  02:40:08  Comments
Round: 6  12:49:83  RECAP
Round: 5  11:55:94  Interpretation
Round: 4  02:22:40  Reading + notes
Round: 3  05:30:67  ART selection
Round: 2  00:44:51  CommentRound: 1  06:11:09  Past JR

2026 NEJMc - Early Transition to Oral ATBs af_H+ for Serious INF (Clin Infect Dis).pdf

Codified by TGA


Glossary: ร† = adverse events, ATB = antibiotic, CNS = central nervous system, COpAT = complex outpatient parenteral antimicrobial therapy, DIS = discharge, OPAT = outpatient parenteral antimicrobial therapy, sevINF = severe infections, TTO = treatment, ๐Ÿ’‰ = intravenous



1. ๐™„๐™Œ๐˜พ BS โžฉ Y, J, C โž– T โž• N โž• t โž– P I C O:


2  ๐™„๐™Œ๐˜พ BS ๐ŸŸฐ 2026, CID, USA (West Virginia) โž– prag_unblin_RCT โž• 90pxs (5H+) โž• Aug 2023 - Feb 2025 (3m f-up) โž– P I C O:

  • ๐Ÿ…ฟ: Outpatients w_sevINF
  • ๐Ÿ…ธ: early oral therapy transition
  • ๐Ÿ…ฒ: continued ๐Ÿ’‰ therapy
  • ๐Ÿ…พ: pOC = safety superiority (complications) + efficacy equivalence

3. EVIDENCE:

a. Trial have shown the EFFICCAY of early transition from ๐Ÿ’‰ to oral ATB TTO.
b. OPAT programs widely adopted.
c. COpAT programs not yet widely adopted.


4. METHODS

  • IN: ATB needed for โ‰ค2w after DIS
  • EX: CNS INF
  • Early transition ๐ŸŸฐ high-bioavailability ATB regimen
  • When was early transition started?
    • at randomization
    • When blood cultures were โŠ– for 2-3d. (bacteremia)

5. RESULTS.

a. Most INF:

i. bone/joint 73%
ii. endovascular 14%
iii. bactermic ~50%

b. Time at transition โ†’ 4d (median)

c. Oral agents:

i. 89% ๐Ÿ…ธ
ii. 39% ๐Ÿ…ฒ

d. TTO in both โ†’ 6w

e. Stopped at 90pxs โ†’ additional enrollment was unlikely to change findings.

f. ๐Ÿ…ธ โ†“ร† โ†’ line complications (25% ๐Ÿ†š 0)

g. Efficacy โžฉ SIMILAR


6. RATIONALE.

a. ๐Ÿ…ธ is useful even w_sevINF

b. Consider ๐Ÿ…ธ activetly:

i. reliable oral options

ii. outpatient monitoring available


7. SOURCE: Juskowich JJ, et al. Using the Comparing Oral versus Parenteral Antimicrobial Therapy (COPAT) clinical trial to influence institutional practice transformation towards earlier transition to oral antibiotics. Clin Infect Dis 2026 Apr 30; 82:e674. DOI: 10.1093/cid/ciaf707.

Thursday, June 11, 2026 at 18:05:08 in BE

EQO, TGA, DEPZ, SLDC, HIBN, AAQC

โณ TIME MANAGEMENT
53:26:97

Round: 6 00:48:24 Comment
Round: 5 25:27:69 RECAP
Round: 4 12:00:54 Interpretation
Round: 3 02:34:34 Reading + notesRound: 2 05:16:94 ART selectionRound: 1 07:19:19 Past JR

June, 2026
November, 2026

Thursday, June 25, 2026 at 18:15:43 in BE

EQO, BAR, HIBN, AAQC

โณ TIME MANAGEMENT
01:41:22

Round: 5 47:06:74 RECAP
Round: 4 14:37:68 Interpretation โ“˜
Round: 3 05:13:57 Reading + notes
Round: 2 33:46:45 Member database update + Program ART description update
Round: 1 00:38:23 Past JR

2026 NEJMc - Yes, Vasopressors Are Safe to Start Peripherally (JAMAno).pdf

Codified by YAPG


Glossary: ร† = adverse events, adm = administration, delivery, CIpxs = critically ill patients, CVC = central venous catheter, VP = vasopressor, VTE = venous thromboembolism



1. ๐™„๐™Œ๐˜พ scope โžฉ Y, J, C โž– T โž• N โž• t โž– P I C O:


2. 2026, JAMAno, โ“ โž– srMA โž• 33k (50 ๐Ÿ“‘ ) โž• โ“ โž– P I C O:

  • ๐Ÿ…ฟ:  CIpxs
  • ๐Ÿ…ธ: peripheral catheters
  • ๐Ÿ…ฒ: CVC
  • ๐Ÿ…พ: pOC = safety (ร†)

3. EVIDENCE:

a. Multiple studies + SSC 2021 โ†’ safety STARTING VP peripherally
b. Pior sr โ†’ low complications BUT no differentiation โ€œโ†” VPsโ€œ โŒ„ โ€œmidline cathetersโ€


4. RESULTS.

a. Minor ร†

i.     rare (no VP distinction)
ii.    pooled incidence 2,3%

              iii.    Most common โ†’ hematoma + extravasation + skin discoloration

b. Major ร†

               i.    absent w_short peripheral IV catheters
               ii.   midline catheters โ†’ 1,4% VTE

              iii.  CVC placement avoided in 60% (varied WIDELY by clinical setting)


5. RATIONALE.

         a. ๐Ÿšจ Downstream implications of not placing CVCs af_stabilization.
         b. Prolonged VP therapy โ†’ CVC benefits > just VP adm.

               i.     position โŒ„ infiltrate
               ii.    labs

              iii.  multiple infusions

         c. Thus, clinicians should maintain the skill in CVC placement.
         d. โ given โ†“ opportunities w_โ†‘ of safe peripheral VP adm. (Michael Billington)


6. SOURCE โ–ถ๏ธŽ ZhangJian S-J, et al. Incidence of adverse events in peripheral intravenous vasopressor use: A systematic review and meta-analysis. JAMA Netw Open 2026 Mar; 9:e260710. DOI: 10.1001/jamanetworkopen.2026.0710.

Thursday, June 18, 2026 at 18:10:56 in BE

EQO, TGA, EMS, RCH, HIBN, AAQC

โณ TIME MANAGEMENT
01:23:24

Round: 9 01:28:81 Comments
Round: 8 40:31:68 RECAP
Round: 7 00:49:39 Comments
Round: 6 04:57:53 Interpretation
Round: 5 01:05:45 Reading + notes
Round: 4 20:14:44 Intrepretation
Round: 3 05:00:25 Reading + notes
Round: 2 04:01:64 ART selectionRound: 1 05:15:47 Past JR

2026 HEALIO - New study could change practice for TTO sinusitis in adults (JAMA).pdf

Codified by ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ (TGA)


Glossary: ร† = adverse events, DB = database, ESCMID = European Society of Clinical Microbiology and Infectious Diseases, ฦ’-up = follow-up, GL = guidelines, IDSA = Infectious Diseases Society of America, outPxs = outpatients, R = resistance, secINF = secondary infections, TTO = treatment(s)



1. ๐™„๐™Œ๐˜พ BS โžฉ Y, J, C โž– T โž• N โž• t โž– P I C O:


2  ๐™„๐™Œ๐˜พ BS ๐ŸŸฐ 2026, JAMA, USA โž– obs_retro_real-world โž• 230k (117,3k each cohort) โž• Jan 2018 - Dec 2023 (5y) โž– P I C O:

  • ๐Ÿ…ฟ: acute sinusitis outPxs
  • ๐Ÿ…ธ: amoxi-clavulanate โ†’ 875 mg-125 mg BID daily ๐ŸŸฐ EXPOSED
  • ๐Ÿ…ฒ: amoxicillin โ†’ 875 mg BID daily or 500 mg TID daily ๐ŸŸฐ REFERENT
  • ๐Ÿ…พ: pOC = TTO failure | sOC = ATBโ†” ร† โž• secINF

3. EVIDENCE:

a. GL IDSA 2012 prefer ๐Ÿ…ธ over ๐Ÿ…ฒ โžฉ as EMPIRIC TTO โ–ถ๏ธŽ low-quality evidence
b. Clavulanate = beta-lactamase โŠ–, added to amoxicillin to mitigate bacterial R.
c. Timothy Savage โžฉ 4M โ†’ ATB prescriptions in USA each year

d. There NOT A CONSENSUS โ†’ 1st-line therapy


4. METHODS

  • IN: 
    - โ‰ค64yo w_new cae of acute sinusitis
    - From a large nationwide DB (>500k pxs)
  • TTO failure: 
    - new ATB dispensation (w_ โŒ„ wo_outPx visit)
    - ED visit
    - Hospitalization (inpatient encounter)

                 - Acute sinusitis โŒ„
                 - A complication (orbital cellulitis โŒ„ osteomyelitis)

  • Propensity score matching โ†’ >115k (65% โ™€)

5. RESULTS.

a. Abstract presented in ESCMID.

b. <64yo

c. Oral agents:

i. ๐Ÿ…ธ 3,1%
ii. ๐Ÿ…ฒ 3%

d. p๐Ÿ…พ:

       i. No DIFF in ATB ร†
       ii. ๐Ÿ…ธ 40% more likely to experience โ–ถ๏ธŽ sec_Yeast INF
       iii. >2x as like to experience โ–ถ๏ธŽ sec_Clostridoides difficile

f. New ATB dispensation (w_ โŒ„ wo_outPx visit) โžฉ 0.03%

g. Strengths โ†’ size โž• scope


6. RATIONALE.

a. This new study casts DOUBT on the standard IDSA recommendation.

b. An attendee asked if an RCT was needed.

       c. โ“ symptom-oriented outcomes 

       d. ๐Ÿ…ธ NO advantage over ๐Ÿ…ฒ โ†’ regarding


EFFECTIVENESS
       e. NO NOTABLE safety issues โ†” both options.


7. SOURCE: Savage TJ, Butler AM, Kronman MP, et al. Amoxicillin-Clavulanate vs Amoxicillin for Acute Sinusitis in Adults. JAMA. 2026;335(19):1694โ€“1705. doi:10.1001/jama.2025.26902

Monday, July 6, 2026 at 18:35:02 in BE

EQO, LPM, OWGG, EMS, MLHG, BAR, HIBN, AAQC

2026 NEJMc - Antibiotics for Pneumonia, Can Courses Get Even Shorter (Ann Intern Med).pdf

Codified by ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ (TGA)


Glossary: ADM = admission, ATBs = antibiotics, INF = infection, lr = low-risk, tte = target trial emulation
tte = target trial emulation


1. ๐™„๐™Œ๐˜พ ๐™จ๐™˜๐™ค๐™ฅ๐™š โ–ถ๏ธŽ Y, J, C โž– T โž• N โž• t โž– P I C O:


2  2026, AIM, โ“ โž– obs_tte โž• 55k โ†’ 10% = 5620pxs โž• โ“ โž– P I C O:

  • ๐Ÿ…ฟ:  nonsevere CAP

  • ๐Ÿ…ธ: short-course (3-4d)

  • ๐Ÿ…ฒ: longer-course (โ‰ฅ5d)

  • ๐Ÿ…พ: OC = MM30 โž• reADM โž• C. difficile INF

3. EVIDENCE:

a. GL โ˜… at least 5d of ATBs
b. Newer guidance ๐Ÿ—ฃ shorter courses (3-4d) โ†’ nonsevere cases

4. METHODS.

  • Nonsevere case = clinical stability:

            -    vital signs

            -     mentation

  • 5620 lr_pxs โ†’ tte comparing ๐Ÿ…ธ ๐Ÿ†š ๐Ÿ…ฒ

  • EX (6)

            -   sev_๐Ÿซ DIS

            -   end-stage โ™พ๏ธ stage

            -   โ—ธ DIS

            -   aspiration pneumonia

            -   immunosuppression

            -   โ‰ฅ2d of TTO for S. aureus โŒ„ P. aeruginosa.


5. RESULTS.

a. 8% elegible for 3-4d of TTO

b. ๐—ก๐—ข ๐——๐—œ๐—™๐—™ ๐Ÿ…ธ ๐Ÿ†š ๐Ÿ…ฒ

              i.     MM30 โ†’ 0.7%

              ii.    reADM โ†’ โ‰ˆ8%

              iii.   C. difficile INF โ†’ 0,2%


6. RATIONALE.

       a. Small proportion of H+ pxs w_CAP for 3d

       b. Azithromycin (long half-life) was used by most pxs (๐Ÿ…ธ) โžฉ unclear if beta-lactams alone would work.

c. Carefully selected pxs โ†’ ๐Ÿ…ธ seems reasonable

       d. โ In my own practice, this will mean shifting toward shorter antibiotic courses for my patients with CAP who improve or stabilize quickly. (Daniel Dressler)


7. SOURCE โ–ถ๏ธŽ Doumat G, et al. Short versus longer antibiotic duration for community-acquired pneumonia: A multicenter target trial emulation. Ann Intern Med 2026 Apr 14; [e-pub]. DOI:10.7326/ANNALS-25-03538.

โณ TIME MANAGEMENT
45:43:40

Round: 7 00:53:40 Comments
Round: 6 17:01:51 RECAP - appraisal
Round: 5 16:03:81 Interpretation 2
Round: 4 00:12:45 Interpretation 1
Round: 3 02:39:38 Reading + notes
Round: 2 04:26:50 ART selection
Round: 1 04:26:32 Past JR

2025 NEJMjw - Is FIT Testing an Alternative to Colonoscopy in pxs at hr_ f_ Colon CA (Clin Gastroenterol Hepatol).pdf

Codified by ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ (RICH)


Glossary: COL = colonoscopy, CRC = colorectal cancer, FIT = fecal immunohistochemical testing, hr_ = high(er) risk, std = studies


1. ๐™„๐™Œ๐˜พ BS โžฉ Y, J, C โž– T โž• N โž• t โž– P I C O:


2  ๐™„๐™Œ๐˜พ BS ๐ŸŸฐ 2025, CGH, EEUU โž– sr โž• 14 std โž• โ“ โž– P I C O:

  • ๐Ÿ…ฟ:  hr_CRC pxs
  • ๐Ÿ…ธ: FIT
  • ๐Ÿ…ฒ: COL
  • ๐Ÿ…พ: pOC = performance

3. EVIDENCE:

a. Pxs are reluctant to COL for CRC screening.
b. Type of risk:

            i.    average โ†’ FIT โœ”๏ธŽ 

            ii.    high โ†’ FIT โ“ 

c. hr_CRC ๐ŸŸฐ history of polyps (personal) โž• CRC (familiar)


4. RESULTS.

a. Variability in OC vas considerable, due to:

i.    Heterogeneous designs
ii.    DIFF DX thresholds โ†’ for โŠ• FIT

b. Sensitivity (hr_CRC) โžฉ 25-100% (one-time FIT)


5. RATIONALE.

       a. WE DO NOT HAVE ENOUGH evidence of FIT instead of COL. (hr_pxs)

       b. Few studies โžฉ beyond one-time testing.

c. โI will not be reassured by negative FIT testing in these patients (Molly Brett)


6. SOURCE: Karna R et al. Performance of fecal immunochemical test in individuals with personal history of polyps and family history of colorectal cancer: A systematic review. Clin Gastroenterol Hepatol 2025 Sep 16; [e-pub]. (https://doi.org/10.1016/j.cgh.2025.09.013)

Thursday, July 2, 2026 at 18:20:30

EQO, EMS, YAPG, DEPZ, MLHG, BAR, HIBN, AAQC

โณ TIME MANAGEMENT
37:50:14

Round: 8 00:02:09 Closure
Round: 7 03:54:41 Comments
Round: 6 15:51:45 RECAP
Round: 5 07:20:82 Interpretation...
Round: 4 00:11:46 Interpretation
Round: 3 02:03:23 Reading + notes
Round: 2 06:19:79 ART selection
Round: 1 02:06:84 Past JR

Thursday, July 9, 2026 at 18:03:27 in BE

EQO, KSQ, YAPG, EMS, SLDC, DEPZ, HIBN, AAQC

2026 NEJMc - Statins and Myasthenia Gravis, Is There a Connection (JIM).pdf

Codified by ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ (YAPG)


Glossary: ร† = adverse events, MG = myasthenia gravis, PD = Parkinsonโ€™s disease, SCAN = somato-cognitive action network, TTO = treatment(s)


1. ๐™„๐™Œ๐˜พ ๐™จ๐™˜๐™ค๐™ฅ๐™š โ–ถ๏ธŽ Y, J, C โž– T โž• N โž• t โž– P I C O:


2.  2026, JIM, HK ๐Ÿ‡ญ๐Ÿ‡ฐ + JP ๐Ÿ‡ฏ๐Ÿ‡ต + UK ๐Ÿ‡ฌ๐Ÿ‡ง โž– self-controlled_DBs โž• 2k โž• ฦ’-up 2y โž– P I C O:

  • ๐Ÿ…ฟ: statin users

  • ๐Ÿ…ธ: MG DX

  • ๐Ÿ…ฒ: NA

  • ๐Ÿ…พ: OC = incidence association

3. EVIDENCE:

a. Case reports โ–ถ๏ธŽ stating โ†” MG
b. Low INCIDENCE of MG โ†’ challenges assessment

4. METHODS.

  • Incidence of MG โ€œโ† statins โ†’โ€

5. RESULTS.

a. MG INCIDENCE

              i.     6m โ†’ 3x โ€œaf_statin initiationโ€ ๐Ÿ†š โ€œbef_statin initiationโ€

b. MG RISK

              i.     6-12m โ†’ substantially โ†“ (โ€p<0.05โ€)

              ii.    โ‰ฅ12m โ†’ ๐—ก๐—ข ๐——๐—œ๐—™๐—™

       c. Subgroup analysis

              i.    low-intensity โ†’ ๐—ก๐—ข ๐——๐—œ๐—™๐—™


6. RATIONALE.

       a. Preexisting symptoms โžฉ might have been attuned to STATIN ร†

       b. Cause-effect is worth knowing

c. MG is exceedingly RARE

       d. Benefits outweigh this risk

       e. IF โ€˜unusual + severe + prolonged muscle problemsโ€™ (mainly weakness) โž• statin use ๐ŸŸฐ think of MG


7. SOURCE โ–ถ๏ธŽ Yan VKC, et al. Myasthenia gravis following the initiation of statin therapy: A multinational self-controlled case series study. J Intern Med 2026 Apr; 299:502. DOI: 10.1111/joim.70072.

2026 NEJMc - A Clinical Practice Update on mm Gastric Polyps (Clin Gastroenterol Hepatol).pdf

Codified by ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ (TGA)


Glossary: EGD = esophageal gastroduodenoscopies, HP = Helicobacter pylori, MEN-1 = multiple endocrine neoplasia type 1, PPI = proton-pump inhibitors, โˆ‘ = update



1. ๐™„๐™Œ๐˜พ BS โžฉ Y, J, C โž– T โž• N โž• t โž– P I C O:
2  ๐™„๐™Œ๐˜พ BS ๐ŸŸฐ 2026, CGH, USA ๐Ÿ‡บ๐Ÿ‡ธ โž– AGA_rev_clinical practice โˆ‘ โž• NA โž• NA โž– P I :

  • ๐Ÿ…ฟ: gastric polyps pxs
  • ๐Ÿ…ธ: epimediology + classication + surveillance

3. EVIDENCE:

a. Incidental gastric POLYPS โžฉ 10% EGD
b. Malignancy incidence

            i.    LOW 

            ii.    Risks based on PATHOLOGY 


4. RESULTS.

a. MANAGEMENT

i.    Polyps removed โžฉ send to biopsy together w_GASTRIC MUCOSA BIOPSY sampling โ†’ to define subtypes. Highest risk:

                         1.  >1cm

                         2. Villous 

                         3. Carpeting
              ii.    Gastric biopsies โžฉ IF HP, treat it โ—๏ธ

              iii.    PPI can continue 

b. HISTOLOGY

              i.     Fundic โžฉ 

                         1. most common
                         2. low risk of DYSPLASIA

              ii.    Hyperplastic โ†” โ€œHP โž• atrophic gastritisโ€

                         1. higher risk of DYSPLASIA

             iii.    Adenomas โžฉ

                          1. 1-10% 

                          2.  cancerous precursors

             iv.    Neuroendocrine tumors โžฉ 

                          1. arise in autoimmune gastritis 

                          2. โ†” Zollinger-Elison โŒ„ MEN-1

       c. SURVEILLANCE

             i.      Frequency based on HISTOLOGY:
                          1. polyps 

                          2. gastric musosa
                          3. Classification

                                   a. LOW-GRADE dysplasic polyps โ†’ EGD at 1y

                                   b. HIGH-GRADE dysplasic polyps โ†’ EGD at 6m

             ii.     Partially resected polyps:

                           1. HIGH-GRADE โ†’ EGD 3m

                           2. LOW-GRADE โ†’ EGD 6m

             iii.    EGD if mucosal biopsy:

                           1. Metaplasia, โŒ„ 

                           2. Atrophic gastritis โŒ„ 

                           3. Both  

5. SOURCE โ–ถ๏ธŽ Buchner AM, et al. AGA clinical practice update on management of gastric polyps: Expert review. Clin Gastroenterol Hepatol 2026 Apr; 24:893. DOI: 10.1016/j.cgh.2026.01.007.

      

โณ TIME MANAGEMENT
01:30:44

Round: 10 03:54:87 Comments
Round: 9 18:12:81 RECAP
Round: 8 17:02:92 Interpretation
Round: 7 03:37:00 Reading + notes
Round: 6 02:04:90 Comments
Round: 5 21:34:77 RECAP
Round: 4 10:46:18 Interpretation
Round: 3 02:19:76 Reading + notes
Round: 2 06:30:35 Comments + ART selection
Round: 1 04:40:46 Past JR

2026 NEJMc - Risk for Acute Pancreatitis from GLP-1s (BMJ Med).pdf

Codified by ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ (TGA)


Glossary: AP = acute pancreatitis, AUD = alcohol use disorder, DB = database, HD = heavy drinking, TG = triglyceridemia, vetAFF = Veteran Affairs, ๐Ÿฅƒ = alcohol


1. ๐™„๐™Œ๐˜พ ๐™จ๐™˜๐™ค๐™ฅ๐™š โ–ถ๏ธŽ Y, J, C โž– T โž• N โž• t โž– P I C O:


2. 2026, BMJ Med, USA ๐Ÿ‡บ๐Ÿ‡ธ โž– obs_vetAFF_DB โž• 130k ๐Ÿ†š 200k โž• 12m โž– P I C O:

  • ๐Ÿ…ฟ: adults w_diabetes

  • ๐Ÿ…ธ: GLP-1 agonists

  • ๐Ÿ…ฒ: sulfonylureas

  • ๐Ÿ…พ: pOC = AP rates

3. EVIDENCE:

a. GLP-1 agonists โ†” PA โ–ถ๏ธŽ
        i. 2023, JAMA, USA ๐Ÿ‡บ๐Ÿ‡ธ

               ii. cohort_OBS โž• 4800 ๐Ÿ†š 650 โž• 1y

               iii. ๐Ÿ…ฟ = Obesity wo_diabetes, ๐Ÿ…ธ = liraglutide and semaglutide, ๐Ÿ…ฒ = bupropion-naltrexone, ๐Ÿ…พ = PA risk

               iv. PA (9,1)+ bowel obstruction (4,2) + gastroparesis (3,7) โ†’ โ†‘ โ†‘ โ†‘ ๐Ÿ…ธ ๐Ÿ†š ๐Ÿ…ฒ 

               v. Liraglutide โžฉ incidence โ€˜PA + bowel obstructionโ€™ โ†’ 7 per 1k pxs


4. METHODS.

  • Adjusted for 

                - sociodemographics

                - comorbidities

                - medications

5. RESULTS.

a. All-cause PA

              i.     DEF: ED visit โŒ„ H+ admission

              ii.     ๐—ก๐—ข ๐——๐—œ๐—™๐—™ 

b. Drug-induced PA

              i.     DEF: not โ†” w_โ€biliary, ๐Ÿฅƒ โŒ„ โ†‘TGโ€

              ii.    MORE COMMON w_๐Ÿ…ธ (24) ๐Ÿ†š ๐Ÿ…ฒ (0,5) per 100k pxs

              iii.   >40% โ†’ 1st 3m

       c. ๐Ÿฅƒ-induced PA

              i.    LESS common w_๐Ÿ…ธ (6) ๐Ÿ†š ๐Ÿ…ฒ (17)

       d. โ†‘TG-associated PA 

              i.    LESS common w_๐Ÿ…ธ (14) ๐Ÿ†š ๐Ÿ…ฒ (31)

Monday, July 13, 2026 at 18:00:33

EQO, OWGG, YAPG, EMS, SLDC, HIBN, AAQC


6. RATIONALE.
    a. Why lr_ โžฉ ๐Ÿฅƒ + โ†‘TG โ“ 

       i.    ๐Ÿ…ธ โ†“ TG

       ii.   ๐Ÿ…ธ โ†“ drinking (AUD)

        1.  2026, LANCET, DK ๐Ÿ‡ฉ๐Ÿ‡ฐ

        2. sc_db_RCT โž• 100 (53 โ™€ ๐Ÿ†š 55 โ™‚๏ธŽ ) โž• 2023-2025 (ฦ’-up 26w)

        3. ๐Ÿ…ฟ AUD + obesity ๐Ÿ…ธ semaglutide 2,4 f_1w ๐Ÿ…ฒ placebo ๐Ÿ…พ โ†“ number days of HD

           4. Days of HD โ†“ (sig)

                       a. ๐Ÿ…ฒ 17 โ†’ 13
                       b. ๐Ÿ…ธ 17 โ†’ 10

            5. Days wo_๐Ÿฅƒ (p=0.051)
                        a. ๐Ÿ…ฒ 9 โ†’ 11

                        b. ๐Ÿ…ธ 9 โ†’ 12

             6. ร†

                        a. ๐Ÿ…ธ >50% pxs โ†’ โ†‘common

    b. COUNSEIL pxs to avoid misinterpretation of GLP-1 agonists use.

        i.     rare

        ii.    few months (3m)

           

7. SOURCE โ–ถ๏ธŽ Xie Y , et al. GLP-1 receptor agonists and risk of all cause and cause specific acute pancreatitis: Target
trial emulation. BMJ Med 2026 Apr 22; 5:e002183. DOI: 10.1136/bmjmed-2025-002183.

      

โณ TIME MANAGEMENT
01:30:44

Round: 10 03:54:87 Comments
Round: 9 18:12:81 RECAP
Round: 8 17:02:92 Interpretation
Round: 7 03:37:00 Reading + notes
Round: 6 02:04:90 Comments
Round: 5 21:34:77 RECAP
Round: 4 10:46:18 Interpretation
Round: 3 02:19:76 Reading + notes
Round: 2 06:30:35 Comments + ART selection
Round: 1 04:40:46 Past JR

Thursday, July 16, 2026 at 18:30:26

EQO, OWGG, YAPG, EMS, LPM, KSQ, MLHG, AAQC

2026 JAMA - Blood Pressure Assessment in Ophthalmology Clinics f_Pxs w_Diabetes (Samayamanthula) [R].pdf

Codified by YAPG


Glossary: > = major, AMA/AHA = American College of Cardiology/American Heart Association, HTA = hypertension, hr_ = high(er) risk, PCC = primary care clinician, rf = risk factor, S1 = stage 1, S2 = stage 2


1. ๐™„๐™Œ๐˜พ ๐™จ๐™˜๐™ค๐™ฅ๐™š โ–ถ๏ธŽ Y, J, C โž– T โž• N โž• t โž– P I C O:
2. 2026, JAMA, USA ๐Ÿ‡บ๐Ÿ‡ธ โž– pros_case series โž• 172 โž• Jul - Aug 2024 1m โž– P I C O

  • ๐Ÿ…ฟ: adults w_diabetes presenting to a retina clinic

  • ๐Ÿ…ธ: in-clinic BP measurements + survey + EMR data

  • ๐Ÿ…ฒ: NA

  • ๐Ÿ…พ: pOC = distribution of BP categories | sOC = prevalence of uncontrolled HTA โž• concordance BP measures โ†” self-reported โž• frequency of unDX & miscontrolled HTA โž• awareness on eye impact โž• perspective on in-office screening.

3. EVIDENCE:

a. HTA is >MODIFIABLE rf โ†’ for diabetic retinopathy

       b. HTA may not be assessed d_ophtalmology visits

4. METHODS.

  • Analyzed Oct - Dec 2025

  • Survey:

                - HTA history

                - monitoring

                - perceived control

                - knowledge 

  • DEF (AMA/AHA 2017)

                - Normal BP โ†’ SBP<120 โž• DBP <80         

                - Elevated โ†’ SBP 120-129 โž• DBP <80

                - S1 HTA โ†’ SBP 130-139 โŒ„ DBP 80-89               

                - S2 HTA โ†’ SBP โ‰ฅ140 โŒ„ DBP โ‰ฅ90               

                - Crisis โ†’ SBP>180 ยฑ DBP >120



5. RESULTS.

            a. 66yo

            b. โ™€ 49%
            c. Normal โ†’ 8%
            d. S2 โ†’ 53%
            e. Crisis โ†’ 10%
            f. Prior DX โ†’ 84%

                 i. w_TTO = 91%

            g. wo_known HTA โ†’ Above-normal BP = 86%

                 i.    S2 & S3 โ†’ 35%

                  ii.    crisis โ†’ 11%
             h. Although 69% w_HTA perceived GOOD โŒ„ excellent CONTROL:
                  i.    S1 โŒ„ > = 80%

              i. Following measurements
                  i.     advised to contact their PCC = 60%
                  ii.     expedited ฦ’-up = 12%
                  

6. RATIONALE.

           a. Highly prevalent HTAโ†’ UNCONTROLLED โŒ„ PREV unrecognized

           b. Screening is FEASIBLE in ophtalmology clinics
           c. ACTIONABLE CVr may be identified

           

7. SOURCE โ–ถ๏ธŽ Samayamanthula S, Williams J, Markowski A, et al. Blood Pressure Assessment in Ophthalmology Clinics for Patients With Diabetes. JAMA Ophthalmol. Published online June 25, 2026. doi:10.1001/jamaophthalmol.2026.2245

      

โณ TIME MANAGEMENT
01:31:19

Round: 8 00:01:24 Closure
Round: 7 12:19:13 Comments
Round: 6 33:05:45 RECAP
Round: 5 21:34:79 Interpretation
Round: 4 04:50:81 Reading + notes
Round: 3 09:10:80 ART selection
Round: 2 00:29:30 Comment
Round: 1 09:47:98 Past JR

2026 NEJMc - Endovascular Therapy for Patients w_Post-Thrombotic Syndrome (NEJM).pdf

Codified by YAPG


Glossary: DVT = deep venous thrombosis, PTS = post-thrombotic syndrome, SOC = standard of care, VCSS = Venous Clinical Severity Score


1. ๐™„๐™Œ๐˜พ ๐™จ๐™˜๐™ค๐™ฅ๐™š โ–ถ๏ธŽ Y, J, C โž– T โž• N โž• t โž– P I C O:
2. 2026, NEJM, โ“ โž– RCT โž• 225 pxs โž• โ“(ฦ’-up 6m) โž– P I C O:

  • ๐Ÿ…ฟ: adults w_mod-to-sev PTS + image (iliac-vein obstruction)
  • ๐Ÿ…ธ: endovascular therapy
  • ๐Ÿ…ฒ: no endovascular therapy
  • ๐Ÿ…พ: pOC = change in the โ€˜30-point VCSSโ€™

3. EVIDENCE:

       a. PTS af_acute lower-extremity DVT:

           i.     pain

           ii.    pruritus

           iii.   edema

           iv.   ulceration

       b. Common in PROXIMAL DVT โ†’ iliac-vein obstruction

4. METHODS.

  • ๐Ÿ…ธ

                - iliac-vein stent

                - antiCOA โ‰ฅ6m

                - aspirin

                - knowledge 

  • Both ๐Ÿ…ธ + ๐Ÿ…ฒ received SOC              
  • SOC = knee-high compression stockings + antiCOA according to r f_recurrent DVT

5. RESULTS.

      a. Baseline โ†’ ๐Ÿ…พ 12 pts

      b. 6m โ†’ ๐Ÿ…พ (p<0.05)

           i.     ๐Ÿ…ธ -4
           ii.    ๐Ÿ…ฒ -2

      c. QOL โ†—๏ธ 
           i.     ๐Ÿ…ธ โœ”๏ธŽ 

           ii.    ๐Ÿ…ฒ โœ–๏ธŽ 

      d. Bleeding

           i.     ๐Ÿ…ธ > common โ†’ 12% 

           ii.    ๐Ÿ…ฒ < common โ†’ 4%

      e. More-potent antithrombotic TTO

           i.     ๐Ÿ…ธ 71%

           ii.    ๐Ÿ…ฒ 21%

6. RATIONALE

      a. Less-experienced operators may NOT APPLY to this study. 

      b. Notice:

7. SOURCE โ–ถ๏ธŽ Vedantham S, et al. Endovascular therapy for post-thrombotic syndrome โ€” A randomized trial. N Engl J Med 2026 Apr 13; [e-pub]. DOI: 10.1056/NEJMoa2519001.

Monday, July 20, 2026 at 18:10:22

EQO, LCO, EMS, LP, MLHG, YAPG, HIBN, AAQC

2025 NEJMc - Cefixime, Might It Be an Option f_ Treating Early Syphilis (JAC).pdf

Codified by YAPG


Glossary: BPG = benzathine penicillin G, RPR = rapid plasma reagin, VDRL = Venereal Disease Research Laboratory test


1. ๐™„๐™Œ๐˜พ ๐™จ๐™˜๐™ค๐™ฅ๐™š โ–ถ๏ธŽ Y, J, C โž– T โž• N โž• t โž– P I C O:
2. 2026, NEJM, โ“ โž– RCT โž• 225 pxs โž• โ“VDRL (ฦ’-up 6m) โž– P I C O:

  • ๐Ÿ…ฟ: adults w_primary, secondary, or early latent syphilis
  • ๐Ÿ…ธ: cefixime 400mg, BID, f_14d
  • ๐Ÿ…ฒ: 2,4M BPG IM
  • ๐Ÿ…พ: 

          - pOC = โ†“โ‰ฅ4-fold VDRL at 3m

          - sOC = โ†“โ‰ฅ4-fold VDRL at 12m

3. EVIDENCE:

       a. โ†‘ prevalence syphilis

       b. shortage of BPG

       c. Abstract cited

           i.     mc_RCT

           ii.    134 pxs (67% w_HIV)

           iii.   ๐Ÿ…ธ 400mg BID f_10d ๐ŸŸฐ 88%

           iv.   ๐Ÿ…ฒ same as current ๐ŸŸฐ 89%

           v.    pOC = โ†“โ‰ฅ4-fold RPR at 3m โŒ„ 6m

    

4. RESULTS.

      a. pOC (3m)

          i.     ๐Ÿ…ธ 73%

          ii.    ๐Ÿ…ฒ 87%

      b. sOC (12m)

          i.     ๐Ÿ…ธ 93%

          ii.    ๐Ÿ…ฒ 97%

      c. Tolerance

          i.     ๐Ÿ…ธ โœ”๏ธŽ 

          ii.    ๐Ÿ…ฒ โœ”๏ธŽ 

5. SOURCE โ–ถ๏ธŽ Klementovรก T et al. Cefixime versus benzathine penicillin G for the treatment of early syphilis โ€” A randomized, controlled open label trial. J Antimicrob Chemother 2025 Aug 7; [e-pub]. (https://doi.org/10.1093/jac/dkaf268)

โณ TIME MANAGEMENT
01:31:19

Round: 8 00:01:24 Closure
Round: 7 12:19:13 Comments
Round: 6 33:05:45 RECAP
Round: 5 21:34:79 Interpretation
Round: 4 04:50:81 Reading + notes
Round: 3 09:10:80 ART selection
Round: 2 00:29:30 Comment
Round: 1 09:47:98 Past JR

Thursday, July 23, 2026 at 18:10:27

EQO, LCO, RMC, JQB, YAPG, MLHG, HIBN, AAQC

2026 NEJMc - Adenosine for Supraventricular Tachycardia, Should We Skip the 6-mg (AEM).pdf

Codified by YAPG


Glossary: ร† = adverse effects, ED = emergency department, NNT = number needed to treat, SVT = supraventricular tachycardia


1. ๐™„๐™Œ๐˜พ ๐™จ๐™˜๐™ค๐™ฅ๐™š โ–ถ๏ธŽ Y, J, C โž– T โž• N โž• t โž– P I C O:
2. 2026, AEM, TR ๐Ÿ‡น๐Ÿ‡ท โž– pros_1c_OBS โž• 142 โž• โ“ โž– P I C O:

  • ๐Ÿ…ฟ: SVT pxs in ED
  • ๐Ÿ…ธ: initial adenosin 12mg
  • ๐Ÿ…ฒ: initial adenosin 6mg
  • ๐Ÿ…พ: 

             - pOC = conversion rate
             - sOC = recurrence โž• ร†

3. EVIDENCE:

      a. GL โ–ถ๏ธŽ HD stable + regular narrow-complex SVT:

           i.     initial adenosine 6mg

           ii.    then 12mg IF no conversion.

       

      b. retro_OBS โ–ถ๏ธŽ consistently show โ†—๏ธ conversion w_12mg

4. RESULTS.

      a. Conversion rate (p<0.05)

               i.    ๐Ÿ…ธ 83% 
               ii.   ๐Ÿ…ฒ 52%

               iii.   NNT 4

      b. Recurrence (p=0.06)

               i.    ๐Ÿ…ธ 1%
               ii.   ๐Ÿ…ฒ 10%

      c. ร†

               i.    ๐Ÿ…ธ ๐—ก๐—ข ๐——๐—œ๐—™๐—™ 

               ii.   ๐Ÿ…ฒ ๐—ก๐—ข ๐——๐—œ๐—™๐—™ 

5. RATIONALE

      a. No โ†‘ in ร†

      b. Until RCTs, CONSIDER initial 12mg โžฉ

           i.     IF history of SVT โž• 

           ii.    who failed to initial 6mg

      c. โ†—๏ธ px experience

           i. Better 1 epidose of discomfort ๐Ÿ†š 2 epidodes.

6. SOURCE โ–ถ๏ธŽ Sert ET, et al. Initial 12 mg versus 6 mg adenosine for supraventricular tachycardia in the emergency department. Acad Emerg Med 2026 May; 33:e70309. DOI: 10.1111/acem.70309.

โณ TIME MANAGEMENT
01:52:59

Round: 11 01:12:26 Comments
Round: 10 40:09:21 RECAP
Round: 9 20:28:02 Interpretation
Round: 8 02:40:10 Reading + notes
Round: 7 01:58:58 Comment
Round: 6 12:06:01 RECAP
Round: 5 15:47:56 Interpretation
Round: 4 03:41:24 Reading + notes
Round: 3 01:21:83 Comments
Round: 2 08:26:08 ART selection
Round: 1 05:08:80 Past JR (+4 min)

2026 NEJMc - Oxygen After Cardiac Arrest, Conservative vs Liberal Strategy (NEJM).pdf

Codified by YAPG


Glossary: C19 = COVID-19, H+dis = hospital discharge, IHCA = in-hospital cardiac arrest, MV = mechanically ventilated, mv_FD = mechanical ventilation-free days, OHCA = out-of-hospital cardiac arrest, ROSC = return of spontaneous circulation, rr_MM = relative risk of mortality


1. ๐™„๐™Œ๐˜พ ๐™จ๐™˜๐™ค๐™ฅ๐™š โ–ถ๏ธŽ Y, J, C โž– T โž• N โž• t โž– P I C O:
2. 2026, NEJM, AUS/NZ ๐Ÿ‡ฆ๐Ÿ‡บ โž– RCT โž• 1800 โž• โ“ (ROSC 25min) โž– P I C O:

  • ๐Ÿ…ฟ: ROSC MV_OHCA โŒ„ IHCA
  • ๐Ÿ…ธ: conservative O2 (SpO2 90-95%)
  • ๐Ÿ…ฒ: liberal O2 (SpO2 no upper limit + FiO2 0.3)
  • ๐Ÿ…พ: 

             - pOC = SS 180 (functional)
             - sOC = MM โž• โ€ฆ

3. EVIDENCE:

      a. O2 can be harmful โ†’ IOTA:

           i.     2018, LANCET, ๐Ÿ‡จ๐Ÿ‡ฆ

           ii.    MA โž• 25 RCT (16k pxs) โž• โ“ 
           iii.   ๐Ÿ…ฟ acutelly ill adults

           iv.   ๐Ÿ…ธ liberal O2

           v.    ๐Ÿ…ฒ conservative O2

           vi.   ๐Ÿ…พ MM30 + MB

           vii.   ยฎ rr_MM30 โ†‘ ๐Ÿ…ธ (RR, 1.14)

           viii.  โˆ‘ logical to test a conservative strategy

      b. Conservative strategy was studied:  


            i.    RCT 1 - PILOT

                     1. 2022, NEJM, Vanderbilt ๐Ÿ‡บ๐Ÿ‡ธ

                     2. RCT โž• 2500 โž• 3y 

                     3. ๐Ÿ…ฟ shock (20%) + CA (13%) pxs (ICU + ED)

                     4. ๐Ÿ…ธ ๐Ÿ…ฒ SpO2 high (96-100%), intermediate (92-96%),                             low (88-92%). Every 2m target adjustment by                                     department. 

                     5. ๐Ÿ…พ MM28 โž• mv_FD 

                     6.โžฉ SpO2 (median) 94%, 95%, 97%

                     7. โžฉ FiO2 (median) 0.31, 0.37, 0.,45

                     8. ยฎ ๐—ก๐—ข ๐——๐—œ๐—™๐—™
              ii.   RCT 2 - EXACT

                     1. 2022, JAMA, ๐Ÿ‡ฆ๐Ÿ‡บ

                     2. RCT โž• 425 โž• stopped early (C19 reasons)

                     3. ๐Ÿ…ฟ ROSC af_OHCA pxs

                     4. ๐Ÿ…ธ low SpO2 (90-94%)

                     5. ๐Ÿ…ฒ high SpO2 (98 - 100%)

                     6. ๐Ÿ…พ H+dis_SS 

                     7. โžฉ FiO2 (median) in ED ๐Ÿ…ธ 0.5 ๐Ÿ†š ๐Ÿ…ฒ 0.8

                     8. โžฉ โ†“O2 ๐Ÿ…ธ 31% ๐Ÿ†š ๐Ÿ…ฒ 16%

                     9. ยฎ BORDERLINE ๐——๐—œ๐—™๐—™ โžฉ 38% ๐Ÿ…ธ ๐Ÿ†š 48% ๐Ÿ…ฒ (p=0.05)

      c. Changes in STRUCTURE โŒ„ COGNITIVE health โ“ 


4. RATIONALE.

      a. SpO2

           i.    ๐Ÿ…ธ 90-95% โ†’ 20% the time

           ii.   ๐Ÿ…ฒ โ‰ฅ97% โ†’ 1/2 the time

      b. pOC โžฉ ๐—ก๐—ข ๐——๐—œ๐—™๐—™

      c. sOC โžฉ ๐—ก๐—ข ๐——๐—œ๐—™๐—™ 


5. SOURCE   

       a. โ Avoid hypoxemia, avoid over-oxygenation, and stay in
the middle ground (oxygen saturations, 90โˆ’98%). (Raja-Elie Abdulnour)     


6. SOURCE โ–ถ๏ธŽ The LOGICAL Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen for unresponsive patients after cardiac arrest. N Engl J Med 2026 Jun 10; [e-pub]. DOI: 10.1056/NEJMoa2513814.

Monday, August 3, 2026 at 18:30:59 CEST

EQO, LCO, RMC, EMS, LP, HIBN, AAQC

2025 NEJMc - A New Bariatric Surgical Option, Single-Anastomosis Duodeno-Ileal Bypass (Lancet).pdf

Codified by YAPG


Glossary: RYGB = Roux-en-Y bypass, SADI-S = single-anastomosis duodeno-ileal bypass with sleeve gastrectomy, Sx = surgery, T2D = type 2 diabetes


1. ๐™„๐™Œ๐˜พ ๐™จ๐™˜๐™ค๐™ฅ๐™š โ–ถ๏ธŽ Y, J, C โž– T โž• N โž• t โž– P I C O:
2. 2025, LANCET, ๐Ÿ‡ซ๐Ÿ‡ท โž– h-t-h_RCT โž• 380 โž• โ“ (ฦ’-up 2y) โž– P I C O:

  • ๐Ÿ…ฟ: Obese adults
  • ๐Ÿ…ธ: SADI-S
  • ๐Ÿ…ฒ: RYGB
  • ๐Ÿ…พ: pOC = weight loss | sOC = complication (early, late, severe)โ€ฆ metabolic (T2D, HTA remission)

3. EVIDENCE:

      a. 2007 โ–ถ๏ธŽ SADI-S:

           i.     Was first described โ†’ simplified bariatric Sx technique

           ii.    Theoretical advantage over RYGB

      

4. RESULTS.

      a. BMI 46 (mean)

               i.    โ€œNo โคน bariatric Sxโ€ โŒ„  
               ii.   โ€œsuboptimal weight โ†“ af_sleeve gastrectomyโ€

      b. Weight loss (p<0.05)

               i.    ๐Ÿ…ธ โœ”๏ธŽ
               ii.   ๐Ÿ…ฒ โœ–๏ธŽ

      c. Early complications โ†’ <30d (p<0.05)

               i.    ๐Ÿ…ธ 6%

               ii.   ๐Ÿ…ฒ 2%

               iii.  e.g. anastomotic leaks

       d. Late complication โ†’ >30d (p<0.05)

               i.    ๐Ÿ…ธ 2%
               ii.   ๐Ÿ…ฒ 10%
               iii.   e.g. internal hernias

       e. Reoperations + severe complications โžฉ ๐—ก๐—ข ๐——๐—œ๐—™๐—™ 

       f.  Diarrhea + reflux

               i.    ๐Ÿ…ธ 2-3x โ†‘ 

               ii.   ๐Ÿ…ฒ โœ–๏ธŽ 

       g. Nutritional deficiencies โžฉ ๐—ก๐—ข ๐——๐—œ๐—™๐—™ 

โณ TIME MANAGEMENT
55:16:16

Round: 7 02:18:05 Comments
Round: 6 21:36:73 RECAP
Round: 5 08:41:61 Interpretation
Round: 4 02:59:85 Reading + notes
Round: 3 06:25:24 ART selection
Round: 2 00:51:92 Comments
Round: 1 12:22:73 Past JR

5. RATIONALE.

      a. ๐Ÿ…ธ was expected to be more popular:

           i.    superior in weight โ†“

           ii.   safety

           iii.  usefulness w_โคน sleeve gastrectomy

      b. Procedure is endorsed by a U.S. professional society on bariatric surgery






































SOURCE โ–ถ๏ธŽ Robert M et al. Efficacy and safety of single-anastomosis duodeno-ileal bypass with sleeve gastrectomy versus Roux-en-Y gastric bypass in France (SADISLEEVE): Results of a randomised, open-label, superiority trial at 2 years of follow-up. Lancet 2025 Aug 23; 406:846. (https://doi.org/10.1016/S0140-6736(25)01070-0)

Monday, August 10, 2026 at 18:02:20 CEST

EQO, LCO, EMS, SLDC, HIBN, AAQC

2026 NEJMc - ACOG Updates Maternal Immunization Guidance (Obstet Gynecol).pdf

Codified by YAPG


Glossary: mAb = monoclonal antibody, MMR = measles, mumps, and rubella, PCT = prenatal care team, PH = public health, Tdap = tetanusโ€“diphtheriaโ€“pertussis, VAX = vaccination, vaccine


1. ๐™„๐™Œ๐˜พ ๐™จ๐™˜๐™ค๐™ฅ๐™š โ–ถ๏ธŽ Y, J, C โž– T โž• N โž• t โž– P I C O:
2. 2026, OG, ๐Ÿ‡บ๐Ÿ‡ธ โž– GL โž• NA โž• NA โž– P I C O: NA

3. EVIDENCE:

      a. Prenatal VAX rates โ†“ in recent years:


           i.     mistrust

           ii.    shift of PH guidance

      b. Many organizations have โ˜… 

      c. ACOG โ–ถ๏ธŽ when VAX is โ˜… by pxsโ€™ prenatal care team (PCT), โ†‘โ†‘โ†‘ ACCEPTANCE 

4. โ˜….

  •   Assessment of PCT:

               -    VAX status
               -    individual risk of illness

  •   SAFETY

               -    ACOG reaffirms it
               -    NO evidence of fetal ร†

  •  ROUTINE

              -    C19 + influenza + Tdap

  •  Tdap

              -    ASAP โ†’ 27-36w

  •  RSV

              -    32-36w
              -    Sep-Jan
              -    IF mother DID NOT receive โ†’ mAb is an option

  •   POSTPARTUM โ†’ For pxs wo_immunity to:  

             -    MMR

             -    VARICELLA

             -    Both are CONTRAINDICATED d_preg

5. RATIONALE.

      a. Re-emergence of this illnesses is a REALITY (USA)

      b. Genuine understanding of consequences:

               i.    mild cases of C19 โ†’ adverse OC

               ii.   Influenza โ†’ severe illness + H+

      c.  USA has the highest MM rate in the world (despite low risk)

      d.  Make sure pxs understand CONTEXT

6. SOURCE โ–ถ๏ธŽ Maternal Immunizations. Obstet Gynecol 2026 May 1; 147:e123. DOI: 10.1097/AOG.0000000000006230. PubMed

โณ TIME MANAGEMENT
55:16:16

Round: 7 02:18:05 Comments
Round: 6 21:36:73 RECAP
Round: 5 08:41:61 Interpretation
Round: 4 02:59:85 Reading + notes
Round: 3 06:25:24 ART selection
Round: 2 00:51:92 Comments
Round: 1 12:22:73 Past JR

2026 NEJMc - Local Anesthesia for Inguinal Hernia Repair (Surgery).pdf

Codified by YAPG


Glossary: COM30 = complications at 30days, INB = ilioinguinal nerve block, intra_OP = intraoperative, post_OP = postoperative


1. ๐™„๐™Œ๐˜พ ๐™จ๐™˜๐™ค๐™ฅ๐™š โ–ถ๏ธŽ Y, J, C โž– T โž• N โž• t โž– P I C O:
2. 2026, SURGERY, โ“ โž– mc_OBS โž• 164 โž• โ“(ฦ’-up 1,5y) โž– P I C O:

  • ๐Ÿ…ฟ: adults w_inguinal hernia
  • ๐Ÿ…ธ: ilioinguinal nerve block (INB)
  • ๐Ÿ…ฒ: NA
  • ๐Ÿ…พ: pOC = safety

3. EVIDENCE:

      a. Symptomatic inguinal hernias = surgical repair

      b. General anesthesia risks โ†’ new option is INB

      c. Limited data


            i.  2023, JAMA Surg, ๐Ÿ‡บ๐Ÿ‡ธ  (U.S. Veterans Affairs)

            ii.  retro_OBS โž• 107k โž• โ“ 

            iii. ๐Ÿ…ฟ inguinal hernia

            iv. ๐Ÿ…ธ 

               -    open repair under general anesthesia
               -    open repair under local anesthesia

               -    laparoscopic repair

             v.  ๐Ÿ…ฒ NA

             vi. ๐Ÿ…พ complications

             vii. ยฎ COM30 

                -   general ๐Ÿ†š laparos โ€œ1% โ†“โ€œ

                -   local ๐Ÿ†š laparos โ†’ ๐—ก๐—ข ๐——๐—œ๐—™๐—™ 

             viii. ยฎ TIME 


4. RESULTS.

      a. 71yo โ†’ DM 15% โž• โ€˜โคน๐Ÿซ€DISโ€™ 45%

      b. intra_OP COM โ†’ NONE

      c. post_OP COM:

               i.    seroma โ†’ 9%

               ii.   temporary drain โ†’ 1px

               iii.  observation โ†’ the rest

      d.  Urinary retention โ†’ 4%

      e.  Cellulitis โ†’ 3pxs (2%)

      f.  Recurrences โž• mesh INF โ†’ NONE

      g. Bill โ†’ 6000 USD

6. RATIONALE.

      a. Minimal symptoms + comorbilities โ†’ might make us doubt on GENERAL ANESTHESIA

      b. Price is โ†“ 

                i. robotic

                ii. laparoscopic

       c. Check availability w_trusted surgical team


6. SOURCE โ–ถ๏ธŽ

โ–ถ๏ธŽ Wiley AJ, et al. Utilizing local anesthesia and monitored anesthesia care sedation in open inguinal hernia repair in complex, comorbid patients. Surgery 2026 Mar; 191:109910. DOI: 10.1016/j.surg.2025.109910.

Monday, August 17, 2026 at 18:20:32 CEST

EQO, LP, YZE, EMS, HIBN, AAQC

2026 NEJMc - 2026 Guidelines on Managing Pediatric Constipation (J Pediatr Gastroenterol Nutr).pdf

Codified by LCO


Glossary: โ˜… = recommendation(s), GPS = good practice statements, PEG = polyethylene glycol, PG = pediatric gastroenterologist, QOL = quality of life, Sx = surgery, TTO = treatment(s)


๐™„๐™Œ๐˜พ ๐™จ๐™˜๐™ค๐™ฅ๐™š โ–ถ๏ธŽ Y, J, C โž– T โž• N โž• t โž– P I C O:
2026, JPGN, ๐Ÿ‡ช๐Ÿ‡บ ๐Ÿ‡บ๐Ÿ‡ธ โž– GL โž• 102 RCT โž• โ“ โž– P I C O:

  • ๐Ÿ…ฟ: 0-18yo

3. EVIDENCE.

       a. Children functional constipation impairs QOL
       b. Update โ–ถ๏ธŽ 2014 GL

4. METHODS.

  • Focus on TTO

5. RESULTS.
       a. Issued:
             i.    11 evidence-based โ˜… 

             ii.   19 GPS
             iii.   Stepwise TTO algorithm
        b. PHARMACOLOGIC
             i.     PEG (w_ โŒ„ wo_ electrolytes) โ†’ maintenance

             ii.    Milk of magnesia 

                       1.   less success than PEG
                       2.   โ†‘ withdrawals โ†’ โ†‘ ร†
             iii.   Linaclotide

                       1.    6 - 17yo
                       2.    Only when TTO failure
                       3.     Prescribed by PG                         


              iv.   Enemas + rectal suppositories

                       1.   NOT SUGGESTED as maintenance
                       2.   due to psychosocial impact

              v.  Enemas โŒ„ high-dose oral PEG (1-1.5 g/Kg/d)

                     1. fecal impaction

      c.  NONPHARMACOLOGIC

              i.    Balanced diet

                      1.   water

                      2.   fiber

                      3.   toilet-training program

              ii.   Adjunt options

                      1.   probiotic
                      2.   synbiotic
                      3.   physiotherapy (pelvic floor)

                      4.   neurostimulation w_pelvic floor exercises

              iii.  Cowโ€™s milk-free diet

                      1.   can be trialed
                      2.   when cowโ€™s milk allergy is suspected

                      3.   when not responded to conventional TTO

       d. ADDITIONAL

               i. Lactulose + laxatives (bisacodyl, senna, or sodium picosulfate)

                      1.   limited evidence

               ii. Mineral oil โ†’ NOT โ˜… (ร†)

               iii. Sx โ†’ refractory constipation (medical TTO)


6. RATIONALE.

       a. PEG = Miralax โ†’ 1st line

       b. Understand the parents (immediate relief)

       c. See table 10 for doses.

       d. โ Although high-dose PEG can require a challenging volume, Iโ€™ve had success administering it through a nasogastric tube. (Clement Lee)


7. SOURCE โ–ถ๏ธŽ Gordon M, et al. European Society for Paediatric Gastroenterology, Hepatology and Nutrition/North American Society for Pediatric Gastroenterology, Hepatology and Nutrition guidelines for treatment of functional constipation in children aged 0โ€“18years. J Pediatr Gastroenterol Nutr 2026 May 20; [e-pub]. DOI: 10.1002/jpn3.70447. PubMed

โณ TIME MANAGEMENT
01:05:45

Round: 6 09:07:23 Comments
Round: 5 30:51:81 RECAP
Round: 4 10:07:85 Interpretation
Round: 3 03:53:82 Reading + notes
Round: 2 06:43:54 ART selection
Round: 1 05:01:54 Past JR

July, 2026

Thursday, August 13, 2026 at 18:05:31 CEST

EQO, RCH, LP, YZE, EMS, HIBN, AAQC

2026 NEJMc - Updated Cervical Cancer Screening Guidelines (Obstet Gynecol).pdf

Codified by YAPG


Glossary: โ˜… = recommendation(s), COTESTING = cytology + hrHPV, hrHPV = high-risk human papillomavirus, mm = management, WPSI = Womenโ€™s Preventive Services Initiative


๐™„๐™Œ๐˜พ ๐™จ๐™˜๐™ค๐™ฅ๐™š โ–ถ๏ธŽ Y, J, C โž– T โž• N โž• t โž– P I C O:
2026, OG, ๐Ÿ‡บ๐Ÿ‡ธ โž– GL โž• NA โž• NA โž– P I C O:

  • ๐Ÿ…ฟ: โ™€ 21-65yo

3. EVIDENCE:

      a. January 2026 โ–ถ๏ธŽ WPSI presented the CA screening GL


    

4. METHODS.

  •  Apply to โ™€ AVERAGE risk of cervical CA
  •  DO NOT APPLY (require INDIVIDUALIZED mm):

               -    HIV INF
               -    immunosuppression

               -    in utero diethylstilbestrol exposure

               -    History of grade โ‰ฅ2 cervical dysplasia

  •  This is an update to 2021 GL โ†’ 2024 US Task Force (draft form)

5. RESULTS.

      a. Cervical CA screening โ†’ 21-65yo

      b. 21-29yo RED + 30-65 GREEN

      c. Cytology:

              i.   21-29yo โ–ถ๏ธŽ should NOT receive COTESTING

              ii.  every 3y (maintains)

      d.  Primary hrHPV testing:

              i.    30-65yo

              ii.   every 5y (๐Ÿ†•)

              iii.  COTESTING every 5y (maintains)

              iv.  Cytology alone (when hrHPV unavailable) every 3y (maintains)

       e. px-collected hrHPV:

               i. 30-65yo

               ii. ACCURACY โ†’ pxs ๐Ÿ†š clinicians โ†’ ๐—ก๐—ข ๐——๐—œ๐—™๐—™


6. RATIONALE.

       a. ACOG:

          i.   endorsed these โ˜… 

          ii.  px-collected hrHPV testing โ†’ every 3y (instead of 5y) only when these systems are in place:

                   - notificaiรณn
                   - ฦ’-up

       b. More common currently (px-collected one)

       c. To evaluate:

           i. โ†“ cervical CA incidence 

           ii. MM


SOURCE โ–ถ๏ธŽ Vosooney A, et al. Screening for Cervical Cancer: A Recommendation From the Womenโ€™s Preventive Services Initiative. Obstet Gynecol 2026 Jul; 148:e3. DOI: 10.1097/AOG.0000000000006315.

โณ TIME MANAGEMENT
57:29:78

Round: 6 06:57:56 Comments
Round: 5 17:18:87 RECAP
Round: 4 11:19:94 Interpretation'
Round: 3 03:18:41 Reading + notes
Round: 2 07:19:66 ART selection
Round: 1 11:15:32 Past JR

Thursday, August 20, 2026 at 18:05:38 CEST

EQO, YZE, EMS, HIBN, AAQC

2026 USweb - Dietary guidelines for Americans (FedGov) [GL].pdf

Codified by ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ (AAQC)


Glossary: cDIS = chronic disease, FFQ = food frequency questionnaire, HC = healthcare, moo = microorganisms, semiQ = semiquantitative


1. ๐™„๐™Œ๐˜พ ๐™จ๐™˜๐™ค๐™ฅ๐™š โ–ถ๏ธŽ Y, J, C โž– T โž• N โž• t โž– P I C O:

2. 2026, USweb, ๐Ÿ‡บ๐Ÿ‡ธ โž– GL โž• NA โž• NA โž– P I C O: ๐Ÿ…ฟ: Adults

3. EVIDENCE.

       a. 90% of HC spending โ†’ TTO
       b. cDIS:
             i.   genetic destiny โœ–๏ธŽ 
             ii.  predictable result โœ”๏ธŽ โžฉ highly processed foods + sedentarism
       c. >70% are overweight โŒ„ obese

       d. 1 in 3 โ†’ prediabetes (12-17yo)

4. METHODS.

  • These Guidelines call on every American to eat more real food
  • Call on farmers, ranchers, health care professionals,
    insurers, educators, community leaders, industry, and lawmakers across all levels โ†’ JOIN THIS CRITICAL EFFORT

5. RESULTS.
       a. AMOUNT:
             i.    Calories โ†’ depends on age, sex, height, weight, and level of
physical activity. 

             ii.    Portion โ†’ pay attention
             iii.   Hydration โ†’ KEY FACTOR (water + unsweetened beverages)
        b. PROTEIN
             i.     High-quality โ†’ nutrient-dense

             ii.    Variety โ†’

                       1.   animal: eggs, poultry, seafood, and red meat,
                       2.   plant-sourced: beans, peas, lentils, legumes, nuts, seeds,
and soy.
             iii.   Method โ†’

                       1.    โœ–๏ธŽ deep-fried cooking n  

                       2.    โœ”๏ธŽ baked, broiled, roasted, stir-fried, or grilled cooking            


              iv.   Meat โ†’ no sugar + carbohydrates โŒ„ starches โŒ„ CHEMICAL ADDITIVES

              v.  Serving goals โ†’ 1,2-1,6 g/Kg/d (adjusted to Cal requirements)

      c.  DAIRY

              i.    Full-fat dairy w_NO added sugar

              ii.   protein, healthy fats, vitamins, and minerals.       

              iii.  Serving goals โ†’ 3 servings (2000 Cal, adjusted)

       d. GUT HEALTH = Microbiome = trillons of bacteria + other moo

               i. Support

                      1.   healthy diet

                      2.   Vegetables

                      3.   Fruits
                      4.   Fermented foods โ†’ sauerkraut, kimchi, kefir, miso
                      5.   High-fiber foods

               ii. Disrupt

                      1.   highly processed foods
         e. VEGGIES + FRUITS

               i.    Colorful
               ii.   Original form โ†’ WASH THOROUGHLY

               iii.   Frozen, dried, or canned (NO or โ†“ added sugars)

               iv.   OK to use salt + spices + herbs
               v.    100% juice โ†’ in LIMITED PORTIONS or DILUTED w_water

               vi.    2021 CRICULATION ๐Ÿ‡บ๐Ÿ‡ธ โž– MA + OBS โž• >65k โ™€ >40k โ™‚๏ธŽ โž• NA โž– 

                        1.   ๐Ÿ…ฟ adults wo_cDIS at baseline

                        2.   ๐Ÿ…ธ validated semiQ FFQ

                        3.   ๐Ÿ…ฒ NA

                        4.   ๐Ÿ…พ acMM + espMM (CA + ๐Ÿซ + ๐Ÿซ€ )

                        5.   ยฎ
                                a.    100-87 = 13% total MM
                                b.    100-88 = 12% ๐Ÿซ€ MM
                                c.    100-90 = 10% CA MM
                                d.    100-65 = 35% ๐Ÿซ MM

                vii.    VEGGIES: 3 serving/day โž• FRUITS: 2 serving/day

         f. HEALTHY FATS
               i.      Plentiful in WHOLE FOODS โ†’ meats, poultry, eggs, 
               ii.     Olive oil 
               iii.    Butter โŒ„ BEEF TALLOW

               iv.    Saturated fat โ†’ <10% of Cal

               v.     Type of fats BEST for l-t health โžฉ โ†‘ high-quality research is needed
         g. ...

6. SOURCE โ–ถ๏ธŽ https://www.dietaryguidelines.gov/?utm_source=chatgpt.com

       

โณ TIME MANAGEMENT
01:35:38

Round: 6 00:56:85 Comments
Round: 5 32:56:40 RECAP
Round: 4 45:19:41 Interpretation
Round: 3 04:25:83 Reading + notes
Round: 2 06:41:59 ART selection
Round: 1 05:18:59 Past JR

Monday, August 24, 2026 at 18:00:24 CEST

EQO, LCO, BAR, RCH, HIBN, AAQC

2026 NEJMc - Sitting with Patients at the Bedside (J Hosp Med).pdf

Codified by ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ (TGA)


Glossary: d_ = during, INF = infection, JHM = Journal of Hospital Medicine


1. ๐™„๐™Œ๐˜พ ๐™จ๐™˜๐™ค๐™ฅ๐™š โ–ถ๏ธŽ Y, J, C โž– T โž• N โž• t โž– P I C O:

2. 2026, JHM, โ“ โž– r โž• NA โž• โ“ โž– P I C O:

  • ๐Ÿ…ฟ: Physicians d_rounds
  • ๐Ÿ…ธ: sitting
  • ๐Ÿ…ฒ: standing
  • ๐Ÿ…พ: OC = communication + visit duration + px satisfaction

3. EVIDENCE.

       a. Standing at the beside d_encounters โ†’ makes us believe it:
             i.   saves time
             ii.  improve clinical efficiency 

4. METHODS.

  • Series: โ€œThings We Do For No Reasonโ„ข

5. RESULTS.
       a. Pxsโ€™ preference
             i.    Studies โ–ถ๏ธŽ they prefer clinicians to sit
       b. Communication
             i.     RCT (small) โ–ถ๏ธŽ โ†—๏ธ significantly w_๐Ÿ…ธ

       c. Visit duration

             i.   Multiple studies โ–ถ๏ธŽ ๐Ÿ…ธ DOES NOT โ†‘

       d. Pxsโ€™ perception

             i.   AS LONGER when physicians are seated

โณ TIME MANAGEMENT
01:00:16

Round: 7 1:32:76 Closure
Round: 6 10:17:72 Comments
Round: 5 20:02:89 Wrap-up
Round: 4 15:09:52 Interpretation
Round: 3 02:49:09 Reading + notes
Round: 2 03:07:86 ART selection
Round: 1 07:57:68 Past JR

6. RATIONALE.

      a. Time to abandon STANDING at the bedside.  

      b. โ sometimes kneelโ€ฆ avoid sitting on the edgeโ€ฆ for purposes of INF + PRIVACY (Daniel Dressler)

      c.  Same time โžฉ pxs feel more HEARD โž• acknowledged.

      d.  Unpublished data โ–ถ๏ธŽ satifaction scores โ†—๏ธ when sitting

      e.  ๐Ÿ…ธ โ†’ inconvenient BUT worth it














              

7. SOURCE โ–ถ๏ธŽ Gray A, et al. Things We Do for No Reasonโ„ข: Standing at the bedside. J Hosp Med 2026 Feb 22; [e-pub]. DOI: 10.1002/jhm.70293.

       

Thursday, August 27, 2026 at 18:15:35 CEST

EQO, LP, YZE, HIBN, AAQC

2025 NEJMc - Updating Community-Acquired Pneumonia Management (Calderon) [r].pdf

Codified by ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ (HIBN)


GLOSSARY: โ˜… = recommendation(s), โ†“ imm = immunocompromised, ATB = antibiotic, ATS = American Thoracic Society, BSAT = broad-spectrum antibiotic therapy, CID = Clin Infect Dis, hLOS = hospital length of stay, InvDev = invasive devices, ipl = individual patient-level, l-t care = long-term care, MDROs = multidrug-resistant organisms, reADM = readmission, SS = survival, trans_ICU = ICU transfers, US = ultrasound


1. 2025 โ–ถ๏ธŽ

  a. BSAT is NOT neccesary in MODERATELY IMMUNOCOMPROMISED

      b. Which px benefit MOST w_steroids

2. 2025, CID, ๐Ÿ‡บ๐Ÿ‡ธ Michigan โž– retroOBS โž• 2700 โž• โ“ โž– P I C O โ–ถ๏ธŽ

       a. ๐Ÿ…ฟ: moderately โ†“imm H+ w_CAP

       b. ๐Ÿ…ธ: BSAT (covers MRSA โŒ„ Pseudomonas โŒ„ both)

       c. ๐Ÿ…ฒ: GL โ˜… narrow-spectrum ATBs

       d. ๐Ÿ…พ: MM + reADM + trans_ICU + โ†‘ hLOS

       e. ยฎ MRDO 3,5% โžฉ โ uncommon

       f.  ยฎ BSAT โžฉ NO SS benefit

       g. โˆ‘ standard CAP regimens ARE ENOUGH (ceftriaxona w_axithro โŒ„ doxy)

       h. โˆ‘ was done in pxs wo_rf for MRDO

           i. MRSA: 

                 1. HC 

                         a. ATB use

                         b. H+ โคน โŒ„ l-t care

                         c. โ†“imm

                         d. Comorb (DM, โ—ธ cirrhosis, โ™พ๏ธ)

                         e. InvDev
                         f. โคน MRSA colonization

                 2. community

                        a. crowded โŒ„ unhygienic living

                        b. skin-to-skin โ†’ contact sports
                        c. utensils sharing

                        d. injection


                

โณ TIME MANAGEMENT
01:33:16

Round: 6 01:17:72 Comments
Round: 5 40:02:89 RECAP
Round: 4 30:09:52 Interpretation
Round: 3 3:49:09 Reading + notes
Round: 2 05:07:86 ART selection
Round: 1 07:57:68 Past JR + 10min

               

      ii. Pseudomonas: โ€œ=MRSAโ€ + โ€œ๐Ÿซ (โ€ฆintubation, MV, DIS)โ€

      iii. SOURCE: Saravolatz L et al. Target trial emulation of empiric antibiotics on clinical outcomes in moderately immunocompromised patients hospitalized with pneumonia Clin Infect Dis 2025 Jul 2; [e-pub]. https://doi.org/10.1093/cid/ciaf344)

3. 2025, LANCETrm, NL โž– ipl_MA (8 RCT) โž• >3200 โž• โ“ โž– P I C O โ–ถ๏ธŽ 

       a. ๐Ÿ…ฟ H+ pxs w_sevCAP

       b. ๐Ÿ…ธ CRP โž• PSI โž• CURB-65 โž• ICU ADM โŒ„ MV 

       c. ๐Ÿ…ฒ NA

       d. ๐Ÿ…พ MM30
       e. ยฎ โ†“MM30 โžฉ CRP > 204 mg/L

       f. ยฎ CRP <204 โžฉ โ†‘GLU + H+ reADM

       g. SOURCE: Smit JM et al. Predicting benefit from adjuvant therapy with corticosteroids in community-acquired pneumonia: A data-driven analysis of randomised trials. Lancet Respir Med 2025 Mar; 13:221. (https://doi.org/10.1016/S2213-2600(24)00405-3)

4. GL โ–ถ๏ธŽ 

       a. ATS

           i. US ๐Ÿซ โœ”๏ธŽ โžฉ ALTERNATIVE for Xrays

           ii. ATBs:

                      1. Withholding โ†’ outPXS w_+VIRAL PANEL โž• no COMORB

                      2. Continue โ†’ H+_PXS โž• outPXS w_COMORB (regarless of VIRAL PANEL)

           iii. SOURCE: Jones BE et al. Diagnosis and management of community-acquired pneumonia: An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med 2025 Jul 18; [e-pub]. (https://doi.org/10.1164/rccm.202507-1692ST)

       b. IDSA

           i. point 2 of ATS โžฉ โœ–๏ธŽ 

                 1. unnecessary ATB overuse

           ii. ATB SHORTER COURSES

                 1. in pxs w_clinical stability

                 2. 3d โ†’ nonsevere CAP

                 3. 5d โ†’ severe CAP

           iii. Steroids

                  1. โœ”๏ธŽ severe (wo_INFLUENZA) 

                  2. โœ–๏ธŽ nonsevere

Monday, August 31, 2026 at 19:07:23 CEST

EQO, KEC, YZE, EMS, AAQC

2026 NEJMc - Antibiotics and the Gut Microbiome(Nat Med).pdf
Codified by YAPG


Glossary: CVD = cardiovascular DIS, DIS = diseases, DM = diabetes, l-t = long-term.

1. ๐™„๐™Œ๐˜พ ๐™จ๐™˜๐™ค๐™ฅ๐™š โ–ถ๏ธŽ Y, J, C โž– T โž• N โž• t โž– P I C O:

2.2026, Nat Med, SW โž– ๐Ÿค“ pros_SURVEILL studies โž• 15k โž• 8y โž– P I C O:

  •  ๐Ÿ…ฟ: adults > receiving ATBs
  •  ๐Ÿ…ธ: l-t patterns in GUT FLORA โžฉ FECAL SPECIMENS
  •  ๐Ÿ…ฒ: NA
  •  ๐Ÿ…พ: pOC = ATB effects

3. EVIDENCE.   

       a. ATBs โ†’ reliably wreak havoc โžฉ gut microbiome

       b. Duration is unknown (systematically)

       

4. RESULTS.

  • SAFETY โ“ 
  • 3 criteria in YEARS:

        a. 70% = ONE COURSE

        b. ALTERATION

          i.    โ†“ bacterial species

          ii.    overgrowth
          iii.   โ†‘courses = โ†‘profound + โ†‘ persistent CHANGES

   


                

    

       c. ENDURING EFFECTS (FFC)

           i.    Clindamycin

           ii.   fluoroquinolones
           iii.  LEAST DRAMATIC (PATAN)

       d. ENDURING EFFECTS (FFC)

            i. penicillin V

            ii. amoxicillin

            iiii. trimethoprim-sulfamethoxazole

            iv. nutrofurantoin
            v.  Amoxi-clavulanate (mild sequealae - rarely used in SW)

       c. In other types of CA โ†’ avoid CTPA and OK YEARS only.

6. RATIONALE.

       a.  Diarrheal DIS โ†’ colorectal CA โžฉ DM โ†’ CVD

       b.   โ Even a brief oral course can have profound and long-lasting sequelae. (Abigail Zuger)

7. SOURCE โ–ถ๏ธŽ Baldanzi G, et al. Antibiotic use and gut microbiome composition links from individual-level prescription data of 14,979 individuals. Nat Med 2026 Mar 11; [e-pub]. DOI: 10.1038/s41591-026-04284-y.

  

โณ TIME MANAGEMENT
01:29:16

Round: 10 01:59:19 Comments
Round: 9 11:47:81 Wrap-up
Round: 8 12:03:26 Interpretation
Round: 7 03:32:76 Reading + notes
Round: 6 01:17:72 Comments
Round: 5 15:02:89 Wrap-up
Round: 4 07:09:52 Interpretation
Round: 3 05:49:09 Reading + notes
Round: 2 03:07:86 ART selectionRound: 1 07:57:68 Past JR + 10min

August, 2026

Monday, September 14, 2026 at 18:01:58 CEST

EQO, BKN, C, KYEC, LP, HIBN, AAQC

2026 NEJMc - A New Guideline on Cardiovascularโ€“Kidneyโ€“Metabolic Syndrome (AHA).pdf

Codified by ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ (LCO)


Glossary: ACC = American College of Cardiology, ADA = American Diabetes Association, AHA = American Heart Association, ASN = American Society of Nephrology, CKD = chronic kidney disease, CKM = cardiovascular-kidney-metabolic syndrome, CVD = cardiovascular disease, HF = heart failure, T2D = type 2 diabetes


1. ๐™„๐™Œ๐˜พ ๐™จ๐™˜๐™ค๐™ฅ๐™š โ–ถ๏ธŽ Y, J, C โž– T โž• N โž• t โž– P I C O:

2. 2026, CIRCULATION, USA ๐Ÿ‡บ๐Ÿ‡ธ โž– GL โž• NA โž• โ“ โž– P I C O:

  •  ๐Ÿ…ฟ: Adults
  •  ๐Ÿ…ธ: CKM
  •  ๐Ÿ…ฒ: NA
  •  ๐Ÿ…พ: pOC = mm + ฦ’-up

3. EVIDENCE.   


       a. CKD risk categories (KDIGO)











       b. Prediabetes CRITERIA 2026 (ADA)









     

       c. T2D criteria (ADA)  














       d. CKD definition - KDIGO 2021











4. METHODS.

  • AHA, ACC, ADA, ASN endorsed.  
  • New syndrome โ†’ unified framework
  • DEF: systemic disorder โ†’ interaction among:

              -  Obesity ๐Ÿงธ

              -  T2D ๐Ÿซ

              -  CKD โ™พ๏ธ

              - CVD ๐Ÿซ€ 

 5. RESULTS.

        a. 4 stages

             i.    1. overweight โŒ„ obesity โŒ„ prediabetes

             ii.   2. HTA โŒ„ T2D โŒ„ mod-hr_CKD

             iii.  3. subclinical CVD (calcifications โŒ„ pre-HF) โŒ„ โ‰ฅ20% (r_10y of CVD) PREVENT calculator โŒ„ hr_CKD

             iv. 4. Clinical CVD w_CKM conditions

        b. PREVENT โ†’ 10-30y r_ASCVD, total CVD, HF
        c. Monitoring:     

           i.  2-3y, S1: 

                  1. lipids

                  2. glycemia

                  3. eGFR
           ii. 1y, other S:

           iii. UACR โ†’ 1y at โ‰ฅS2

โณ TIME MANAGEMENT
02:27:28

Round: 6 00:55:42 Comments
Round: 5 02:05:13 RECAP
Round: 4 09:20:02 Interpretation
Round: 3 03:35:38 Reading + notes
Round: 2 04:31:72 ART selectionRound: 1 03:52:22 Past JR

    

       d. Overweight + obesity โ†’ CONSIDERED root cause of CKM

           i.   AGGRESIVE lifesyle modification

           ii.  pharmacologic TTO (selected pxs)









   









6. RATIONALE.

       a. We should know the NEW FRAMEWORK

       b. Tan Y, Wu Y, Ding X, et al. A prospective cohort study on the 














       c. Li N, Li Y, Cui L, et al. Association between different stages of cardiovascular-kidney-metabolic syndrome and the risk of all-cause mortality. Atherosclerosis. 2024;397:118585. doi:10.1016/j.atherosclerosis.2024.118585






       d. Li J, Wei X. Association of cardiovascular-kidney-metabolic syndrome with all-cause and cardiovascular mortality: A prospective cohort study. Am J Prev Cardiol. 2025;22:100985. Published 2025 Mar 29. doi:10.1016/j.ajpc.2025.100985















7. SOURCE โ–ถ๏ธŽ Ndumele CE, et al. AHA/ACC/ADA/ASN guideline for the prevention, detection, evaluation, and management of cardiovascularโ€“kidneyโ€“metabolic syndrome: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2026 Jun 9; 2026; [e-pub]. DOI: 10.1161/CIR.0000000000001453. PubMed

  

Monday, September 10, 2026 at 19:07:23 CEST

EQO, BKN, C, KYEC, LP, HIBN, AAQC

2026 NEJMc - Antibiotics and the Gut Microbiome(Nat Med).pdf

Codified by YAPG


Glossary: CVD = cardiovascular DIS, DIS = diseases, DM = diabetes, l-t = long-term.


1. ๐™„๐™Œ๐˜พ ๐™จ๐™˜๐™ค๐™ฅ๐™š โ–ถ๏ธŽ Y, J, C โž– T โž• N โž• t โž– P I C O:

2. 2026, Nat Med, SW โž– ๐Ÿค“ pros_SURVEILL studies โž• 15k โž• 8y โž– P I C O:

  •  ๐Ÿ…ฟ: adults > receiving ATBs
  •  ๐Ÿ…ธ: l-t patterns in GUT FLORA โžฉ FECAL SPECIMENS
  •  ๐Ÿ…ฒ: NA
  •  ๐Ÿ…พ: pOC = ATB effects

3. EVIDENCE.   

       a. ATBs โ†’ reliably wreak havoc โžฉ gut microbiome

       b. Duration is unknown (systematically)

4. RESULTS.

  • SAFETY โ“ 
  • 3 criteria in YEARS:

              -  deep-vein thrombosis

              -  hemoptysis

              -  PE as most likely DX

  • โž• D-dimer
  • Can we exclude PE wo_CTPAโ“ 

     


                

โณ TIME MANAGEMENT
37:54:51

Round: 5 02:19:54 Comments
Round: 4 14:06:68 RECAP
Round: 3 17:26:47 โ“˜
Round: 2 02:39:89 Reading + notes
Round: 1 01:21:92 ART selection

    

5. RESULTS.

       a. Frequency ๐Ÿ…พ

           i. YEARS < โ†’ 1,8%

           ii. CTPA > โ†’ 5,5%

       b. Avoid CTPA

           i. 22%

6. RATIONALE.

       a. Safe always w_D-DIMER. 

       b. Editorialists โ†’ might NOT APPLY:

            i. โ†‘ thrombogenic CA

            ii. pancreatic

            iiii. hepatobiliary

       c. In other types of CA โ†’ avoid CTPA and OK YEARS only.

7. SOURCE โ–ถ๏ธŽ Akerboom B, et al. YEARS algorithm for diagnosis of suspected pulmonary embolism in patients with cancer: A randomized clinical trial. JAMA 2026 Jul 12; [e-pub]. DOI: 10.1001/jama.2026.10676. PubMed

8. SOURCE โ–ถ๏ธŽ Han HB, Beckman JA. Ruling Out PE in Cancer โ€” Can YEARS Reduce CT Imaging? JAMA 2026 Jul 12; [e-pub]. DOI: 10.1001/jama.2026.12480. PubMed

  

2026 NEJMc - Guideline Watch Roundup.pdf โ€“ Anemia in Chronic Kidney Disease: A New Guideline from KDIGO

Codified by ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ (EQO)


Glossary: CBC = complete blood count, CKD = chronic kidney disease, DEF = definition, ESAs = erythropoiesis-stimulating agents, Sโ€  = stroke, TSAT = transferrin saturation, TTO = treatment(s)


1. ๐™„๐™Œ๐˜พ ๐™จ๐™˜๐™ค๐™ฅ๐™š โ–ถ๏ธŽ 2026, KI, โ“ โž– GL โž• NA โž• NA โž– P I C O:

  •  ๐Ÿ…ฟ: Adults + โ€œchildrenโ€
  •  ๐Ÿ…ธ: Anemia โ†’ CKD

2. EVIDENCE.   


       a. GL โ†’ sr w_evidence appraisal โ†’ Expert opinion โ†’ PRACTICE POINTS

       b. Last GL on anemia โ†’ a DECADE ago

       c. 

Thursday, September 17, 2026 at 18:20:58 CEST

EQO, BKN, C, KYEC, LP, HIBN, AAQC

โณ TIME MANAGEMENT
01:39:14

Round: 6 00:35:85 Comments
Round: 5 32:23:32 RECAP
Round: 4 26:27:00 Interpretation
Round: 3 04:31:48 Reading + notes
Round: 2 05:38:91 ART selection
Round: 1 29:37:99 Past JR

    

3. DX โž• EVAL.

  • Screen

           i.    CBC

           ii.   reticulocytes

           iii.  ferritin

           iv.   TSAT

  • Screen frequency:

            i.    1x a YEAR โ†’ S3

            ii.   2X a YEAR โ†’ S4
            iii.  4x a YEAR (every 3m) โ†’ S5

  • Anemia DEF

            i.    โ™€ Hb <12

            ii.   โ™‚๏ธŽ Hb <13

            iii.  <15yo โ†’ age-specific thresholds

  • EVAL sources of blood loss

            i.    Ferritin <45ng/mL OR 

            ii.   microcytic anemia

5. Fe โ†“ โž• supplementation.

      a. IRON:

            i.   HD

                    1.    ferritin โ‰ค500 โž• TSAT โ‰ค30

            ii.   wo_HD

                     1.   ferritin โ‰ค100 โž• TSAT โ‰ค40, OR

                     2.   ferritin 100-300 โž• TSAT โ‰ค25

       b. w_Fe therapy, monitor:

             i.   CBC

             ii.   ferritin

             iii.  TSAT

       c. w_Fe therapy, frequency:

             i.    HD โ†’ every 1-3m

             ii.    wo_HD โ†’ every 3m

       d. โœ–๏ธŽ Fe in SYSTEMIC INF

6. Anemia MEDS

       a.  ESAs when Hb โ‰ค9-10

            i.     HD

            ii.    peritoneal dyalysis

       b. Better ESAs than โ€œhypoxia-inducible factorโ€“prolyl hydroxylase inhibitorsโ€

       c. wo_dialysis โžฉ INDIVIDUALIZE (symptoms โž• harm-benefit)

       d. Target Hb <11,5 

             i. Sโ€  risk

       e. โœ–๏ธŽ ESAs โ†’ r_thromboembolic (d_acute Sโ€ )

7. RATIONALE

        a. Expert opinion or low-certainty evidence. 

        b. Diligent โ†’ Fe supplementation in CKD

        c. Unnecessary supplementation?

        d. Clinical judgement GUIDES TTO decision.

8. SOURCE โ–ถ๏ธŽ Babitt JL, et al. Executive summary of the KDIGO 2026 Clinical Practice Guideline for the management of anemia in chronic
kidney disease (CKD). Kidney Int 2026 Jan; 109:44. DOI: 10.1016/j.kint.2025.06.005.








   

2026 NEJMc - Acute Coronary Syndromes in Premenopausal โ™€ (C).pdf

Codified by KYEC


ACS = acute coronary syndrome, DAPT = dual antiplatelet therapy, ID = identify, MECHs = mechanisms, MINOCA = myocardial infarction with nonobstructive coronary arteries, mm = management, PCI = percutaneous coronary intervention, rf = risk factor(s), SAP = systolic arterial pressure, SCAD = spontaneous coronary artery dissection, TTO = treatment(s)


1. ๐™„๐™Œ๐˜พ ๐™จ๐™˜๐™ค๐™ฅ๐™š โ–ถ๏ธŽ 2026, CIRCULATION, USA ๐Ÿ‡บ๐Ÿ‡ธ โž– GL โž• NA โž• NA โž– P I C O:

  • ๐Ÿ…ฟ: premenopausal โ™€
  • ๐Ÿ…ธ: ACS
  • ๐Ÿ…ฒ: โ€œolder โ™€โ€
  • ๐Ÿ…พ: recognizing + mm โ†’ etiologies & rf

2. EVIDENCE.   


       a. ACS โ†’ distinct + understuded + w_unique etiologieS

       b. Nonobstructive + nonatherosclerotic causes:

           i.    โ†‘ :โ™€ premenopausal + โ™€-specific factors (๐Ÿคฐ๐Ÿป + hormonal influences) 

           ii.   โ†“ : older population 

       c. DIFF โ†’ DX challenges + TTO uncertainty + underrepresentation in clinical trial.
       d. mm โžฉ

           i.   cause-specific TTO

           ii.   ๐Ÿค“ โ™€-specific risks

           iii.  more-agressive lifetime prevention

3. GL โ˜… ๐Ÿ—ฃ 

  • PPHY โ–ถ๏ธŽ Young โ™€ โ†’ HIGHER PREVALENCE:

           i.    SCAD

           ii.   MINOCA

           iii.  LESS COMMON: Atherosclerosis

  • DX โ–ถ๏ธŽ Angiography NOT ENOUGH โ—๏ธ

Monday, September 21, 2026 at 18:15:29 CEST

EQO, BKN, C, KYEC, LP, HIBN, AAQC

โณ TIME MANAGEMENT
01:16:01

Round: 7 02:03:27 Comments
Round: 6 28:58:36 RECAP
Round: 5 14:39:15 Interpretation
Round: 4 11:00:40 Reading + notes
Round: 3 04:51:69 ART selection
Round: 2 00:39:52 Comments
Round: 1 13:49:41 Past JR

  •    DX โ–ถ๏ธŽ Angiography NOT ENOUGH โ—๏ธ 

           i.   Could miss โ†’ SCAD + plaque erosion

           ii.  So โ†’ do INTRACORONARY imaging + multimodality imaging.

  • cause-specific TTO โ–ถ๏ธŽ

            i.    Standard GL-directed medical TTO โœ”๏ธŽ โ†’ youngโ™€ 

            ii.   For SCAD
                     1.    PCI โœ–๏ธŽ

                     2.    DAPT โœ–๏ธŽ 

                     3.    Conservative โœ”๏ธŽ 


            iii.  DAPT

                     1.    PCI

                     2.    plaque disruption

                     3.    โœ–๏ธŽ : SCAD โŒ„ vasospastic MECHS

            iv.   B-blockers

                     1.   MINOCA to prevents recurrence.


  • rf TTO โ–ถ๏ธŽ

             i.   Aggressive. Why? long lifetime risk in premenopausal โ™€

             ii.   LDL โ†’ <55-70

             iii.  SAP โ†’ <120, if tolerated

             iv.   โ™€-specific rf:

            

4. RATIONALE.

       a.  Not simply a โ€œearly atherosclerosisโ€

       b. Earlier + more-aggresive LIFETIME risk โ†“

       c. Evidence gaps (mm largely empirical):

             i. SCAD

             ii. MINOCA

       d. โ€œnoncardiac chest painโ€ โ†’ ID properly

5. SOURCE โ–ถ๏ธŽ Kovacic JC, et al. Acute coronary syndromes in premenopausal women: A scientific statement from the American Heart Association. Circulation 2026 Feb 17; 153:e89. DOI: 10.1161/CIR.0000000000001416.


       







   

2026 BMJ - Early treatment with rasburicase + risk of KRT + death in adults w_ TLS (Shenoy) [R].pdf

Codified by KYEC


DHL = lactate dehydrogenase, RRT= renal replacement therapy, โ†” = association

TLS = tumor lysis syndrome

ADM = admission



1. ๐™„๐™Œ๐˜พ ๐™จ๐™˜๐™ค๐™ฅ๐™š โ–ถ๏ธŽ ๐™„๐™Œ๐˜พ ๐™จ๐™˜๐™ค๐™ฅ๐™š โ–ถ๏ธŽ 2026, BMJ, USA ๐Ÿ‡บ๐Ÿ‡ธ โž– emul_TargetTrial โž• <1500 (36 US H+) โž• 2014-2023 (9a) โž– P I C O:

  • ๐Ÿ…ฟ: TLS pxs (adults)
  • ๐Ÿ…ธ: rasburicase within 12h after TLS onset
  • ๐Ÿ…ฒ: not received (delayed)
  • ๐Ÿ…พ: pOC = โ€˜AKI w_RRTโ€™ โŒ„ โ€˜MM d_H+ADMโ€™ | sOC = MM90

2. EVIDENCE.   


       a. TLS โ†’ life threatening oncological EMERGENCY

       b. Results from the TUMOR CELLS + TTO

       c. MECH โ†’ โ†‘K, โ†‘phophate, โ†‘nucleic acids โ†’ uric acid

       d. Crystals in tubules โ†’ due to poorly soluble at low pH โžฉ AKI + MM + mm 

       e. Rasburicase โ†’ prophylaxis + TTO

       f. ๐Ÿ…ธ converts โžฉ uric acid โ†’ allantoin

      g. Clinical OC โ†’ NO STUDY
      h. FDA โ†’ approved for children + adults โžฉ small RCT

          i.   โ†“ uric acid

          ii.   no โ†—๏ธ MM + AKI

      i. Evidence for prophylaxis PRIMARILY

3.  METHODS.

  • ๐Ÿ…ฟ โžฉ Activ_Hemato โŒ„ SOLID tumor w_:

             -  metastasis
             - โ†‘ tumor burden
             - LAB + clinical features (TLS)

  • Logistic regression w_inverse probability โ†’ adjust for confounding
  • TLS DEFINITION

            - ACTIVE hematological malignancy (known or suspected) โŒ„ metastasis

            - โ†‘ tumor burden

                  - WBC >50, โŒ„ 

                  - DHL >3x ULN

         

Monday, September 28, 2026 at 18:10:59

EQO, MJLD, LCO, KYEC, LP, HIBN, AAQC

  
       -  LABs

              -    Uric acid >8, โž•

              -    At least 1/3: ( within 24h โ€œโ†hyperuricemiaโ†’โ€)

                         -   K >6

                         -   tCa <1,75, iCa <1,12

                         -   PO4 >1,45

       -  Clinical findings 

4. RESULTS.

       a. Received ๐Ÿ…ธ 

             i.    55%

       b. Administration time 

             i.    5h

       c. Uric acid (mg/dL)

             i.    ๐Ÿ…ธ 12
             ii.   ๐Ÿ…ฒ 10

       d. Severity โ†’ well balanced (inverse probability)

       e. pOC (p<0.001)

             i.    ๐Ÿ…ธ 33%

             ii.   ๐Ÿ…ฒ 42%

             iii.   โˆ‘ 1/3 lower r w_๐Ÿ…ธ 

      f. ยฎ consistent โ†’ sOC

















5. SOURCE โ–ถ๏ธŽ  Shenoy T, Sanchez-Almanzar D, Dias JA, et al. Early treatment with rasburicase and risk of kidney replacement therapy and death in adults with tumour lysis syndrome: emulated target trial. BMJ. 2026;394:e100040. Published 2026 Jul 23. doi:10.1136/bmj-2026-100040


       







   

โณ TIME MANAGEMENT
01:15:16

Round: 8 05:03:26 Comments
Round: 7 23:32:76 Methods
Round: 6 10:17:72 Interpretation
Round: 5 15:02:89 Intro
Round: 4 07:09:52 Interpretation
Round: 3 04:49:09 Reading + notes
Round: 2 05:07:86 ART selectionRound: 1 07:57:68 Past JR

2026 NEUROLOGY - Risk of Stevens-Johnson Syndrome + TEN af_Initiation of Antiseizure MED (Heerfordt) [R].pdf

Codified by KYEC


abs = absolute, ATC = Anatomical Therapeutic Chemical, popul = population, REG = registries, SJS = Stevens-Johnson Syndrome, TEN = Toxic Epidermal Necrolysis


1. ๐™„๐™Œ๐˜พ ๐™จ๐™˜๐™ค๐™ฅ๐™š โ–ถ๏ธŽ 2026, NEUROLOGY, DA ๐Ÿ‡ฉ๐Ÿ‡ฐ โž– cohort_popul-based REG (1. National Prescription, 2. Patient Register, 3. Civil Registration System)โž• 1,4M โž• 1995-2024 (29y) โž– P I C O:

  • ๐Ÿ…ฟ: Danish adult residents
  • ๐Ÿ…ธ: registration ฦ’-up
  • ๐Ÿ…ฒ: general population
  • ๐Ÿ…พ: pOC = r_90d of SJS/TEN | sOC = time from initiation to DX โž– 1y MM โž– background r_90d

2. EVIDENCE.   


       a. SJS/TEN โ†’ serious cutaneous ร† โ†” several ANTISEIZURE MEDS: lamotrigine โž• carbamazepine

       

3.  METHODS.

  • 25 MEDs were studied.
  • Exposure โžฉ initation of any antiseizure MED in ATC category N03 (antiepileptics) during the study
    period
  • Gabapentinoids were IN but later reassigned to another ATC category.

4. RESULTS.

       a. 55yo [40-70]

       b. โ™€ 56%

       c. 90d af_initiation

           i.    83 (1st weeks)

       d. 1y MM

           i.    1,4M = 17% 

           ii.    83 cases = 7%

       e. โ†‘ abs_r (cases per 100k initiators)

           i.     lamotrigine (29)

           ii.    carbamazepine (16)

           iii.    phenobarbital (15)
           iv.    oxcarbazepine (11)

           v.    valproic acid (7)

       f.  โ†“ r_

           i.    โ†“ r_
           ii.   gabapentina (1,2)

      

Thursday, September 24, 2026 at 18:35:57

EQO,  MLLD, LCO, RCH, JQB, KYEC, LP, BAR, HIBN, AAQC

โณ TIME MANAGEMENT
01:11:46

Round: 8 01:12:58 Comments
Round: 7 28:22:23 RECAP
Round: 6 06:57:24 METHODS
Round: 5 15:52:33 Interpretation
Round: 4 04:45:06 Reading + notes
Round: 3 00:02:76 Lapsus
Round: 2 05:55:18 ART selectionRound: 1 08:38:76 Past JR


       g. Newer antiseizure MED     
             i.    NO SJS/TEN

       h. 90d background_r (cases per 100k individuals)

            i.    general population (0.17)

       i. PD โ–ถ๏ธŽ โ†‘ connectivity:

             i.    SCAN โ†” subcortical structures

             ii.    โ†‘ โ†‘ โ†‘ hyperconnectivity โ‰ˆ WORSE motor โž• cognitive impairment.

      


















5. RATIONALE.

      a. This data updates and extend older evidence

      b. Provide a contemporary reference for SJS/TEN_r in antiseizure MED (including newer agents)


6. SOURCE โ–ถ๏ธŽ Heerfordt IM, Mogensen M, Horwitz A, et al. Risk of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis After Initiation of Antiseizure Medication: A Danish Nationwide Cohort Study. Neurology. 2026;107(3):e218355. doi:10.1212/WNL.0000000000218355


       







   

September, 2026

2026 NEJMc - Does Initial Diuretic Dose Matter in HF Exacerbation (JAHA).pdf

Codified by SLDC


BID = bis in die, CREA = creatinine, DEF = definition, HF = heart failure, LOS = length of stay


1. ๐™„๐™Œ๐˜พ ๐™จ๐™˜๐™ค๐™ฅ๐™š โ–ถ๏ธŽ  2026, JAHA, USA ๐Ÿ‡บ๐Ÿ‡ธ โž– retros โž• >14k (24H+) โž• โ“ โž– P I C O:

  • ๐Ÿ…ฟ: HF
  • ๐Ÿ…ธ: diuretic use โ†’ 3 groups:

             -  < home dose = G1

             -  = home dose = G2 

             -  > home dose = G3

  • ๐Ÿ…ฒ: NA
  • ๐Ÿ…พ: pOC = โ€˜AKI w_RRTโ€™ โŒ„ โ€˜MM d_H+ADMโ€™ | sOC = MM90

2. EVIDENCE.   

       a. DOSE trial
            i.    2011, NEJM, USA ๐Ÿ‡บ๐Ÿ‡ธ โž– RCT โž• 308 โž• โ“ โž– P I C O:

                   1. ๐Ÿ…ฟ decompensated HF โ†’ decompensated โคน 24h โž• chronic HF โž• diuretic at home โคน month      

                    2. ๐Ÿ…ธ furo bolus โค furo high-dose

                    3. ๐Ÿ…ฒ furo infusion โค furo low-dose

                    4. ๐Ÿ…พ 

                          a. pOC: efficacy = symtomps 72h, safety = creatinine 72h,

                          b. sOC โžฉ H+ LOS, H+ readmission

            ii.   ยฎ ๐—ก๐—ข ๐——๐—œ๐—™๐—™

            iii.  SYMPTOMS โžฉ โ†“ (numeric) in high-dose (p=0.06)

                    1. โ†‘ diuresis

                    2. โ†‘ weight loss

            iv.  CREATININE โžฉ โ†‘ in high-dose (p=0.04)

            v.   Bolus ๐Ÿ†š continuous โžฉ ๐—ก๐—ข ๐——๐—œ๐—™๐—™ 

            vi.  sOC โžฉ ๐—ก๐—ข ๐——๐—œ๐—™๐—™ 

            vii. SOURCE โ–ถ๏ธŽ Felker GM et al for the NHLBI Heart Failure Clinical Research Network. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011 Mar 3; 364:797.

         

Thursday, October 1, 2026 at 18:20:22 CEST

EQO, MJLD, LCO, RCH, KYEC, LP, HIBN, AAQC

  
3. METHODS.

  •   EX: 

              -  not taking loop diuretics at home

              -  using thiazides

4. RESULTS.

       a. 3 groups

             i.    < home dose โžฉ 13%
             ii.   = home dose โžฉ 22%

             iii.  > home dose โžฉ 65%

       b. LOS (p<0.05)
             i.   G1 = 5d

             ii.  G2 โž• G3 = -0.5d โž• -0.7d

       c. READMISSIONS (<0.05)

             i.    G1 + G2 โžฉ 18%

             ii.   G3 โžฉ 15%

       d. AKI (DEF. โ†‘CREA >0.3)

            i.  G3 โžฉ more common

            ii. G2

        e. MM

            i. G1, G2, G3 โžฉ ๐—ก๐—ข ๐——๐—œ๐—™๐—™ 

5. RATIONALE.
        a. Underdosing is due to:

            i. incorrect dose-conversion

            ii. lack of dose-conversion

        b. How to adjust?

            i. Step 1. Torsemide โŒ„ bumetanide โ†’ convert to โ†’ furo-equivalent home dosing

            ii. Step 2. Torsemide x 2 โค bumetanide x 2,5

            iii. Step 3. Usually BID while in H+

        c. โ I also tolerate a small bump in creatinine level, as long as Iโ€™m
seeing good diuresis and weight loss. (Daniel Dressler)


6. SOURCE โ–ถ๏ธŽ  6. Qadri N, et al. Cohort study of initial diuretic dosing and outcomes among patients hospitalized for congestive heart failure: Insights from the Cardiovascular Quality Improvement and Care Innovation Consortium. J Am Heart Assoc 2026 Mar 17;
15:e038783. DOI: 10.1161/JAHA.124.038783.



       







   

โณ TIME MANAGEMENT
01:20:13

Round: 7 05:33:52 Comments
Round: 6 35:22:28 RECAP
Round: 5 07:23:50 DOSE
Round: 4 09:50:69 โ“˜ interpretation
Round: 3 03:12:64 Reading + notes
Round: 2 07:54:67 ART selection
Round: 1 10:56:11 Past JR

2026 Clin Microbiol Infect - Duration of antibiotic therapy f_ bacteraemia in immune compromised hosts (Hamani) [R].pdf

Codified by KYEC


โ†‘R = highly resistant, โ†“imm = immunocompromised, BALANCE = Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness, dMV = duration of mechanical ventilation, fd_ATB = antibiotic-free days, mITT = modified intention-to-treat, MM90 = 90-day mortality, secINF = secondary infections

ร† = adverse events



1. ๐™„๐™Œ๐˜พ ๐™จ๐™˜๐™ค๐™ฅ๐™š โ–ถ๏ธŽ 2026, Clin Microbiol Infect, CA ๐Ÿ‡จ๐Ÿ‡ฆ โž– RCT BALANCE post-hoc โž• >1k (>500 each group) โž• 2014-2023 (<10y) โž– P I C O:

  • ๐Ÿ…ฟ: adults w_bactermia โ†’ โ†“imm
  • ๐Ÿ…ธ: 7d ATB
  • ๐Ÿ…ฒ: 14d ATB
  • ๐Ÿ…พ: pOC = MM90 | sOC = H+&ICU_MM โž• H+ LOS โž• RELAPSE โž• ร† โž• dMV โž• fd_ATB โž• secINF โž• colonization (โ†‘R organisms)

2. METHODS.

  •  EX

                    1. Neutropenia (<0.5)    

                    2. Transplantation: solid organ โŒ„ bone marrow

                    3. Blood cultures:

                          a. S. aureus โŒ„ S. lugdunensis

                          b. yeast โŒ„ other fungus

                          c. prostetic ๐Ÿซ€ valves

                          d. prolonged ATB duration 

                              i.    endocarditis,

                              ii.   osteomyelitis, 

                              iii.  septic arthritis,

                              iv.  undrained abscesses, and 

                              v.   unremoved prosthetic infection).

  • Primary ๐Ÿค“  โž• intention-to-treat โž• sensitivity ๐Ÿค“

                 -   just for SURVIVED โ‰ฅ7d

Monday, October 5, 2026 at 18:15:21 CEST

EQO, MJLD, RCH, ASMA, KYEC, JAPG, HIBN, AAQC

  
3. RESULTS..

       a. โ†“ compromised

             i.    28%

       b. Randomization
             i.   7d โ†’ 530

             ii.  14d โ†’ 507

       c. Most common

             i.    Solid malignancies 75%

             ii.   lymphoma 10%
             iii.  chemotherapy 15%

             iv.  HIV/AIDS 2,3%

       d. Neutropenic

            i.  small number

            ii. 2,5%

        e. Days of ATB (median)

            i. 8

            ii. 14

         f. MM90 โ†’ ITT (p=0.16)

            i. 7 โ†’ 20%

            ii. 14 โ†’ 24%

         g. MM90 โ†’ mITT (p=0.18)

             i. 7 โ†’ 20%

             ii. 14 โ†’ 23% 










SOURCE โ–ถ๏ธŽ Hamani M, Pinto R, Lee TC, et al. Duration of antibiotic therapy for bacteraemia in immune compromised hosts-a post-hoc subgroup analysis of the Bacteremia Antibiotic Length Actually Needed For Clinical Effectiveness (BALANCE) randomized clinical trial. Clin Microbiol Infect. Published online June 9, 2026. doi:10.1016/j.cmi.2026.06.


   

โณ TIME MANAGEMENT
01:48:58

Round: 10 19:52:78 Comments
Round: 9 13:18:32 Results
Round: 8 06:14:63 MEthods
Round: 7 02:15:10 Interpretation
Round: 6 01:38:13 Intro โ†’ reading + notes
Round: 5 29:47:25 RECAP
Round: 4 09:21:87 Interpretation
Round: 3 04:08:70 Reading + notes
Round: 2 07:13:56 ART selection
Round: 1 15:08:48 Past JC

2026 ICUmmp - Cardiac Output Monitoring Made E.A.S.Y. (+ Only When You Need It) (Michard) [r].pdf

Codified by KYEC


โ†“ HR = bradycardia, โ†“ VOL = hypovolemia, ๐Ÿซ€ DYSF = cardiac dysfunction, APSF = Anesthesia Patient Safety Foundation, ESAIC = European Society of Anaesthesiology and Intensive Care, hrSx = high-risk surgery, PLR = passive leg raising


1. ๐™„๐™Œ๐˜พ ๐™จ๐™˜๐™ค๐™ฅ๐™š โ–ถ๏ธŽ 2026, ICUmmp, CH โž– r โž• NA โž• NA โž– P I C O:

  • ๐Ÿ…ฟ: hr Sx pxs + . Transplantation: solid organ โŒ„ bone marrow
  • ๐Ÿ…ธ: CO monitoring. Transplantation: solid organ โŒ„ bone marrow
  • ๐Ÿ…ฒ: NA
    . Transplantation: solid organ โŒ„ bone marrow
  • ๐Ÿ…พ: pOC = EASY โžฉ Easy to use โž• Affordable โž• Sustainable โž• Yielding insights

2. Barriers for clinical adoption

       a. lack of access

       b. high cost

3. Solution

        a. โ†—๏ธ accessibility โ†’ DIGITAL APP (in the monitor)                                b. visual decision support โ†’ UNDERLYING MECHS

4. Main point 

        a. Identify the UNDERLYING CAUSES (root causes):

            i.     โ†“ VOL

            ii.    โ†“ HR

            iii.   ๐Ÿซ€ DYSF   

        b. Recommended by:

            i.    APSF 

            ii.   ESAIC

5. Challenging to distinguish the 3 root causes COMPARED TO bradycardia. 

6. PRESSURE ๐Ÿ†š FLOW

       a. ๐Ÿ’จ โžฉ CO

       b. โžฐ โžฉ MAP

       c. โ†“โžฐ โž• ok ๐Ÿ’จ (N โŒ„ โ†‘ CO)

             i.   VASODILATION

       d. โ†“โžฐ โž• โ†“ ๐Ÿ’จ 

             i. Options:

                   1. โ†“ VOL

                   2. ๐Ÿซ€ DYSF

             ii. How to distinguish?

                   1. fluid challenge

                   2. PLR

             iii. Fluid responder?

                  1. YES โ†’ โ†“VOL

                  2. NO โ†’ ๐Ÿซ€ DYSF

7. Who should we monitor CO โ“ (ESAIC)

       a. hr baseline for complication (rA)

       b. hrSx (rB)

8. hrQx patients

       a. underused

       b. surveys โž• observational

9. OBS

       a. 23 H+

       b. FR ๐Ÿ‡ซ๐Ÿ‡ท

       c. rA

       d. CO MONITORING โ†’ 10% 

10. large OBS

       a. 28 EU nations

       b. rB 

       c. CO MONITORING โ†’ ~10% 

Thursday, October 8, 2026 at 18:20:26

EQO, MJLD, RCH, ASMA, KYEC, JAPG, HIBN, AAQC

  
11. โˆ‘ GAP โ†’ GL ๐Ÿ†š real-life PRACTICE

12. WHY people do no follow GL?

       a. SURVEY 1
             i.   2 year ago

             ii.  ESAIC members

             iii. Primary barrier

                     1. lack of access 
                     2. high cost of tools

       b. SURVEY 2

             i.    WORLDWIDE

             ii.   39 nations
             iii.  middle-income countries

             iv.  72% respondents

             v.   They would use IF they were LESS EXPENSIVEโ—๏ธ

13. CO monitoring is EXPENSIVE 

        a. Cost? โ†’ >50k EUR

        b. Pressure sensors โ†’ 100 - 400 EUR per unit

        c. Spent when used โ†’ 67 MILLON per year EUR

        d. COMPARED TO

             i.   nurses salaires โ†’ >200 nurses / year

             ii.  pocket ECHO devices โ†’ >10k

14. ESAIC GL

         a. consumable pressure sensors โ†’ 1 billion EUR / year

15. All these considerations apply to โ†’ CIRCULATORY SHOCK (w_AL)





































SOURCE โ–ถ๏ธŽ SOURCE โ–ถ๏ธŽ Michard F, Lakhal K, Rex S. Cardiac output monitoring made E.A.S.Y. (and only when you need it). ICU Management & Practice. 2026;26(3):177-180. 


   

โณ TIME MANAGEMENT
02:29:16

Round: 6 60:17:72 Comments
Round: 5 15:02:89 Wrap-up
Round: 4 50:09:52 Interpretation
Round: 3 4:49:09 Reading + notes
Round: 2 05:07:86 ART selection
Round: 1 07:57:68 Past JR

2026 NEJMc - Statin Benefits in Healthy Older Adults (NEJM).pdf

Codified by JAGP


ร† = adverse events, CVD = cardiovascular disease, DEM = dementia, DM = diabetes, hr = high risk, medIMP = medically important, nfMI = nonfatal myocardial infarction, PHYdis = physical disability, reVASC = revascularization, Sโ€  = stroke


1. ๐™„๐™Œ๐˜พ ๐™จ๐™˜๐™ค๐™ฅ๐™š โ–ถ๏ธŽ 2026, NEJM, AUS ๐Ÿ‡ฆ๐Ÿ‡บ โž– RCT โž• 10K โž• 6y ฦ’-up โž– PI CO:

  • ๐Ÿ…ฟ: Healthy adults >70yo
  • ๐Ÿ…ธ: statins (atorvastatin 40mg)
  • ๐Ÿ…ฒ: placebo
  • ๐Ÿ…พ: 
      pOC = cvMM โŒ„ nfMI โŒ„ Sโ€  โŒ„ coronary reVASC
  • sOC = disability-free SS โž• serious ร† โž• medIMP ร†

2. EVIDENCE.

       a. Statins โ†“ CV events โ†’ specially in hr pxs

       b. Safety โž• effectiveness is DEBATED in ๐Ÿ…ฟ , in regard to:

            i.     prevention of CV events

            ii.    extending SS free of DEM โŒ„ PHYdis

3. METHODS.

  • IN: independent + no history of CVD, DM, DEM
  • Baseline:

             1.   LDL = 127

             2.   BP = 136/80

             3.   46% w_antiHTA

Thursday, October 15, 2026 at 17:30:37 WEST

EQO, MJLD, RCH, ASMA, KYEC, JAPG, HIBN, AAQC

  
4. RESULTS.

        a.    75yo

        b.    ฦ’-up 6y โžฉ โ†“r pOC (p<0.05)

               i.     ๐Ÿ…ธ 6% โœ”๏ธŽ

               ii.    ๐Ÿ…ฒ 8,3%

               iii.    nfMI โž• coronary reVASC โžฉ LARGE DIFF

               iv.    Sโ€  โž• cvMM โžฉ ๐—ก๐—ข ๐——๐—œ๐—™๐—™

        c.    disability-free SS โž• serious ร†

               i.     ๐Ÿ…ธ ๐Ÿ†š ๐Ÿ…ฒ โ†’ ๐—ก๐—ข ๐——๐—œ๐—™๐—™

        d.    medIMP ร† (p<0.05)

               i.     ๐Ÿ…ธ 9% โœ–๏ธŽ


               ii.    ๐Ÿ…ฒ 7%

5. RATIONALE.

       a.    6y ฦ’-up might be TOO SHORT. 
       b.    โ The CV benefits are compelling and will prompt me to discuss
statins with my older patients, even the healthiest ones (Karol Watson)
6. SOURCE โ–ถ๏ธŽ Zoungas S, et al. Atorvastatin, cardiovascular events, and disability-free survival in older adults. N Engl J Med
2026 Aug 29; [e-pub]. DOI: 10.1056/NEJMoa2607314. PubMed








































   

โณ TIME MANAGEMENT
01:15:27

Round: 7 01:31:58 Comments
Round: 6 20:19:71 RECAP
Round: 5 24:59:23 Continue
Round: 4 00:08:09 Interpretation
Round: 3 02:35:74 Reading + notes
Round: 2 09:59:04 ART selection
Round: 1 15:53:88 Past JR + 5min

2026 NEJMc - Age and Early TAVR for Asymptomatic Aortic Stenosis (Circ Cardiovasc Interv).pdf

Codified by YAPG


โ˜… = recommendation(s), AF = atrial fibrillation, AS = aortic stenosis, CS = clinical surveillance, ind_fun = industry-funded, PD = Parkinsonโ€™s disease, pLVEF = preserved left ventricular ejection fraction, SCAN = somato-cognitive action network, TTO = treatment(s), US = ultrasound 


1. ๐™„๐™Œ๐˜พ ๐™จ๐™˜๐™ค๐™ฅ๐™š โ–ถ๏ธŽ 2026, Circ Cardiovasc Interv, USA ๐Ÿ‡บ๐Ÿ‡ธ โž– ind (Edwads LifeSciences)_fun_ post hoc_ RCT โž• 901 (141, 263, 250, 246) โž• ฦ’-up 5y โž– P I C O:

  • ๐Ÿ…ฟ: pxs โ†’ 4 groups: 65-69 โž– 70-74 โž– 75-79 โž– โ‰ฅ80
  • ๐Ÿ…ธ: TAVR
  • ๐Ÿ…ฒ: CS
  • ๐Ÿ…พ: Age โ†” pOC = MM โŒ„ Sโ€  โŒ„ unplanned H+ CV_causes โžฉ 6m

2. EVIDENCE.

       a. Original paper:

            i. EARLY TAVR โ–ถ๏ธŽ 2025, NEJM, USA ๐Ÿ‡บ๐Ÿ‡ธ + CA ๐Ÿ‡จ๐Ÿ‡ฆ โž– pros_mc_ol_RCT โž• 901 โž• Mar 2017 - Dec 2021 | ฦ’-up 5y โž– P I C O:  

  • ๐Ÿ…ฟ โ‰ฅ65yo wo_symp of AS + pLVEF
  • ๐Ÿ…ธ TAVR
  • ๐Ÿ…ฒ clinical surveillance
  • ๐Ÿ…พ pOC = MM โŒ„ Sโ€  โŒ„ unplanned H+ CV_causes โžฉ 6m

Monday, October 19, 2026 at 17:20:07 WEST

EQO, MJLD, RCH, ASMA, KYEC, JAPG, HIBN, AAQC



        1.    ยฎ pOC (p<0.001)

                   a.  ๐Ÿ…ธ 27%

                   b.  ๐Ÿ…ฒ 45%

        2.    ยฎ MM (95%CI 0.6-1.44)

                   a.  ๐Ÿ…ธ 8%

                   b.  ๐Ÿ…ฒ 9%
        3.     ยฎ Sโ€  (95%CI 0.35-1.1)

                   a.  ๐Ÿ…ธ 4%

                   b.  ๐Ÿ…ฒ 7%

         4.    ยฎ unplanned H+ CV-causes (95%CI 0.33-0.55)

                   a.  ๐Ÿ…ธ 21%

                   b.  ๐Ÿ…ฒ 42%


3. SOURCE โ–ถ๏ธŽ Goel K, et al. Age and procedural timing for asymptomatic severe aortic stenosis: Analysis from the EARLY TAVR trial. Circ Cardiovasc Interv 2026 Jun 3; [e-pub].10.1161/CIRCINTERVENTIONS.125.016370. PubMed








































   

โณ TIME MANAGEMENT
02:00:55

Round: 6 46:39:86 RECAP
Round: 5 20:28:89 Interpretation
Round: 4 02:52:88 Reading + notes
Round: 3 05:23:71 ART selection
Round: 2 00:24:24 Comments
Round: 1 16:05:86 Past JR

2026 NEJMc - Age and Early TAVR for Asymptomatic Aortic Stenosis (Circ Cardiovasc Interv).pdf

Codified by YAPG


โ˜… = recommendation(s), AF = atrial fibrillation, AS = aortic stenosis, CS = clinical surveillance, ind_fun = industry-funded, PD = Parkinsonโ€™s disease, pLVEF = preserved left ventricular ejection fraction, SCAN = somato-cognitive action network, TTO = treatment(s), US = ultrasound



1.  ...

2. RESULTS.

       a.   Age โ†’ pOC โž• Sโ€  โž• u_H+_HF

            i.   ๐—ก๐—ข ๐——๐—œ๐—™๐—™ 

       b.   Sโ€  โ†’ 65-69y (ฦ’-up 5y)

            i.   ๐Ÿ…ธ 0% โœ”๏ธŽ

       c.   Sโ€  โ†’ โ‰ฅ80y (ฦ’-up 5y)

            i.   ๐Ÿ…ธ 4% โœ”๏ธŽ 

            ii.  ๐Ÿ…ฒ 16%

       d.  H+_HF โ†’ โ‰ฅ80y (ฦ’-up 5y)

            i.   ๐Ÿ…ธ 9% โœ”๏ธŽ 
            ii.  ๐Ÿ…ฒ 19%

Thursday, October 22, 2026 at 18:17:32 CEST

EQO, MJLD, RCH, ASMA, KYEC, JAPG, HIBN, AAQC

  
3. RATIONALE.

       a. FDA approved TAVR for this ๐Ÿ…ธ

       b. Critics
             i.   lack of SS benefit

             ii.  โ†‘ rate of early conversion to TAVR (87%)

       c. REINFORCES NEJM 2025

       d. Test RISKS of the POSSIBILITY:

            i.    of late TAVR failure

            ii.   HF

            iii.   urgent TAVR d_CS

        e. However, TAVR may reduce:

            i.    Hospital length of stay.

            ii. ICU resource utilization.

            iii. Postoperative complications.

            iv. Rehabilitation requirements.

            v. Readmissions and subsequent healthcare costs.

4. SOURCE โ–ถ๏ธŽ Goel K, et al. Age and procedural timing for asymptomatic severe aortic stenosis: Analysis from the EARLY TAVR trial. Circ Cardiovasc Interv 2026 Jun 3; [e-pub].10.1161/CIRCINTERVENTIONS.125.016370. PubMed

     

โณ TIME MANAGEMENT
01:29:16 (estimated)

Round: 9 11:47:81 RECAP
Round: 8 12:03:26 Interpretation
Round: 7 03:32:76 Reading + notes
Round: 6 01:17:72 Comments
Round: 5 15:02:89 Wrap-up
Round: 4 07:09:52 Interpretation
Round: 3 05:49:09 Reading + notes
Round: 2 03:07:86 ART selection
Round: 1 07:57:68 Past JR

2026 NEJMc - Is It Safe to Stop Long Term BB after MI (LANCET).pdf

Codified by YAPG


BB = beta blockers, CHF = chronic heart failure, CVE = cardiovascular event, LVEF = left ventricular ejection fraction, MI = myocardial infarction, nfMI = nonfatal myocardial infarction, nfSโ€  = nonfatal stroke, PROBE = prospective, randomized, open-label, blinded endpoint, prQOL = patient-reported quality of life, reVASC = revascularization, BB = Beta blockers



1.  ๐™„AO โ–ถ๏ธŽ 2026, LANCET, โ“ โž– pooled ๐Ÿค“  โž• 6k โž• 3,6y (ฦ’-up 3y) โž– P I C O:

  • ๐Ÿ…ฟ: past MI + reVASC + pLVEF
  • ๐Ÿ…ธ: BB stop
  • ๐Ÿ…ฒ: BB continue
  • ๐Ÿ…พ: pOC = safety |

         

Monday, October 26, 2026 at 18:00:41 CET

EQO, MJLD, RCH, ASMA, KYEC, JAPG, HIBN, AAQC

โณ TIME MANAGEMENT
01:43:58

Round: 6 01:14:26 RECAP
Round: 5 12:22:82 Interpretation
Round: 4 03:00:95 Reading + notes
Round: 3 08:20:16 ART selection
Round: 2 00:15:86 Comments
Round: 1 05:32:03 Past JR

2026 NEJMc - Is It Safe to Stop Long Term BB after MI (LANCET).pdf

Codified by ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ (EQO)


ACE-i = angiotensin-converting enzyme inhibitor, AF_H+ = atrial fibrillation hospitalization, antiPLA = antiplatelets, ARB = angiotensin receptor blocker, lr = low risk, MI = myocardial infarction, PCI = percutaneous coronary intervention, pg = parallel-group, safOC = safety outcomes, STEMI = ST-segment elevation myocardial infarction, MI = Myocardial infarction



1. Continuationโ€ฆ

2. EVIDENCE.

       a. REDUCE-AMI โ–ถ๏ธŽ 2024, NEJM, SW ๐Ÿ‡ธ๐Ÿ‡ช, ES ๐Ÿ‡ช๐Ÿ‡ช NZ ๐Ÿ‡ณ๐Ÿ‡ฟ โž– reg-emb_pg_ol_RCT โž• >5k โž• Sep 2017 - May 2023 (6y) โž– P I C O

  • ๐Ÿ…ฟ: adults | past MI
  • ๐Ÿ…ธ: BB stop (weaning 2-4w)
  • ๐Ÿ…ฒ: BB continue
  • ๐Ÿ…พ: 

               -   pOC = Composite: MM โŒ„ newMI (โ€recurrentโ€)

               -   sOC = MM โŒ„ cvMM โŒ„ newMI โŒ„ AF_H+ โŒ„ hf_H+

               -   safOC = bradycardia โŒ„ AVB II or III โŒ„ โ†“AP โŒ„ syncope โŒ„ pacemaker โŒ„ asthma or COPD_H+ โŒ„ Sโ€ _H+ 

  • IN: angiography + LVEF โ‰ฅ50% โž• BB (metoprolol โŒ„ bisoprolol)
  • ยฎ 35% w_STEMI s_PCI
  • ยฎ 65yo โค < โ™€ โค 95% from ๐Ÿ‡ธ๐Ÿ‡ช

Thursday, October 29, 2026 at 18:44:12 CET

EQO, MJLD, RCH, ASMA, KYEC, JAPG, HIBN, AAQC

โณ TIME MANAGEMENT
01:40:16

Round: 6 2:17:72 Comments
Round: 5 25:02:89 RECAP
Round: 4 20:09:52 Interpretation
Round: 3 05:49:09 Reading + notes
Round: 2 10:07:86 Continuation
Round: 1 07:57:68 Past JR

2026 NEJMc - Is It Safe to Stop Long Term BB after MI (LANCET).pdf

Codified by YAPG


๐Ÿ“ˆ = arrhythmia, AF = atrial fibrillation, IND = indication, l-tBB = long-term beta blocker, ni = noninferiority, PD = Parkinsonโ€™s disease, SCAN = somato-cognitive action network, STEMI = ST-segment elevation myocardial infarction, TTO = treatment(s)
๐Ÿ“ˆ = arrhythmia;


1. ๐™„AO โ–ถ๏ธŽ 2026, LANCET, โ“ โž– pooled ๐Ÿค“  โž• 6k โž• 3,6y (ฦ’-up 3y) โž– P I C O:

  • ๐Ÿ…ฟ: past MI + reVASC + pLVEF
  • ๐Ÿ…ธ: BB stop
  • ๐Ÿ…ฒ: BB continue
  • ๐Ÿ…พ: pOC = safety = MM, MI, Sโ€ , cv_H+, reVASC

2. EVIDENCE.

       a. ABYSS 2024

       b. REDUCE-AMI 2024

c. SMART-DECISION โ–ถ๏ธŽ 2026, NEJM, KR ๐Ÿ‡ฐ๐Ÿ‡ท  โž– ol_ni_RCT โž• >2,5k โž• Apr 2021 - Apr 7 2023 (2y) โž– P I C O

  • ๐Ÿ…ฟ: adults | past MI
  • ๐Ÿ…ธ: BB stop 
  • ๐Ÿ…ฒ: BB continue
  • ๐Ÿ…พ: pOC = Composite: MM โŒ„ recurrent MI โŒ„ hf_H+
  • IN: w_BB 1y af_MI + LVEF โ‰ฅ40% โž• wo_AF
  • ยฎ  63yo โค 87% โ™‚๏ธŽ  โค 57% STEMI
  • ยฎ 3y ฦ’-up โ†’ pOC (p=0.001)

            -     ๐Ÿ…ธ 7,2%

            -     ๐Ÿ…ฒ 9%

  • ยฎ serious ร†

            -     ๐—ก๐—ข ๐——๐—œ๐—™๐—™

  • Rationale:

         - Re-evaluation the necessity of l-tBB

              - 2 previous trials already suggested NO CLEAR ACUTE benefit (lr_pxs)

Monday, November 2, 2026 at 18:31:12 CET

EQO, MJLD, RCH, ASMA, KYEC, JAPG, HIBN, AAQC

โณ TIME MANAGEMENT
01:16:05

Round: 9 09:05:51 Comments
Round: 8 12:37:61 RECAP current
Round: 7 24:55:75 Original ART
Round: 6 02:31:44 RECAP
Round: 5 10:18:35 Interpretation
Round: 4 02:33:69 READING + notes
Round: 3 04:28:78 continue... ART
Round: 2 01:23:90 CommentsRound: 1 08:10:30 Past JR

2026 NEJMc - New ACC Scientific Statement on Antiplatelet Therapy in Atherosclerotic DIS (J Am Coll Cardiol).pdf

Codified by ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ (EQO)


โ˜… = recommendation(s), ๐Ÿณ๏ธ = prevention, โœ‹๐Ÿฝ = stop, ACS = acute coronary syndrome, AF = atrial fibrillation, antiCOAG = anticoagulation = anticoagulant, APT = antiplatelet therapy, ASCVD = atherosclerotic cardiovascular diseases, BLEED = bleeding, Carotid AD = carotid artery disease, CCS = chronic coronary syndromes, DAPT = dual antiplatelet therapy, hrBLEED = high risk of bleeding, l-dASA = low-dose aspirin, PAD = peripheral artery disease, PCI = percutaneous coronary intervention, periACS = peri-ACS, rISCH = ischemic risk, TTO = treatment(s)


1. ๐™„๐™Œ๐˜พ ๐™จ๐™˜๐™ค๐™ฅ๐™š โ–ถ๏ธŽ 2026, JACC, USA ๐Ÿ‡บ๐Ÿ‡ธ โž– scientific statement โž• NA โž• NA โž– P I C O:

  • ๐Ÿ…ฟ: adult pxs
  • ๐Ÿ…ธ: APT
  • ๐Ÿ…ฒ: NA
  • ๐Ÿ…พ: NA

2. EVIDENCE.

       a.  2025 ACC/AHA GL ACS

            i.  Short_d DAPT if rBLEED is โ†‘

            ii. Bivalirudin instead of heparin โ†’ PCI.

  • Underlying DIS โž• px-specific risk โžฉ KEY FACTORS
  • DECISION MAKING โžฉ thrombotic ๐Ÿ†š BLEED
  • 2026 ACC update โ†’ ACS
  1. Cover many other ASCVD
  2. CCS
  3. PAD
  4. Carotid AD

3. KEY โ˜….

       a.  PRIMARY ๐Ÿณ๏ธ 

            i.     low dose ASA โ†’ limited

                      1.   40-70 yo

                      2.   โœ”๏ธŽ โ†’ โ†‘ rCV

                      3.   โœ–๏ธŽ โ†’ โ†‘ rBLEED

       b.  SECONDARY ๐Ÿณ๏ธ 

            i.     Prasugrel โŒ„ Ticagrelor

                       1.   โŠ• Prasugrel ๐Ÿ†š Ticagrelor

                       2.    Some studies

            ii.     DAPT

                       1.    Default strategy: periACS โŒ„ PCI

                       2.    For 1m (minimum) 
                       3.    Duration:

                                a.   6m โ†’ CCS
                                b.   12m โ†’ ACS
  

Thursday, November 5, 2026 at 18:05:42 CET

EQO, MJLD, RCH, ASMA, KYEC, JAPG, HIBN, AAQC

  

            iii.    TRANSITION

                       1.   FROM: DAPT

                       2.   TO: single APT (โ€SAPTโ€) w_PRASUGREL โŒ„ TICAGRELOR

                       3.   Reasonable โž• โ†“ rBLEED (wo_> rISCH)

                               a.    Af_1-3m DAPT

                       4.   Useful for โ†’ hrBLEED

            iv.    TRANSITION (1-3m)

                       1.   FROM: DAPT

                       2.   TO: SAPT w_ CLOPI โŒ„ ASA

                                a.    โœ–๏ธŽ bad idea โ€œnot advisableโ€

                                b.    UNLESS hrBLEED

            v.     ANTICOAGULANT

                       1.    ACS โŒ„ PCI โ†’ w_indication of antiCOAG

                       2.    Triple therapy = antiCOAGs โž• DAPT
                                  a.   โœ–๏ธŽ bad idea โ€œdiscouragedโ€

                                  b.   โœ‹๐Ÿฝ ASA โ†’ 1m (sometimes af_1st w)

                                  c.    โœ”๏ธŽ CLOPI โž• DOAC โ†’ continue 
             vi.   DAPT

                      1.  CABG

                      2.  โŠ•

                             a.    โ†“ r_veinGraft FAILURE 

                      3. โŠ–

                             a.   NO โ†—๏ธ โ†’ ๐Ÿซ€ end points  
                             b.   โ†‘ rBLEED

       c.  OTHER conditions

             i.    CAD (particularly PAD)

                      1.  IF not hrBLEED โ†’ VERY-LOW dose RIVAROXABAN

                            a.   2,5mg BID

                            b.   add-on to l-d_ASA

             ii.    l-dASA MONOTHERAPY
                        1.  reasonable โžฉ bioprosthetic valves

5. RATIONALE.

        a.  ROADMAP for a wide variety of ASCVD
        b.  Complex to decide - still lack of conclusive evidence

        c.  GENOTYPE โ“
              i.      Intra-individual variability

              ii.     inter-individual variability













6. SOURCE โ–ถ๏ธŽ Kumbhani DJ, et al. Antiplatelet therapy in the management of atherosclerotic cardiovascular disease: 2026 ACC Scientific Statement: A report of the American College of Cardiology. J Am Coll Cardiol 2026 Jun 30; [e-pub]. DOI: 10.1016/j.jacc.2026.05.037. PubMed


   

โณ TIME MANAGEMENT
01:50:31

Round: 7 03:33:48 Comments
Round: 6 44:36:33 RECAP
Round: 5 34:38:29 Interpretation
Round: 4 04:11:94 Reading + notes
Round: 3 02:52:86 Votes
Round: 2 06:00:70 ART selection
Round: 1 14:38:12 Past JR

2026 NEJMc - SGLT-2 Inhibitors and GLP-1 Agonists Better Together (CMAJ).pdf

Codified by ๐™„๐™‰๐˜ผ๐˜ผ๐™Œ๐˜พ แดฎแดผ (LCO)


โ˜… = recommendation(s), ADA = American Diabetes Association, CMAJ = Canadian Medical Association Journal, DM2 = type 2 diabetes mellitus, MACE = major adverse cardiovascular events, MAKE = major adverse kidney events, safOC = safety outcomes


1. ๐™„๐™Œ๐˜พ ๐™จ๐™˜๐™ค๐™ฅ๐™š โ–ถ๏ธŽ 2026, CMAJ, โ“ โž– networkMA โž• 6 RCT (SGLT-2i) 6 RCT (GLP-1RA) โž• โ“ โž– P I C O:

  • ๐Ÿ…ฟ: DM2
  • ๐Ÿ…ธ: combination
  • ๐Ÿ…ฒ: each alone (SLGT-2i โŒ„ GLP-1RA)
  • ๐Ÿ…พ: pOC = pOC = ๐Ÿซ€ + โ™พ๏ธ | sOC = H+_HF

2. EVIDENCE.

       a.   SLGT-2i โ†—๏ธ OC ๐Ÿซ€ โ™พ๏ธ 

       b.   GLP-1RA โ†—๏ธ OC ๐Ÿซ€ โ™พ๏ธ 

       c.   Combined โ“

Monday, November 9, 2026 at 18:41:32

EQO, MJLD, RCH, ASMA, KYEC, JAPG, HIBN, AAQC

  
3. RESULTS.

       a.   MACE + MAKE

             i.    ๐—ก๐—ข ๐——๐—œ๐—™๐—™

       b.   sOC โ†’ H+_HF (p<0.05)
             i.   Combination ๐Ÿ†š SLGT-2i โ†’ โ†“ 28%

             ii.  Combination ๐Ÿ†š GLP-1RA โ†’ โ†“ 38%

       c.   safOC

             i.    ๐—ก๐—ข ๐——๐—œ๐—™๐—™

       d. Certainty โ†’ LOW

4. RATIONALE.

       a.   No RCT to compare both (combination ๐Ÿ†š each alone)

       b.   Combination is OK (ADA supported):

             i.     not achieved GLU goals

             ii.    hr โ†’ heart DIS โž• HF โž• CKD

5. SOURCE โ–ถ๏ธŽ Chuang M-H, et al. Cardiovascular and renal outcomes of combined SGLT2 inhibitors and GLP-1 receptor agonists versus monotherapy in patients with type 2 diabetes mellitus: A network meta-analysis. CMAJ 2026 Jul 12; 198:E992. DOI: 10.1503/cmaj.250369. PubMed












   

โณ TIME MANAGEMENT
00:58:16

Round: 6 00:10:19 Comments
Round: 5 10:02:89 RECAP
Round: 4 10:09:52 Interpretation
Round: 3 05:49:09 Reading + notes
Round: 2 03:07:86 ART selection
Round: 1 07:57:68 Past JR

October, 2026

Journal Reviews




2. EVIDENCE.

       a.   ABYSS โ–ถ๏ธŽ 2024, NEJM, FR ๐Ÿ‡ซ๐Ÿ‡ท โž– mc (49 centers)_PROBE_RCT โž• >3,5k โž• Aug 2018 - Sep 2022 (4y) โž– P I C O 

  • ๐Ÿ…ฟ: adults | past MI
  • ๐Ÿ…ธ: BB stop
  • ๐Ÿ…ฒ: BB continue
  • ๐Ÿ…พ: pOC = Composite: MM + nfMI + nfSโ€  + cv_H+
  • IN: LVEF โ‰ฅ40 โž• NO recent CVE โŒ„ CHF
  • ยฎ ๐Ÿ…ธ โ†’ interrupted BB โ‰ฅ6m af_MI
  • ยฎ prQOL โžฉ ๐—ก๐—ข ๐——๐—œ๐—™๐—™
  •  ยฎ pOC noninferiority (p>0.05 ๐ŸŸฐ p=0.44)
  • ๐Ÿ…ธ 24%
  • ๐Ÿ…ฒ 21%

3. SOURCE โ–ถ๏ธŽ Silvain J, et al. Discontinuation of ฮฒ-blockers in stable patients with previous myocardial infarction, preserved left ventricular ejection fraction, and no heart failure: A pooled analysis of individual patient data. Lancet 2026 Aug 30; [e-pub]. DOI: 10.1016/S0140-6736(26)01426-1. PubMed


         

  • ยฎ BB started at H+ stay โž• DISCHARGED: 

               -    ASA โ†’ 97%

               -    P2Y12 blockers โ†’ 96%
               -    Statins โ†’ 98%

               -    ACE-i โŒ„ ARB โ†’ 80%

  • ยฎ BB ADHERENCE at 1y:

               -     ๐Ÿ…ธ 80%

               -     ๐Ÿ…ฒ 14%

  •  FOLLOW-UP of 3,5y

               -     pOC (p>0.05 ๐ŸŸฐ 0.64)

                         ๐Ÿ…ธ 7,9%

                         ๐Ÿ…ฒ 8,3%

               -      sOC

                         ๐—ก๐—ข ๐——๐—œ๐—™๐—™ 

               -      safOC

                         ๐—ก๐—ข ๐——๐—œ๐—™๐—™ 

                         pacemaker (3,4 yes BB ๐Ÿ†š 3,2 no BB) 

                         asthma or COPD_H+ (0.6 ๐Ÿ†š 0.6)

                         Sโ€ _H+ (1,4 ๐Ÿ†š 1,8)

  • Rationale:

                 -     Predates advances:

                               PCI

                               antiPLA regimens

                 -     Relatively lr population

                 -     Lower-than-expected event rate resulted in limited
statistical power โ†’ CANNOT exclude CLINICALLY MEANINGFUL benefit from BB

                 -     universal registry participation 

                 -     national data sources

3. SOURCE โ–ถ๏ธŽ Yndigegn T et al. Beta-blockers after myocardial infarction and preserved ejection fraction. N Engl J Med 2024 Apr 7; [e-pub].(https://doi.org/10.1056/NEJMoa2401479)

               -    ABYSS โ†’ failed to meet ni criteria

               -    If BB is needed - like HTA, just continue.

               -    Be inclined to REVIEW + potentially DISCONTINUE BB (suitable patients)

  • SOURCE โ–ถ๏ธŽ Choi KH, et al. Discontinuation of beta-blocker therapy after myocardial infarction. N Engl J Med 2026 Apr 2; 394:1302. DOI: 10.1056/NEJMoa2601005.

3. METHODS.

  • 2 studies pooled:

               -     ABYSS

               -     SMART-DECISION

  •  IN:

               -     BB since โคน MI

               -     no IND HF โŒ„ ๐Ÿ“ˆ

               -     FEVI >59%

  • Enrollment โ†’ 3,6y since index MI
  • Index MI = STEMI 60% โ†’ 95% revascularization

4. RESULTS.

       a.    At 3y: incidence pOC

               i.    ๐—ก๐—ข ๐——๐—œ๐—™๐—™ 

       b.    QOL: 

               i.    ๐Ÿ…ธ no โ†—๏ธ 

               ii.   ๐Ÿ…ฒ 

5. RATIONALE.

       a.     Good evidence to STOP BB w_normal EF 

       b.     QOL benefits โ†’ IMPRESSION NOT SUPPORTED

       c.     โ†“ POLYPHARMACY is worthwhile.

       d.     BB โ†’ โ†“ BP โžฉ if STOP, please CHECK BP regularly (even at home)

6. SOURCE โ–ถ๏ธŽ Silvain J, et al. Discontinuation of ฮฒ-blockers in stable patients with previous myocardial infarction, preserved left ventricular ejection fraction, and no heart failure: A pooled analysis of individual patient data. Lancet 2026 Aug 30; [e-pub]. DOI: 10.1016/S0140-6736(26)01426-1. PubMed.